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Organ-specific metastasis is dependent on both the intrinsic properties of the 
tumour cells and the receptiveness of the host organ. Primary tumour cell-
derived factors can modulate distant microenvironment to become more 
receptive to colonisation by circulating tumour cells. Such sites are known as 
the pre-metastatic niche. The endothelium is a physical barrier that the 
disseminated tumour cells encounter during extravasation into the secondary 
site. However, it is not known whether tumour secreted factors could alter 
endothelial function during pre-metastatic niche formation to augment tumour-
endothelial interactions. The aim of this study is to develop a robust co-culture 
model using breast tumour cells, endothelial cells derived from lung (FLEC), 
and in-vitro differentiated macrophages to systematically examine the cell-cell 
interactions between these three cell types. Data from this study will help 
elucidate the mechanisms underlying the homing and extravasation of breast 
cancer cells to the lung.   
Using breast tumour cells (MDA-MB-231 and MCF-7) and endothelial cells 
isolated from various organs, tumour-endothelial interactions including stable 
binding and trans-endothelial migration were examined in-vitro. In order to 
simulate the systemic effect of tumour-secreted factors on extravasation, the 
different types of endothelium were subjected to stimulation with various 
factors (TNF-α, conditioned media from MDA-MB-231 (MDA-MB-231 CM) 
and from tumour-conditioned macrophages (MDA-mϕ CM)) prior to use in 
the tumour-endothelial interaction assays. The adhesion molecules involved in 
these interactions and the signalling pathways that regulate the endothelial 
responses were also studied. 
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My data revealed that FLEC was more susceptible to invasion by breast cancer 
cells, MDA-MB-231, compared to endothelium isolated from the umbilical 
cord vein and saphenous vein, which represent the vasculature at non-
metastatic sites. In addition, FLEC-derived MMP2 and a yet unidentified 
MMP(s) secreted by MDA-MB-231 acted in concert to disrupt FLEC 
monolayer integrity. This resulted in the formation of “gaps” in the FLEC 
monolayer, thus allowing the tumour cells to transmigrate across endothelial 
monolayer more readily. FLEC subjected to stimulation with TNF-α and 
MDA-mϕ CM exhibited significantly more interactions with MDA-MB-231 
and MCF-7 cells than untreated FLEC or FLEC treated with MDA-MB-231 
CM. Such enhanced interactions were not observed with endothelium from 
non-metastatic sites under similar conditions.  
The observed tumour cell-FLEC interactions were mediated by the binding of 
tumour-α5β1 integrin to fibronectin expressed on the MDA-mϕ-primed FLEC 
surface. The enhanced expression of fibronectin on MDA-mϕ primed FLEC 
was regulated by the activation of the JNK/cJUN and STAT3 signalling 
pathways. My data also identified MDA-mϕ-derived interleukin 6 (IL-6) as 
the dominant mediator that primed FLEC in this model system.  
Data from this study suggest that factors secreted by breast cancer cells can 
transform resident macrophages in target organs to become M2-like with pro-
tumour properties; and these conditioned-macrophages in turn prime the organ 
microenvironment. Macrophage-derived IL-6 enhances fibronectin expression 
in the endothelial cells via the activation of JNK and STAT3 pathways. The 
activation of the endothelium ensuing surface fibronectin up-regulation in pre-
ix 
 
metastatic niche is the key to the successful homing of disseminated tumour 
cells into the lung parenchyma. 
(489 words)  
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CHAPTER 1: GENERAL INTRODUCTION 
1.1 Metastasis 
Metastasis, the most feared aspect of cancer, contributes to 90% of  deaths 
seen in all cancers 
1
. This uncontrolled widespread of tumour cells from its 
primary site to distant organs, and sometimes body cavities, limits the 
effectiveness of most cancer treatments. It is a complex process consisting of a 
series of sequential and interrelated steps 
2
, including proliferation and growth 
of primary tumour, angiogenesis, local invasion of detached tumour cells from 
at the primary tumour, the intravasation of detached cells into circulation 
(lymphatics or vasculature), survival of tumour cells in circulation, arrest at 
the endothelial wall or exposed basement membrane, extravasation into 
secondary site, colonization and formation of micrometastases and lastly 
proliferation and initiation of neo-vascularisation to form macrometastases 
3,4
. 
During tumour development, the immune system typically recognises the 
tumour cells as foreign bodies and elicits an anti-tumour immune response to 
kill the tumour cells and hinder their growth and progression 
5
. Therefore, only 
tumour cells that can evade the immune surveillance are able to survive and 




1.1.1 Organ specific metastasis 
The release of tumour cells into the systemic circulation disseminates the 
tumour cells to every organ in the body and yet secondary growth is only 
observed in some organs. While the general steps of the metastatic process are 
probably the same for all cancer, the frequency of successful establishment of 
2 
 
a secondary lesion may differ depending on the barriers and ‘resistance’ 




Different cancer types have different organ preferences for metastasis. For 
example, colorectal and breast cancer usually metastasize to liver and lung, 
while prostate cancer preferentially metastasizes to bone (Table 1). 
Observation of this organ specific distribution was first documented by 
Stephen Paget over a century ago. He hypothesized that tumour cells (“seed”) 
have preference for the unique microenvironment of a particular organ (“soil”) 
that is favourable for their survival and proliferation 
7,8
. The “seed and soil” 
hypothesis was challenged by James Ewing who hypothesized that the site of 
metastasis is purely due to the mechanical factors exerted on the circulating 
tumour cells resulting in their arrest within the vasculature 
9
. According to 
Ewing’s theory, tumour cells can get trapped in the capillaries due to their size, 
which resulted in adhesion and subsequent invasion on site. Although tumour 
cells could probably be trapped in the capillaries, clinical observations showed 
that metastasis occurrences are rarely found in highly vascularized organs such 
as the heart and spleen. Thus these observations suggest that the choice of the 
secondary site is not due to chance and that some organs are more prone to 
colonization by certain tumour types than others 
10
. To date, Paget’s “seed and 
soil” hypothesis remains the basis of organ specific metastasis; that the 
outcome of the metastatic process depends on the multiple complex 




Table 1.1: Principle sites of metastasis for solid tumours 
6
 
Tumour Type Principal sites of metastasis 
Breast Lungs, bone, liver and brain 
Lung adenocarcinoma Brain, bones, adrenal gland and liver 
Skin melanoma Lungs, brain, skin and liver 
Colorectal Liver and lungs 
Pancreatic Liver and lungs 
Prostate Bones 
Sarcoma Lungs 
 (Adapted by permission from Macmillan Publishers Ltd: Nature Reviews, 
Cancer, 9, 274-284 (2009), copyright 2009) 
 
 
1.2 Tumour adhesive interactions with endothelium  
The extravasation of circulating tumour cells to the target organ sites is 
dependent on successive interactions between adhesive proteins expressed on 
the endothelium with their ligands or counter-receptors present on the tumour 
cells 
11
. The current hypothesis is that tumour cells interact with and 
transmigrate across the endothelium using mechanisms similar to those that 
mediate leukocyte recruitment during inflammation 
12
. These interactions 
begin with transient adhesion which is, followed rapidly by firm adhesion of 
tumour cells to the endothelium and finally transmigration of the tumour cells 
from the luminal surface into the sub-endothelial tissue. There are different 
classes of adhesion molecules which might mediate these adhesive 
interactions: namely the selectins, cadherins, members of the immunoglobulin 






Apart from adhesion molecules, there are also binding sites for activators such 
as interleukin-1 (IL-1) and tumour necrosis factor-α (TNF-α) 14. These 
cytokine activators could be present in the microenvironment due to the host’s 
local inflammatory response or may be released by the cancer cells themselves. 
They can initiate the synthesis/expression/activation of adhesion molecules 
(e.g. E-selectin) that are either absent or of low expression on unstimulated 
endothelium. In addition, the adhesion of the tumour cells may also involve 
host immune cells such as the platelets and neutrophils 
15
. Platelets and 
neutrophils could act as a bridge between the tumour cells and the 
endothelium by bringing these cells into closer proximity of each other. 
Platelets that are attached to the tumour cells can adhere to the endothelium 
16
 
while β2 integrin expressed on neutrophils can bind to the intercellular cell 




1.2.1 E-selectins and Immunoglobulin superfamily  
The first step in the recruitment of the leukocytes is the transient adhesion of 
the leukocytes that results in rolling of the leukocytes on the endothelium. 
This step is mediated by selectins. The selectin family comprises L-, P- and E-
selectin. E-selectin is found on endothelial cells, and P-selectin is found on 
both platelets and endothelial cells. L-selectin is expressed constitutively on 
leukocytes including neutrophils, monocytes and eosinophils 
4
. Selectin-
mediated rolling allows chemokine receptors as well as integrins expressed on 
the leukocyte to come into close contact with their respective endothelial 
cognate ligands, leading to the initial transient adhesion and eventual firm 
arrest on the endothelium. Expression of P-selectin and E-selectin can be 
5 
 
inducible. P-selectin inducing agents include thrombin, histamine complement 
fragments, oxygen-derived free radicals and cytokines. Expression of P-
selectin is very short-lived. E-selectin production is strongly and rapidly 
induced by IL-1β, TNF-α, interferon-γ (IFN-γ) and lipopolysaccharide (LPS) 
18
. Upon TNF-αactivation, E-selectin expression on lung endothelial cells 
peaks at 4-6 hours and remained higher than basal level even after 24 hours 
19
. 
Selectins bind to carbohydrate moieties such as sialyl Lewis presented on a 




Another family of adhesion molecule that is involved in leukocyte adhesion 
and transmigration is the endothelial immunoglobulin superfamily (IgSF). The 
IgSF members includes ICAM-1, vascular endothelial cell adhesion molecule-
1 (VCAM-1) and platelet endothelial cell adhesion molecule-1 (PECAM-1). 
ICAM-1 expression level on endothelium is low and is up-regulated during 
inflammation 
21,22
. LFA-1 (integrin αLβ2) is the ligand for ICAM-1 that 
mediates the adhesion of leukocytes that are rolling on the endothelium and 
the subsequent transmigration 
23
. As for VCAM-1, it is absent on resting 
endothelium but is up-regulated during inflammation 
22
. Both integrins α4β1 
and α4β7 on leukocytes are ligands for VCAM-1 24. Integrin α4β1 has higher 
affinity for VCAM-1 compared to integrin α4β7 25 and the binding to VCAM-
1 supports the adhesion of leukocytes to activated endothelium 
26
. VCAM-1 is 
also found to be involved in mediating transmigration of monocytes and 
eosinophils across activated endothelium 
27,28
. PECAM-1, also known as 
CD31, is concentrated in the endothelial cell-cell junction and is known as a 
signature marker of the endothelial cell 
29
. PECAM-1 is involved in 
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transmigration of monocytes and neutrophils across normal resting 




1.2.2 Integrins  
Integrins form an extensive family of adhesion molecules which consist of 18 
α-subunits and 8 β-subunits. Integrins are heterodimers that are made up of an 
α-subunit and a β-subunit. To date, at least 24 integrin heterodimers have been 
identified (Fig 1.1) 
32,33
. Integrins are responsible for cell-cell and cell-
substrate interactions. They bind to a wide variety of ligands which includes 
extra-cellular matrix (ECM) materials (i.e. fibronectin, laminin, vitronectin, 
collagen, fibrillin) 
34-38
, plasma proteins (i.e. fibrinogen, thrombospondin)
39,40
 
and other adhesion molecules (i.e. VCAM-1, ICAM, PECAM-1, Ecadherin) 
41-43
 (Fig 1.2). Integrins bind to these ligands via different binding regions on 
the ligands such as the RGD motif and LDV motif, 
44
 (Fig 1.2). All five αV 
integrins, integrins α5β1, α8β1 and αIIbβ3 recognise the RGD region. 
Examples of the ligands are fibronectin, fibrillin and vitronectin. Integrins that 
recognise the LDV motif are the β2 integrins, integrins α4β1, α4β7, α9β1 and 
αEβ7. Examples of ligands containing LDV motif are ICAM-1, VCAM-1, 
MadCAM-1 and fibronectin.  Other ligands, such as collagen and laminin are 
known to bind to α1, α2, α10 and α11 subunits of β1 integrin family that 
contain the αA-domain. Laminin is also found to bind to non-αA-domain 




Integrins also function as signalling molecules. When a cell receives a cell-
activating signal, intracellular signalling cascade (inside-out signalling) leads 
to a conformational change in the extracellular portion of the integrin which 
activates the integrin 
47,48
. Following activation and ligand engagement, there 
is transmission of other signals into the cell (outside-in signalling) which 
result in cellular responses such as cell survival, proliferation, differentiation, 




Figure 1.1 Integrins family: Integrins are heterodimers that consist of an α-
subunit and a β-subunit. There are 18 α-subunits (in brown) and 8 β-subunits 
(in green) in the integrin family. The respective partners of the α- and β-
subunits are connected or joint together. Currently, these are the 24 integrins 
heterodimers that have been identified.  
32
. 
(Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews, 







Figure 1.2 Integrins and their 
ligands: Integrins bind to a wide 
variety of ligands. Some of the 
ligands are ECM, such as 
fibronectin, collagen, laminin, 
vitronectin, fibrillin and tenascin. 
Some of the ligands are plasma 
proteins, such as fibrinogen, 
thrombospondin and von 
willebrand factor. Other cellular 
adhesion molecules such as 
VCAM-1, ICAM, E-cadherin and 
PECAM-1 (CD31), expressed on 
cellular membranes are also 
ligands of integrins 
44
.   
(Reprinted by permission from 
Company of Biologist Ltd: Journal 
of cell science, 119, 3901-3903 




1.2.3 E-selectins and Immunoglobulin superfamily in cancer 
Several studies showed that cancer cells utilized the state of inflammation and 
interaction with selectins to facilitate their extravasation. Interactions between 
E-selectin and its ligands on tumour cells play a role in metastasis 
53,54
. 
Malignant transformation of tumour cells can lead to aberrant glycosylation 
53
 
resulting in expression of sialylated, fucosylated and/or sulphated 
oligosaccharides determinants, which may serve as E-selectin ligands 
4
. E-
selectin mediated interactions are involved in the rolling of prostate tumour 
cells on bone endothelium 
55
, interactions of breast and colon cancer cells with 
activated endothelium 
56
 and metastases of colon carcinoma cells to the liver 
57
. 
Furthermore, E-selectin is up-regulated on the endothelium within the primary 
lesion in invasive breast cancer 
58
 and metastatic lesion in colorectal cancer 
59
. 
Taken together, these studies indicated that E-selectin expression on the 
endothelium might be involved in cancer metastasis.  
 
The initial interaction between E-selectin and its ligand on tumour cells alone 
is not sufficient for metastatic progression. Similar to leukocyte recruitment, 
firm adhesion of tumour cells to ‘lock’ the transient adhesive bonds is 
essential to prevent the subsequent release back into the circulation due to the 
shear force of blood flow 
60
. Studies suggested that ICAM-1 and VCAM-1 
also mediate firm adhesion of tumour cells during the process of metastasis 
61
. 
Integrin αLβ2 and mucin 1 (MUC1) can bind to ICAM-1 to mediate breast 
cancer cells adhesion 
62,63
. Similarly, integrin α4β1 interacts with VCAM-1 to 
mediate adhesion of renal cancer cells 
64
 and melanoma cells 
65
 to endothelium.  
10 
 
1.2.4 Integrins in cancer 
Due to the signalling effects, integrins have critical roles in cancer progression. 
Integrins expressed on tumour cells allow them to attach to ECM and to 
adjacent cells, thus promoting survival, angiogenesis, migration and invasion 
66-70
. Adhesion via integrins will trigger intracellular signalling as integrins 
mediate the activation of focal adhesion kinase (FAK), which, in turn will 
activate downstream survival signals through the phosphatidylinositol-3 
kinase (PI3K) pathway, and the mitogen-activated protein kinase (MAPK) 
pathway 
71
. Other than survival, activation of FAK in response to TGF-β 





Expression of some integrins, especially members of the β1 subfamily, has 
also been shown to be up-regulated in metastatic tumour cells leading to 
enhanced invasiveness and mediating extravasation 
74,75
. Integrins of the β3 
and β4 subfamilies have also been implicated in cancer progression. Integrin 
αvβ3 is known to regulate cell survival 76,  and is associated with lymph node 
metastasis in melanoma 
77,78
, pancreatic cancer 
79
; and with bone metastasis in 
breast 
80,81
 and prostate cancers 
82
. Similarly, α6β4 expression in breast cancer 
could be correlated to increase in tumour size and reduced survival 
83,84
. 
Function blocking studies have also supported the important role of integrins 
(and their respective receptors) in tumour cell adhesion and metastasis. For 
example, blockade of α6- 85,86, αv- 87,88 and β1- 89,90 subunits with monoclonal 
antibodies inhibited adhesion of tumour cells to the endothelium or/and 
tumour invasion into the tissue.  
11 
 
1.3 Extravasation of tumour cells 
Extravasation is the exit of cells from vascular circulation into the tissue. 
Among all the steps that lead to metastasis, extravasation of the tumour cells 
has been described as the rate-limiting step 
60
. Leukocyte extravasation during 
inflammation provides insights to the mechanisms employed by tumour cells 
to extravasate at target organs 
91
. Tumour extravasation can be affected by 
different cell adhesion molecules expressed on the tumour cells and target 
tissues; chemokines in the organ microenvironment produced by the tumour 
cells, stromal cells or host response; and cell clustering as well as local 
inflammatory response to the tumour cells due to microvessel obstruction or 
host immunity 
12,15
. As shown in figure 1.3, the process of extravasation itself 
is a series of interrelated steps involving multiple cell-cell and cell-matrix 
interactions 
12,15,92
. The early adhesion of the tumour cells can be mediated by 
endothelial E-selectin and tumour sialyl Lewis a (sLea) or sLex and CD44. 
The subsequent stable adhesion is mediated by tumour integrins. Following 
the adhesion and arrest on the endothelium, the tumour cells have to 
transmigrate across the endothelium and the underlying basement membrane 
in order to reach the interstitium 
4,12,93
. Cell division control protein 42 
(CDC42) and RAC1 expression in tumour cells have been shown to enable 
tumour cells to extend pseudopodia when adhered on endothelium which 







Figure 1.3 Tumour cells extravasate the vasculature to enter the 
secondary organ: This process consists of several sequential steps which 
require the contribution of chemokines in the microenvironment and the 




((Reprinted by permission from Macmillan Publishers Ltd: Nat Rev Cancer 13, 
858-70 (2013), copyright 2013) 
 
1.3.1 Endothelium disruption by tumour cells 
Leukocytes can transmigrate across the endothelium in two ways, via the 
paracellular route or transcellular route. Leukocytes would often seek out the 
endothelial cell junctions to extravasate using the paracellular route. It has 
been shown that the passage of leukocytes through the tight junctions and 
adherent junctions of the endothelium involves the engagement of junctional 
adhesion molecules, such as JAMs (JAM-A to -C)
 
and PECAM-1(CD31) on 
the endothelium 
97,98
. Transcellular route involves the leukocytes 
transmigrating through the endothelial cells which required the interactions 
ICAM-1 
99-101




It has been proposed that tumour cells also transmigrate across the 
endothelium via the same methods as leukocytes. However, the adherence and 
transmigration of tumour cells to and across the endothelium can induce 
changes to the endothelium such as endothelial retraction, morphological 
changes and sometimes apoptosis or necrosis 
12
. This could be due to the size 
of the tumour cells, leading to the difficulty in squeezing through the 
endothelium without damaging it. The mechanism leading to endothelium 
retraction is unclear and it has long been suggested that tumour cell adhesion 
disrupts endothelial junctions by secreting  factors, such as VEGF, which 
cause the endothelial cells to retract; thus exposing the underlying basement 
membrane 
11
. Whether the retraction of endothelium is reversible or 
irreversible is still controversial. While retraction of endothelium is reversible 
following the transmigration of melanoma cells 
102
, the endothelium was 
permanently impaired following either breast adenocarcinoma 
103
 or bladder 
carcinoma cell transmigration 
92
. Using real-time visualization techniques, 
Heyder et al showed that after the complete transmigration of bladder tumour 




Several mechanisms have been suggested to explain the fate of the 
endothelium after tumour cell adhesion and invasion. The irreversible damage 
could be due to loss of cell-cell contact resulting in the induction of apoptosis 
in endothelial cells 
93
. The tumour cells could also release factors such as lipid, 
12 (S) hydroxyeicosatetraenoic acid to induce endothelial retraction and 
promote tumour adhesion to the basement membrane 
104,105
. Vascular 
endothelial growth factor (VEGF) is also shown to compromise the 
14 
 
endothelial layer integrity resulting in retraction and increased permeability 
106,107
. To successfully enter an organ site, the tumour cells have to transverse 
the endothelium and the basement membrane into the underlying tissue. 
Therefore, matrix metalloproteinases (MMPs) may play a role in mediating 
the transmigration of tumour cells 
108
 by degrading the basement membrane 
and extracellular matrix. MMPs could also disrupt the integrity of the 
endothelium 
109
. Degradation of the underlying basement membrane might 
result in the loss of endothelial cell-to-matrix and intracellular contacts, thus 
disrupting the endothelial junctions.  
 
1.3.2 Matrix metalloproteinases  
MMPs are proteolytic enzymes that are responsible for degradation of ECM 
and other non-matrix proteins 
110
. To date, 23 MMPs have been identified in 
humans and they are categorised into eight classes according to their structure. 
Five classes of MMPs are secreted and three others are membrane-type MMPs 
(MT-MMPs) 
111
. Secreted MMPs consist of three collagenases (MMP-1, 
MMP-8, MMP-13), three stromelysins (MMP-3, MMP-10, MMP-11), two 
matrilysins (MMP-7 and MMP-26), two gelatinases (MMP-2, MMP-9), one 
each for metalloelastase (MMP-12), enamelysin (MMP-20), epilysin (MMP-
28) and enzymes for other substrates (MMP-19, MMP-21, MMP-27). MT-
MMPs are localized to the membranes. There are 6 types of MT-MMPs 
(MMP-14, MMP-15, MMP-16, MMP-17, MMP-24, MMP-25) 
111
.  Other than 
ECM components, MMPs also act on other substrates such as cell-membrane-
bound precursor forms of growth factors (i.e. transforming growth factor alpha 
and beta, TGF-α and TGF-β) 112,113, growth-factor receptors (i.e. fibroblast-
15 
 
growth-factor receptor, FGFR, epidermal-growth-factor receptor, EGFR) 
114,115
, adhesion molecules (i.e. E-cadherin, CD44, αv integrin)116-118. 
 
MMPs are synthesized as inactive zymogens (pro-MMPs) which require 
proteinase cleavage to be activated. The cleavage between the cysteine-
sulphydryl group in the pro-peptide domain and the zinc ion bound at the 
catalytic site activates the MMPs. Most of the activation happens extracellular. 
Pro-MMPs can be activated by other MMPs such as MT-MMPs 
119
 or be 
activated upon engagement with its ligand or substrate 
120
. MMPs activity is 
also controlled by endogenous inhibitors such as α2-macroglobulin, tissue 
inhibitors of metalloproteinases (TIMPs), small molecules with TIMP-like 
domain and membrane-bound inhibitor RECK (reversion-inducing cysteine-




Under physiological conditions, MMPs activities are controlled for tissue 
homeostasis. The expression and activity of MMPs are regulated at different 
level, such as transcription, mRNA stability, translation efficiency, enzyme 
compartmentalization, zymogen activation, secretory, activity inhibition by 
TIMPs and cellular uptake 
110,121
. The controlled activity of MMPs is required 
for many biological processes such as embryonic development, organ 
morphogenesis, ovulation, endometrial cycling, hair follicle cycling, bone 
remodelling, wound healing and angiogenesis 
110,126
. However, dysregulation 






1.3.3 Matrix metalloproteinases in cancer 
MMPs play a role in cancer metastasis as they act by degrading extra cellular 
matrix and basement membrane to facilitate tumour cell invasion 
108
. In 
addition, degradation of ECM components by MMPs will also affect cellular 
signalling and functions as cells have adhesion receptors (i.e. integrins) for 
ECM components 
127
. Presence or elevated levels of MMPs in the tumour cells 
have been associated with metastasis of various cancer types. For example, 
overexpression of MMP7 contributes to liver metastases in colorectal cancer 
128




As mentioned earlier, MMPs can release growth factors and active proteins by 
acting on cell membrane-bound molecules. Studies have shown that several 
pro-angiogenic factors such as VEGF, FGF and TGF-β are induced or 
activated by MMPs to trigger the angiogenic switch, and facilitate 
neovascularization at the primary and distant tumour sites 
130,131
. MMPs can 
also help the tumour cells in evading the host immune response. Tumour-
derived MMP-9 cleaves IL-2 receptor alpha and disrupt the IL-2 signalling. 
This decreases the proliferation of CD8
+
 T cells and possibly facilitates 
tumour immunoescape 
132
. MMP-1, MMP-3, MMP-7, MMP-8 and MMP-11 
are able to cleave the α1-proteinase inhibitor (αPI) to release a carboxyl 
terminal fragment (αPI-C) 133. Ka and colleagues showed that MMP-11 
contributed to the generation of αPI-C in the pericellular microenvironment 
which decreases the sensitivity of natural killer cells towards tumour cells and 





1.4 Tumour microenvironment 
Tumour cells are not the sole participant in this complex process of cancer 
progression. The dynamic interactions between the tumour cells and other cell 
types present in the tissue are essential to drive tumourigenesis and tumour 
progression. Tumour cells are known to actively recruit a variety of cells, 
including fibroblast/myofibroblasts, adipocytes, endothelial cells, pericytes 
and immune cells into the lesion (Fig 1.4); and exploit them to induce a pro-
tumour microenvironment which promotes tumour cell survival, proliferation, 
angiogenesis, invasion and ultimately metastasis 
135-138
. 
Figure 1.4 The primary tumour microenvironment: In the primary tumour, 
tumour cells are surrounded by numerous stromal cells such as endothelial 
cells, fibroblasts, lymphocytes, bone marrow derived cells (BMDC) such as 
macrophages, myeloid derived suppressor cells (MDSC), mesenchymal stem 
cells (MSC) and TIE2 expressing monocytes (TEM) 
135
. 
((Reprinted by permission from Macmillan Publishers Ltd: Nat Rev Cancer 9, 
239-52 (2009), copyright 2009) 
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1.4.1 Inflammation and cancer 
Two pathways, extrinsic and intrinsic, linked inflammation and cancer. First, 
in the extrinsic pathway, inflammatory conditions in the body, as a 
consequence of disease or chronic infection, can increase the risk of cancer 
development 
139
. For instance, the presence of inflammatory bowel diseases 
such as ulcerative colitis and Crohn’s disease increases the risk for colorectal 
cancer by 10 folds 
140
, chronic hepatitis due to Hepatitis B or C viral infection 
predisposes the patient to hepatocellular carcinoma 
141
 and chronic asthma 
increases the risk for lung cancer 
142
.  The intrinsic pathway refers to the 
formation of an inflammatory microenvironment due to immune cells (i.e. 
leukocytes and macrophages) recruitment and release of inflammatory 
cytokines (i.e. TNF-α and IL-6) in response to genetic alterations within the 
would-be-tumour cells such as the activation of oncogenes or the mutation of 
tumour suppressor genes 
139
. For example, the overexpression of transcription 
factor Myc in pancreatic islet tumour cells results in uncontrolled proliferation 





In both pathways, the recruitment of inflammatory cells and secretion of 
inflammatory cytokines initiate the inflammation cascade. To prevent 
prolonged inflammation response in the tissue, resolution must take place 
leading to clearance of inflammatory cells by apoptosis and phagocytosis of 
apoptotic cells. However, the presence the persistent stimulus together with 
possible impaired clearance of inflammatory cells will give rise to chronic 
inflammation 
144
. In the chronic inflammatory microenvironment, activated 
19 
 
macrophages and other leukocytes release growth factors, cytokines and 
reactive oxygen and nitrogen species will cause massive structural and genetic 
damages including DNA breakage and mutations 
145,146
. Together, the constant 
tissue damage, excessive amount of pro-inflammatory cytokines and growth 
factors driving accelerated cell proliferation and defective repair in genetic 





The infiltration of immune cells into the lesion was first thought to repress 
tumour growth as the presence of T cells in the tumour was associated with 
better survival in some cases 
144,148,149
. However, there are increasing evidence 
that the inflammatory cells also act as tumour promoters 
146
. In immune 
surveillance, tumour cells are deemed as foreign cells and are destroyed by 




 T helper (Th) 1 T cells, M1 
macrophages and natural killer (NK) cells. However, some tumour cells were 
able to escape destruction by “immunoediting” to activate the anti-
inflammatory regulatory T cells (Treg), CD4
+





The tumour-suppressive or tumour-promoting properties of the immune cell 
infiltrate are dependent on the combination of stimuli present in the 
microenvironment. Presence of cytokines such as IL-4, IL-23 and TGFβ can 
differentiate naïve CD4
+
 T cells into CD4
+
 Th2 T cells, CD4
+












 Th1 T cells 
151-153
 and NK cells 
154
 
resulting in tumour cell survival and proliferation. Therefore, the presence of 
CD4
+
 Th2 T cells and CD4
+




One important cell type in the tumour microenvironment is the macrophage, 
which may constitute up to 50% of the tumour mass in some lesions. These 
are termed tumour-associated macrophages (TAMs) and are generally 
accepted to be of M2 phenotype. The presence of CD4
+
 Th2 T cells and CD4
+
 
Treg help to polarize recruited monocytes into M2 macrophages by secreting 
IL-4, IL-13, IL-10 and TGFβ 165,166. TAMs promote tumour cell survival by 
creating an immunosuppressive microenvironment. TAMs secrete IL-10 that 
is able to drive the differentiation of monocytes to macrophages instead of 
dendritic cells 
167
. TAMs also secrete chemokines such as CCL17 and CCL22 
that can attract CD4
+




. Together, TAMs, Th2 T 
cells and Treg act in concert to create an immune-suppressive 
microenvironment that favours the tumour cells. TAMs also play a role in 





. TAMs can increase microvessel density by secreting pro-
angiogenic factors such as VEGF, FGF, platelet-derived growth factors 
(PDGF) and TGFβ 170,171. Lastly, TAMs are also involved in the dissemination 
of the tumour cells to distant organs by producing inflammatory cytokines 
such as TNF-α and IL-1β 172,173. As major producers of MMPs, TAMs can 






The inflammatory cells present in the microenvironment secrete inflammatory 
factors that orchestrate cancer progression and direct metastasis. Two key 
cytokines present in the microenvironment that mediate both the intrinsic and 
extrinsic pathways are TNF-α and IL-6 144. Both have been shown to promote 
different stages of cancer progression such as tumour cell proliferation, 




1.4.2 Tumour Necrosis Factor-alpha (TNF-α) and its role in cancer 
TNF ligand superfamily consists of 27 known ligands that share the same TNF 
homology domain. They are type II transmembrane proteins and some can be 
secreted as soluble ligand after the proteolytic cleavage of the extracellular 
domain 
177
. TNF ligands carried out their biological functions by binding to 
and activating the members of the TNF receptor (TNFR) superfamily. These 
TNFRs are trimeric type I transmembrane proteins characterized by the 
cysteine-rich domains. One of the key members of the TNF ligand superfamily 
is TNF-α which is involved in the maintenance of inflammation and host 
defence. TNF-α is secreted by macrophages, monocytes, mast cells, 
neutrophils, NK cells, T cells, keratinocytes, astrocytes, microglial cells, 
smooth muscles cells and tumour cells 
178,179
. These cells will secrete TNF-α 
upon activation. For example, the activation of macrophages and monocytes 
with LPS increase the TNF-α release by 10 times while NK cells and T cells 
will only release TNF-α when stimulated with IL-2 179. TNF-α is a well-
known pro-inflammatory mediator that is responsible for many biological 





There are two known receptors for TNF-α, TNFRI, which is found on most 
cells, and TNFRII, which is found on haemopoietic cells 
180
. Soluble TNF-α 
binds to both TNFRI and TNFRII. However, TNFRII is the main receptor for 
membrane-associated TNF-α. Upon binding of TNF-α, TNFRI activates the 
IKK complex which activates downstream NFκB signalling. On the other 
hand, TNFRII activates IKK complex and JNK which leads to NFκB and AP-
1 signalling respectively 
181
. The activation of TNFRI and TNFRII results in 
two extreme end points: induction of inflammatory responses; and cell 
survival or apoptosis 
180,181
. The downstream transcription targets of these 
pathways are inflammatory mediators, growth factors, cell cycle regulators 
and negative regulators of apoptosis such as IL-1, IL-6, TNF-α, cyclin D1 and 
B-cell lymphoma 2 (BCL-2) 
175,182
. While the role of TNF-α is to induce 
inflammation, it is able to induce apoptosis. TNF-α-induced apoptosis has 
been shown to be mediated by JNK/AP-1 signalling but is also dependent on 
NFκB activation 181. TNF-α transient activation of JNK is prolonged when 
NFκB signalling is inhibited 183,184. JNK activation results in the cleavage of 
Bid and ensuing translocation into the mitochondria which leads to the release 
of Smac. Smac then dissociate the cIAP1-TRAF2 complex and relieve the 




Dysregulation of TNF-α production is a common occurrence of chronic 
inflammation which increases the rise of cancer. Many studies showed the 
involvement of TNF-α as tumour promoter in cancer progression with AP-1 
and NFκB transcription factors as key molecular links 175,185-187. TNF-α and 




 indicating the genetic evidence between TNF-α induced inflammation 
and cancer. Clinically, TNF-α is often detected in tumour cells and stromal 
cells in several cancers. TNF-α can be produced by the tumour cells in ovarian 
and renal cancer; or the stromal cells in breast cancer 
185,190
. TNF-α can also be 
detected in cancer patients’ serum and is associated with advanced disease and 
poor prognosis 
190,191
. Studies showed that TAM promotes gastric tumour 
development through TNF-α activation of Wnt/beta-catenin signalling 192 and 
the deletion of IKKβ (kinase for NFκB activation) in liver kupffer cells 
resulted in decreased TNF-α production and decreased liver tumour formation 
193
.   
 
The presence of TNF-α, whether derived from cancer cells or stromal cells, is 
also related to metastasis. One key step for enhanced tumour invasion is EMT 
of tumour cells which results in the acquisition of migratory ability. Bates et al. 
showed that the co-culture of tumour cells and macrophages can induce EMT 
due to the presence of macrophage-derived TNF-α 194. In a mouse colon 
adenocarcinoma model, TNF-α production by host haematopoietic cells 
activated NFκB signalling in colon tumour cells resulting in enhanced 
proliferation and survival; and lung metastasis 
195
. TNF-α stimulation of 
endothelial cells is known to up-regulate the expression of E-selectin, ICAM-1 
and VCAM-1 which is responsible for leukocytes recruitment during 
inflammation. Up-regulation of these adhesion molecules following TNF-α 
administration in mice has been shown to mediate lung metastasis in a 
melanoma mouse model 
196
 and a fibrosarcoma mouse model 
197
. TNF-α can 
also induce the production of chemokines which may contribute to the organ 
24 
 
specific metastasis in cancer 
198
. Tumour-derived TNF-α was shown to up-
regulated CXCR4 expression in ovarian cancer cells which facilitated their 
migration towards its ligand CXCL12 
199
. The CXCR4-CXCL12 chemokine 
axis has been shown to direct organ specific metastasis in breast and prostate 
cancer 
200,201
. All these studies suggested that TNF-α stimulation can direct 
secondary growth during cancer progression.  
 
1.4.3 Interleukin-6 (IL-6) and its role in cancer 
IL-6 is an interleukin that acts as both pro-inflammatory and anti-
inflammatory cytokine. IL-6 is essential for the proliferation and survival of 
leukocytes, T cell recruitment; and differentiation of B cell and M1 
macrophages 
202
. IL-6 is also involved in regenerative processes (i.e. liver 
regeneration), regulation of metabolism, formation of osteoclasts for 
maintenance of bone homeostasis and regulation of neural sensory functions 




IL-6 is produced by T cells, endothelial cells, fibroblasts, macrophages and 
epithelial cells 
203
. The active IL-6 receptor (IL-6R) comprises two subunits, 
IL6Rα and IL6Rβ (gycoprotein130 (gp130)). IL-6Rα is mainly expressed on 
hepatocytes and leukocytes. IL6Rα is readily shed via proteolytic cleavage or 
alternate splicing of the IL-6Rα transcript to become soluble IL6Rα in 
circulation. Gp130 is expressed on most cell types 
204,205
. There are two types 
of IL-6 signalling, namely classical signalling and trans-signalling. Classical 
signalling involves the binding of IL-6 to membrane bound IL-6Rα and the 
25 
 
IL6/ IL-6Rα complex will bind in cis to membrane bound gp130 204. Since the 
expression of membrane bound IL-6Rα is restricted to some cells only, IL-6 
signalling via the classical mechanism is limited to only these cell types.  The 
trans-signalling works via the binding of IL-6 to soluble IL-6Rα to form the 
IL-6/ IL-6Rα complex which then in turn binds in trans to membrane bound 
gp130 
205
. Therefore, through circulating soluble IL6Rα and trans-signalling, 
IL-6 signalling is expanded to all gp130-expression cells. Initial low affinity 
binding to IL-6Rα subunit and subsequent association with the signal 
transduction IL-6Rβ subunit activates downstream IL-6 signalling via signal 
transducer and activator of transcription (STAT), PI3K, and MAPK pathways 
203,206
.   
 
IL-6 is secreted by tumour cells and stromal cells such as TAMs, MDSC, 
CD4
+
 T cells and fibroblasts into the tumour microenvironment. The role of 
IL-6 in regulating cell proliferation and survival contributes to cancer 
initiation and progression 
176,207
. Tumour cells can undergo mutations or 
epigenetic changes that confer them the ability to produce IL-6. For example, 
the activation of miRNA Lin28 increases the production of IL-6 in cancer cells 
208
. Tumour-derived IL-6, in addition to prolonging survival through autocrine 
effects, can also influence stromal cells within the lesion to support 
tumourigenesis. IL-6 activates cell proliferation via STAT3 signalling that 
target transcription of cell cycle regulation genes such as cyclin D1 and c-myc 
202,209
. IL6-induced STAT3 signalling also promotes tumour cell survival 
through the expression of anti-apoptotic proteins such as bcl2, bcl-XL and 
survivin 
207,210
. In myeloma cells, IL-6/STAT3 activates DNA (cytosine-5)-
26 
 
methyltransferase 1 which deactivates tumour suppressor gene p53 through 
methylation within the p53 promoter region 
211
. This allows the tumour cells 
to bypass cell cycle checkpoints and evade apoptosis, leading to uncontrolled 
proliferation.  IL-6 is found to suppress the activation or maturation of 
dendritic cells (DC) or inhibit the polarization of monocytes towards the 
macrophage lineage to prevent DC differentiation 
212,213
, which in turn 
prevents the priming of cytotoxic CD8
+
 T cells which is known to kill tumour 
cells.   
 
The pro-tumour effect of IL-6 is not only restricted to promotion of tumour 
growth. The activation of IL-6 signalling in the tumour cells also increases 
tumour invasiveness and cause angiogenesis and metastasis. IL-6 induces the 
expression of VEGF and FGF by cervical tumour cells to support neo-
vascularization that is needed for larger tumour growth and invasion via the 
STAT3 pathway 
214
. The tumour-derived IL-6 can also act on tumour-
associated stromal cells such as the endothelial cells, TAM and MDSC to 
induce the secretion of pro-angiogenic factors to further promote angiogenesis 
within the tumour 
215
. In response to the IL-6, MDSC can also secrete IL-6 and 
release IL-6Rα resulting in a mutual activation loop to maintain the amount of 
IL-6 and IL-6 trans-signalling present in the tumour microenvironment and 
also to facilitate metastasis 
216
. Presence of IL-6 in distant organ sites can lead 
to metastatic outgrowth. For example, IL-6 produced by osteoclasts in the 
bone leads to bone metastasis in breast cancer 
217
. Similarly, IL-6 secretion by 
the bone marrow stromal cells activates osteoclasts to induce a favourable 





Collectively, IL-6 signalling in both tumour cells and stromal cells in the 
microenvironment is pro-tumour due to its effect on tumour proliferation, 
evasion from immune surveillance, survival, angiogenesis, invasion and 
metastasis.  
 
High serum IL-6 concentration is associated with poor prognosis in several 
cancers such as breast, gastric, pancreatic, melanoma, colorectal and lung 
cancer 
219-221
. Furthermore, breast cancer patients that have two or more 
metastatic sites have higher serum IL-6 compared to patients with only one 
metastatic site 
219
. IL-6 level also correlates with the extent of bone metastasis 
and the size of metastases in prostate cancer 
222
. These clinical evidence 
suggest that IL-6 level correlated with the extent of the disease and is 
associated with poor survival in cancer patients. . Serum IL-6 level has also 
been used as predictive marker for therapeutic responses. In a prospective 
study of prostate cancer patients, IL-6 level decreased by 35% in treatment 
responders and increased by 76% in non-responders 
223
.  Currently, there are 
several monoclonal antibodies to IL-6 or IL-6R (i.e. Tocilizumab, Siltuximab, 
C326, AMG-220) in phase I/II trials for prostate cancer, kidney cancer, renal 
cell carcinoma and multiple myeloma treatment 
224-227
. Although these IL-6 
antibodies have shown promising treatment results when used for diseases 
such as rheumatoid arthritis 
227,228
, preliminary results from the clinical trials 







1.4.4 Pre-metastatic niche 
The importance of the tumour microenvironment to the primary tumour 
growth and cancer progression is well established and has been discussed 
above. However, the microenvironment at the secondary sites that permit the 
metastatic tumour cells to colonize and grow is poorly understood. In the last 
decade, it is becoming more evident that primary tumour cells could remotely 
modulate the microenvironment in distant organs to become metastatic sites.  
The pre-metastatic niche refers to a suitably conducive microenvironment in 
the target organ that is favourable for tumour cell engraftment and 
proliferation 
229
. This concept suggests that the primary tumour could dictate 
the precise location of metastasis even before the arrival of the first 
disseminated tumour cell. Tumour secreted factors are the key factor leading 




The importance of pre-metastatic niche in directing metastasis was first 
observed by Kaplan et al. In that study, they observed that tumour secreted 
factors such as VEGF and placental growth factor promoted the recruitment of 
VEGFR1
+
 bone marrow-derived haematopoietic progenitor cells in distant 
organ (lung). The newly arrived haematopoietic progenitor cells secreted 
factors and together with the tumour-derived factors stimulate resident 
fibroblast to up-regulate fibronectin locally to create a pre-metastatic niche for 
incoming tumour cells 
230
. This highlighted that tumour-derived factors and 
the presence of myeloid cells are necessary for the formation of the pre-
metastatic niche within specific organ. Subsequent studies in different tumour 
models in mice have also identified various tumour secreted factors and other 
29 
 
bone marrow derived cells in pre-metastatic niche formation. Hirastuka et al. 
showed that VEGF, TNF-α and TGFβ released by the primary tumour induced 
the expression of inflammatory proteins S100A8 and S100A9 in the distant 
organ (lung) but not in other organ sites (liver and kidney). These 
inflammatory proteins then attracted MAC1
+
 (integrin αM)/CD11b+ myeloid 
cells to the lung and promoted secondary tumour growth 
231
. Another study by 
Kowanetz et al. showed that the secretion of granulocyte-colony stimulating 
factor (G-CSF) by the tumour cells promoted the recruitment of 
Ly6G+/Ly6C+ myeloid cells to the lung but not to the kidneys, resulting in 
lung metastasis 
233
. From these studies, it is evident that while the tumour 
secreted factors may be systemic, the pre-metastatic niche is only formed in 
organs that are commonly known to be sites of metastasis in human cancers, 
such as the lung. Thus, intriguingly, organ-specific metastasis could be driven 
by factors secreted by primary tumour cells. However, it is currently unclear 
whether tumour secreted factors could directly create an immunosuppressive 
or inflammatory microenvironment in the pre-metastatic niche. 
 
The myeloid cells recruited to the distant organ in response to the tumour 
secreted factors contribute to the formation of the pre-metastatic niche by 
producing various chemokines, growth factors, angiogenic factors and 
inflammatory cytokines 
229
. Yan et al. showed that the Gr-1+/CD11b+ 
myeloid cells create an immunosuppressive environment in the pre-metastatic 
niche by inhibiting the production of IFNγ and secreting immunosuppressive 
cytokines such as IL-4, IL-5, IL-9 and IL-10 
234
. The myeloid cells in the pre-
metastatic niche can also suppress the activity of NK cells 
235
. Another study 
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showed that tumour-derived versican activates myeloid cells in the pre-
metastatic niche to produce TNF-α and IL-6 through activation of Toll-like 
receptor 2 and 6 
236
 which may promote metastatic growth of the newly 
arrived tumour cells.   
 
The study of the role of exosomes and microvesicles in cancer progression is 
relatively new, however many studies have revealed the potential of exosomes 
and microvesicles in promoting tumour growth at both the primary and 
secondary sites through immunosuppression 
237,238
. Tumour-derived exosomes 
or microvesicles are also capable of inducing the formation of pre-metastatic 
niche. Exosomes are cell-derived vesicles that originate by direct budding of 
the plasma membrane. They are 30 to 150nm in size and are capable of 
mediating intercellular communication and transfer of content such as 
cytosolic protein, lipids and RNA to recipient cells 
239
. Melanoma cells-
derived exosomes reprogram bone marrow derived progenitor cells to induce 
vascular leakiness at pre-metastatic lung 
240
. In another study, exosomes 
derived from CD44
+
 rat pancreatic adenocarcinoma cells were able to activate 
leukocytes and endothelial cells in pre-metastatic organs (the lung and lymph 
nodes) 
241
. Microvesicles shed from CD105
+
 human renal cancer stem cells, 
which contained pro-angiogenic mRNAs and microRNAs, were able to trigger 
the angiogenic switch and induce VEGFR1 expression on lung endothelial 
cells 
242





During cancer progression, there is inadequate blood supply in solid tumours 
when the tumour grows beyond 1cm
3
 in volume leading to a reduction in 
tissue oxygen tension, a condition known as hypoxia. Hypoxic conditions 
activate a key transcription factor, the hypoxia-inducible factor (HIF), which 
regulates genes that can be exploited by the hypoxic tumour cells for survival, 
angiogenesis and metastasis 
243
. Studies revealed that hypoxia at the primary 
tumour site could induce tumour cells to secrete factors that promote pre-
metastatic niche formation. Hypoxic breast cells orthotopically implanted in 
mice secrete lysyl oxidase (LOX) and LOX-like (LOXL) protein that co-
localised with fibronectin and cross-linked with collagen in the distant lung to 
recruit CD11b
+ 
myeloid cells which are essential for conditioning the milieu of 
the pre-metastatic niche 
244
. Subsequently it was shown that inhibition of HIF-
1 resulted in lower LOX and LOXL expression, a reduction in collagen cross-
linking in the lung; reduced CD11b
+ 
myeloid cells recruitment; and a decrease 
in the number of metastases detected in the lung 
245
. Hypoxic breast tumour 







myeloid cells. In response to the tumour-derived 
CCL2, the natural killer cells in the pre-metastatic niche also have lowered 





Studies in mouse models showed that the formation of the pre-metastatic niche 
starts within 1-2 weeks after the injection of tumour secreted factors 
230,235
. 
These tumour-derived factors comprise pro-angiogenic factors, hypoxia-
dependent factors, inflammatory cytokines, chemokines, ECM remodelling 
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factors, exosomes and microvesicles. This suggests that the formation of the 
pre-metastatic niche in-vivo is dependent on the systemic concentration of 
tumour-derived factors rather than the size of/number of cells in the primary 
tumour itself. It is therefore also probably that pre-metastatic niche formation 
could occur concurrently with the development of the primary lesion. When 
the primary tumour recruits the bone-marrow derived progenitor cells into the 
primary lesion, these cells could also be simultaneously recruited to the 
potential secondary sites to initiate the pre-metastatic niche 
229
. A shown in 
Fig 1.5, in response to tumour-derived factors, bone marrow derived cells at 
the pre-metastatic site would alter the microenvironment via inflammation, 
increase vascular hyperpermeability, ECM remodelling, and the creation of an 
immunosuppressive microenvironment that is conducive to tumour cell 
homing and engraftment 
229
 (Fig 1.5). 
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Figure 1.5 Mechanism of pre-metastatic niche formation: Both the tumour 
and stroma cells contribute to the pro-tumour microenvironment at the primary 
site. The primary tumour cells also secrete factors that drive the formation of 
pre-metastatic niche in distant organs  
229
. 
(Reproduced with kind permission from Springer Science and Business Media: 
Cancer metastasis reviews, 32, 449-464 (2013), copyright 2013) 
 
 
1.4.5 Fibronectin and its role in cancer 
ECM components are vital determinants for growth and cancer progression as 
well. The ECM of a tumour lesion is constantly being remodelled via 2 main 
processes: 1. degradation of the existing ECM due to enzymes such as 
proteases and MMPs and 2. Up-regulation or neo-synthesis of ECM 
components that are not present or at low concentration in normal tissues 
246
. 
One of the key ECM components associated with cancer progression is 
fibronectin and it has been the target for tumour therapy development. Recent 
34 
 





Fibronectin (FN) is an adhesive glycoprotein of high molecular weight and is 
abundant in the body. It is present as an insoluble form in the ECM and as 
soluble form in the plasma 
248
. In normal physiology, FN is mainly involved in 
ECM assembly, vascular remodelling and embryonic cell migration 
249
. Each 
FN monomer is made up of three protein domains, namely the type I, II and III 
domains. These domains contain binding sites for other ECM components (i.e. 
collagen), blood protein (i.e. fibrin), glycosaminoglycans (i.e. heparin) and 
cell adhesion receptors (i.e. integrins) 
250
. Alternate splicing of the pre-mRNA 
FN gene can give rise to 20 variants of human FN 
251
. Two repeats in the type 
III domain namely extra-domain A (EDA) and extra-domain B (EDB) can be 
spliced to be included or excluded, resulting in different FN variants. Another 
repeat known as the type III connecting segment (IIICS) near the C-terminal 
of the molecule may be spliced at several positions and this gives rise to 5 
variants 
252
. In cancer, the splicing pattern of the pre-mRNA FN gene can be 
altered resulting in increased expression of FN isoforms that contains EDA, 
EDB and IIICS sequences. These tumour-modulated FN variants are known as 
oncofetal FN 
253,254
.  The EDB domain is usually absent in adult FN. However, 
it is present in FN during active remodelling at the proliferative phase of blood 
vessels in endometrium and ovaries 
255
. EDB domain is also present during 
angiogenesis in tumour progression 
256
. The accumulation of FN with EDB 





 and squamous cell carcinoma of head and neck 
257
. The 
expression is correlated to poor survival in patients 
257
.    
 
FN is the ligand for several integrins, including α3β1, α4β1, α5β1, αvβ1, αvβ3, 
αvβ5, αvβ6, αIIbβ3 and α4β7. Most of these integrins recognize the Arg-Gly-
Asp (RGD) site on the 10
th
 repeat in the type III domain on the FN molecule 
258. Other than the RGD site, integrin αIIbβ3 also recognizes the PHSRN 
synergy site on the 9
th
 repeat in the type III domain 
259
 while α4β1 and α4β7 




 repeat in the 
type III domain respectively; as well as the LDV and REDV sequences of the 
IIICS region 
260-262. Integrin α5β1 is the major FN receptor on most cells and 
is involved in adhesion, migration, cytoskeleton organization and ECM 
assembly 
263. The binding of integrin α5β1 to FN requires the attachment to 
both RGD site and the PHSRN synergy site for maximum binding affinity 
264
. 
α5β1 can also bind to the 1st-9th repeat in type I and 1st-2nd repeat in type II 
domain 
262
. Depending on the binding site engaged,  interaction between α5β1 




FN is found to be an important component in the pre-metastatic niche. 
Although the source of the FN is still unclear, FN expression is observed 
around the terminal bronchioles and the bronchiolar veins in the pre-metastatic 
lung 
230,244
. Kaplan et al. hypothesized that the FN is deposited by fibroblast in 
response to the secreted factors from both the recruited myeloid cells and the 
primary tumour cells 
230
. In addition, Erler et al. and Deng et al. showed that 
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some of the FN deposited in the pre-metastatic niche is tumour-derived 
244,265
. 
These suggest that the tumour-derived FN is carried along with the other 
tumour-derived factors to the distant organ systemically. It is also possible that 
FN deposition is an early event and it is required for the recruitment of 
myeloid cells during the initiation of the pre-metastatic niche as demonstrated 






1.5 Signalling pathways in cancer 
The cell receives information from binding of many different soluble factors; 
and through cell-cell and cell-ECM contacts. In response to these stimulants 
and contacts, multiple cellular signalling pathways in the cell are activated to 
regulate diverse processes such as cell proliferation, motility, survival, 
differentiation and protein synthesis. In cancer, the tumour cells are 
genetically unstable resulting in aberrant signalling that either can activate or 
suppress cellular functions to promote tumourigenesis. These activated 
signalling can result in unlimited proliferation in the absence of growth factor, 
evade apoptosis and senescence, increase motility through EMT, activate 






1.5.1 JNK/cJUN signalling and its role in cancer 
JNK proteins are part of the MAPK family. JNK signalling is primarily 
activated by cytokines and environmental stress 
266
. JNK family is encoded by 
three genes, namely JNK1, JNK2 and JNK3. Alternate splicing of these three 
genes gives rise to 10 different JNK isoforms 
267
. JNK1 and JNK2 are 
expressed in all cells while JNK3 is only expressed in the brain, heart and 
testis 
268
. JNK is activated by the upstream kinases MKK4 and MKK7 
269
. One 
major target of JNK is transcription factor AP-1, which is composed of 
members from the JUN, FOS, activating transcription factor (ATF) and 
musculoaponeurotic fibrosarcoma (MAF) families 
270
. JNK regulates AP-1 
transcription activity by phosphorylation of c-JUN and ATF2 
269
. AP-1 
complex, which is formed from the dimerization of the different members in 
varied combinations, regulates a wide array of genes involved in proliferation, 
apoptosis and differentiation 
182,271,272
. JNK signalling regulates the apoptosis 
of neuron via the activation of AP-1 as well as Bcl-2 and the release of 
cytochrome c 
273
. Activation of JNK also regulates proliferation in fibroblast 





One hallmark of cancer is the uncontrolled proliferation of the malignant cells. 
JNK/c-JUN signalling pathway regulates the cell cycle progression as c-JUN 
containing AP-1 complex activates the transcription of cell-cycle regulator 
genes such as cyclin D1 and represses tumour suppressor p53 and p16INK4A 
275-277
. c-JUN is known to be an oncoprotein that is able to transform cells in-





. JNK/c-JUN pathway represses tumour-suppressor p53 
expression and leads to accelerated cell proliferation and thus tumour 




c-JUN has been shown to be both pro-apoptotic and anti-apoptotic. c-JUN 
regulates the expression of pro-apoptotic BCL2 family member, Bim, 
282
 and 
also the transcription of Fas ligand which can trigger apoptosis 
283
. To inhibit 
apoptosis, c-JUN represses p53 or induces BCL3 
284
. In chronic myeloid 
leukemia, BCR-ABL protein activates JNK/c-JUN pathway in haematopoietic 
cells which leads to the inhibition of apoptosis 
285
. These studies support the 
notion that activation of c-JUN, which differentially regulates both pro-
apoptotic and anti-apoptotic related genes, can promote apoptosis in some 
tumour types while inducing survival in others. 
 
JNK signalling is critical in regulating various processes in the tumour 
microenvironment that is essential to tumour progression, such as enhancing 
the invasiveness of tumour cells, remodelling of ECM and promoting 
angiogenesis. In a smoke-induced lung cancer study, JNK signalling pathway 
induces TNF-α and IL-6 expression leading to inflammation and subsequent 
tumour formation 
286
. In the tumour stromal, TGFβ secreted by the 
macrophages activates JNK signalling in fibroblast which regulates fibronectin 
expression and contributes towards ECM remodelling 
137
. JNK signalling also 





that are required for ECM remodelling in the tumour microenvironment and 
for subsequent invasion. 
 
Neo-vascularization of the tumour mass is also regulated by JNK/c-JUN 
signalling. Hypoxia induction of VEGF gene expression is regulated by 
JNK/c-JUN signalling 
290
.  Without JNK signalling in endothelial cells, 
VEGF-induced proliferation and migration are suppressed, thus affecting 
angiogenesis 
291
. c-JUN is also involved in the regulation of angiogenic gene 





1.5.2 STAT3 signalling and its role in cancer 
STATs proteins are localised in the cytoplasm as inactive homodimers when 
cells are in an inactivated state. Upon ligand binding, receptor associated 
JAKs (upstream of STAT) becomes activated and recruit specific STATs 
which will dimerise. The activated STAT dimers will translocate into the 
nucleus and bind to specific enhancer elements and regulate transcription of 
STAT-related genes 
293
. STAT3 is a member of the STAT family and was first 
identified as an IL-6 dependent transcription factor 
294
. STAT3 signalling is 
known to be activated by numerous cytokines and factors including members 
of the IL-6 family (IL-6, IL-11, IL-31, LIF, CNTF, CLC/CLF, NP, CT1 and 
OSM), IL-10 family (IL-10, IL-19, IL-20, IL-22, IL-24 and IL-26), G-CSF, 





As STAT3 signalling can be activated by a wide array of soluble factors, it is 
involved in various cellular processes. Knockout studies showed that STAT3 
is essential for early foetal development as STAT3 deficient mice have severe 
developmental defect resulting in early embryonic lethality 
296,297
. STAT3 
signalling is important for development of skin and hair. Deletion of STAT3 
results in hyperplasia of the epidermis (acanthosis), hyperkeratosis and scaling 
298
. The absence of STAT3 inhibits second hair growth in postnatal 




STAT3 activation is required for induction of optimal inflammatory response 
in various inflammatory and immune cells. Commitment and differentiation of 
haematopoietic stem cells to the dendritic cell lineage also requires STAT3 
activation 
300
. G-CSF activation of STAT3 signalling is required for 
granulocytes and neutrophils maturation and mobilization of neutrophils in 
response to G-CSF 
301
. STAT3-deficient T cells have defective proliferation in 
response to IL-2 and IL-6 
302,303
. Similarly, STAT3-deficient macrophages and 




STAT3 is an oncogene and upon activation, signalling could result in cellular 
transformation 
305,306
. In epithelial carcinogenesis, activation of STAT3 
maintained the survival and proliferation of DNA-damaged stem cells and 
ultraviolet (UV)-irradiated keratinocytes resulting in clonal expansion of 
‘damaged’ cells and tumour growth 306,307. STAT3 is constitutively activated 
in tumour cells due to mutations and by environmental stimuli such as 
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carcinogens, stress and infection 
308
. The activation of STAT3 results in the 
transcription of genes that regulate tumour cell proliferation, survival, 
angiogenesis and invasion 
306
. Cytokines and chemokines such as IL-6, IL-1β 
and macrophage colony stimulating factor (MCSF) are implicated in 
orchestrating the pro-tumour inflammatory environment and STAT3 
activation is required for their expression 
139
. The very same mediators are 
essential for STAT3 activation in the tumour cells 
309
. This STAT3 feedfoward 
loop explains the persistent STAT3 signalling in human cancer. For example, 
activation of STAT3 in bone marrow stromal cells regulate the secretion of IL-
6 which, in turn, activates the JAK/STAT3 signalling in myeloma cells 
resulting in tumour cell survival via transcription of anti-apoptotic genes 
310
. 
Many inflammation-induced cancers, including H. pylori-induced gastric 
cancer 
311
 and hepatitis B virus-induced hepatocellular carcinoma 
312
 also 
exhibit STAT3 activation in response to the infection. Together, the activation 
of the intrinsic inflammatory pathway due to genetic mutations in tumour cells 
and the extrinsic inflammatory pathway due to environmental stress such as 
UV and pathogens contribute to tumourigenesis through STAT3 signalling.  
 
STAT3 signalling activation in tumour-associated stromal cells also 
contributes to tumour progression 
215,218,310
. IL-6 secretion by the bone marrow 
stromal cells activates STAT3 in osteoclasts to promote bone metastasis 
218
. 
STAT3 activation in the myeloid cells and stromal cells in distant organ is 
crucial for the formation of a pre-metastatic niche to facilitate metastasis 
265
. 
TAMs in the tumour microenvironment become pro-tumour when STAT3 
signalling is activated. Furthermore, tumour-associated myeloid cells and 
42 
 
TAMs express immunosuppressive factors and angiogenic factors when 
STAT3 signalling pathways are activated 
215,313-315
. STAT3 activation in TAM 
induces the expression of IL-23 which subsequently activates STAT3 in Treg 
leading to IL-10 expression. STAT3 also inhibits IL-12 expression in dendritic 
cells in the tumour microenvironment 
315,316
. Together the up-regulation of IL-




1.6 Breast cancer  
Breast cancer is one of the most common cancers and the leading cause for 
cancer death among women in Singapore 
317
. Despite the success of the 
treatment for primary breast tumour with surgery, radiotherapy, hormonal 
therapy and chemotherapy, mortality associated with breast cancer remains 
high due to the complications of metastasis 
318
. Generally, there are two broad 
categories of breast cancer, namely basal breast cancer and the luminal breast 
cancer 
6
. Basal breast cancer is the more aggressive subtype of breast cancer 
with characteristics of mammary basal cells. These tumour cells often lack the 
expression of oestrogen and progesterone receptors. Tumour cells of the 
luminal breast cancer subtype exhibit characteristics of the differentiated 
normal lumen or mammary gland duct cells 
6
. Breast cancer is also classified 
based on molecular characteristics such as the expression of oestrogen 
receptor (ER), progesterone receptor (PR) and HER-2 protein 
319
. Status of the 
receptor expression contributes to overall survival and disease-free survival. 
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 subtype) have the 
poorest prognosis compared to other types 
320
. There is often a long remission 
period that precedes the detection of the metastases. The more aggressive 
basal breast cancers subtype relapses earlier than the luminal breast cancers 
320
. 
This suggests that the disseminated primary breast tumour cells, which are 
unable to engraft at secondary sites initially, eventually develop the ability to 
colonize under the selective pressure of different organ microenvironments 
321
. 
The common metastatic sites are bone, lung, liver and brain, with bone and 
lung being the most frequent sites 
322
. Breast cancer cells express different 
mediators or surface adhesion molecules that contribute to the preferential 
homing to specific secondary site. Genetic studies showed that up-regulation 
of transcriptional regulator Inhibitor of Differentiation 1, chemokines 
(CXCL1), cell adhesion receptor (VCAM-1) and extracellular proteases 
(MMP1 and 2) contribute to the preferential metastasis to lung 
322
. The 
interactions between the cytokines, chemokines and their respective receptors 
expressed on the breast cancer cells and the subsequent activated signalling 
pathways can also direct the eventual metastatic outcome 
135
. Breast tumour 
cells with higher expression of CXCR4, compared to the non-malignant breast 
cells in uninvolved regions, and its ligand CXCL12 were preferentially found 





1.6.1 Tumour microenvironment and breast cancer progression 
Breast research in the past has focused on the malignant transformation of the 
breast epithelial cells into malignant cells due to the accumulation of genetic 
44 
 
mutations. However, studies focusing on the surrounding stroma have 
revealed the role of the stromal and ECM components in tumour initiation, 
progression and metastasis. Fibroblast, macrophages, T cells, endothelial cells 
and adipose tissues are stromal cells in the tumour microenvironment that 




Cancer-associated fibroblasts (CAFs) increase the activity of 17 beta-estradiol 
dehydrogenase (E2DH) activity which increases the estradiol levels in the 
microenvironment and enhance the growth of ER-positive breast cancer cells 
324
.  In-vitro studies have also shown that, IL-6 secreted by CAFs and mast 
cells enhance migration of MDA-MB-231 cells and induce EMT in MCF-7 
and T47D (ER-positive cells) 
325
. CAFs also secrete chemokines such as 
CXCL12, CCL2 and CCL5 to promote angiogenesis and metastasis in the lung. 
CXCL12 promotes tumour growth and attracts endothelial progenitor cells to 
form vessels in the tumour mass 
326
 while CCL2 attracts CCR2
+
 monocytes 
which facilitate tumour extravasation to form lung metastases 
327
. CCL5 
recruits Treg which also facilitate lung metastasis 
328
. Other than CAFs, TAMs 
also secrete chemokines such as CCL18 that promote invasion and metastasis 
by triggering integrin clustering on the tumour cells to enhance adhesion to 
ECM in breast tumour xenograft model 
329
. Overexpression of MCSF is often 
observed in breast carcinoma and is correlated to enhanced infiltration of 
TAMs in the primary tumour, and increased metastatic potential of the tumour 
cells 
330
. Besides secretion of soluble factors, in-vitro TAMs are reported to 
secrete microvesicles containing oncogenic miRNA such as miR-223, which 





of infiltrating TAMs in breast cancer patients is correlated with angiogenesis, 
poor prognosis, higher tumour grade and decreased survival 
171,332,333
. Stromal 
cells also contribute to tumour resistance to treatment. Hepatocyte growth 
factor secreted by CAFs confers resistance to EGFR tyrosine kinase inhibitor, 
gefitinib, treatment in triple-negative breast cancer 
334
. The tumour 
microenvironment can also protect breast tumour cells from tamoxifen-
induced cell death 
335
. The tumour microenvironment is evidently critical in 




1.7 Aims and objectives 
As outlined in the preceding sections, the tumour microenvironment and the 
stromal cells are vital to metastasis. The concept of modulated distant organ 
microenvironment to become pre-metastatic niche prior to metastasis is 
relatively new and requires further study. While pre-metastatic niche 
formation is accepted to be a process driven by the primary tumour-derived 
factors to promote and direct metastatic growth, the exact mechanism 
underlying the formation and how it affects tumour homing during metastasis 
remain unclear. Though the role of the stromal cells in the primary tumour 
microenvironment is well-studied, the precise role of the different stromal 
cells in the distant organ microenvironment during pre-metastatic niche 




When disseminated tumour cells exit from circulation to enter the interstitium 
of a distant organ, the endothelium is the first barrier that the tumour cells 
would encounter. It is accepted that cancer cells are able to intravasate into the 
vasculature or the lymphatics to be carried to distant sites; however, the 
precise mechanisms by which they extravasate the vasculature is still not well-
defined. The majority of findings in this exciting new area of cancer research 
are derived mainly from mouse models with different cancer types. While 
useful, animal models are complex systems that are unsuitable for step-by-step 
dissection of the diverse cell-cell cross-talks/interactions occurring 
simultaneously within the specific microenvironment of interest. As such, I 
strived to develop a robust in-vitro model using breast cancer cells, endothelial 
cells derived from lung and macrophages to systematically examine the 
interactions between these cells and to elucidate the mechanisms underlying 
the extravasation step that leads to organ-specific metastasis. Data from my 
study will provide an insight to the interactions between tumour and stromal 
cells during pre-metastatic niche formation in-vivo. Breast cancer was chosen 
as the cancer type to be the model in this study as breast cancer is the leading 
cancer among women in Singapore.  
 
The working hypothesis for this study is that disseminated breast tumour 
cells can preferentially interact with the lung endothelium that has been 
primed by primary tumour-conditioned macrophages resulting in 




I aimed to first: 
 investigate whether the breast tumour cells have a preference for lung 
endothelium over endothelial cells isolated from human umbilical cord 
vein and human saphenous vein 
 identify the mechanisms underlying the interactions between the breast 
tumour cells and the lung endothelium  
 
Secondly, due to the importance of the tumour microenvironment and the 
formation of a pre-metastatic niche in facilitating organ-specific metastasis, I 
sought to: 
 examine whether the different soluble factors that is present in the 
microenvironment (listed below) can prime the different types of  
endothelium to enhance tumour interactions.  The soluble factors 
examined were: 
- key inflammatory cytokine, TNF-α  
- breast tumour cells, MDA-MB-231, secreted factors 
- MDA-MB-231-conditioned macrophage secreted factors 
 identify the adhesion molecules that mediate the adhesion of breast 
tumour cells to the lung endothelium under various stimulatory 
conditions.  
 elucidate the activated signalling pathway(s) in the lung endothelium 
that regulate(s) the expression of the adhesion molecule(s) on the 
endothelium that is/are important for binding of breast tumour cells. 
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 identify the factor(s) secreted by the breast tumour-conditioned 
macrophages that could enhance the breast tumour-lung endothelium 
interactions. 
 
Findings from this study will provide novel insights to the modulation of the 
endothelium by the tumour secreted factors to form the pre-metastatic niche. 
This study will also highlight the role of macrophages in the distant organ to 
prime the endothelium on-site and how this can influence the homing of 
disseminated tumour cells. These findings will help us better understand the 
influence of the primary tumour on the stromal cells in the distant organ and 
their role in facilitating organ-specific metastasis. Understanding the pre-
metastatic events and identifying the soluble factors and signalling pathways 










CHAPTER 2: MATERIALS AND METHODS 
2.1 Breast Cells Culture 
Breast carcinoma cell lines, MDA-MB-231 and MCF-7, normal breast 
epithelial cell line, MCF-10A were purchased from ATCC. MDA-MB-231 
and MCF-7 were cultured in RPMI 1640 medium (Gibco) supplemented with 
10% fetal calf serum (FCS) (HyClone, Thermo Scientific), 2mM L-glutamine 
(Gibco), 100 U/ml penicillin and 100μg/ml streptomycin (Gibco). This RPMI 
1640 culture medium is henceforth called R10. MCF-10A was cultured in 
Mammary Epithelial Cell Growth Medium complete (MEGM Complete) 
supplemented with bovine pituitary extract (Clonetics, Lonza). All cells were 
grown in a humidified incubator at 37
o
C in 5% CO2. The cells were passaged 
every 2 days and maintained at optimal cell density recommended by ATCC. 
Hank’s Balanced Salt solution (HBSS) without Ca2+ and Mg2+ (Sigma Aldrich) 
was used for washing adhered cells prior to medium change and cell 
detachment. The concentration of trypsin (Gibco) used is 0.02%. To neutralize 
the trypsin after MDA-MB-231, MCF-7 and MCF-10A cell detachment, 7ml 
of RPMI 1640 medium supplemented with 5% FCS was added.     
 
2.1.1 Preparation of tumour-conditioned media 
MDA-MB-231 cells were plated in R10 at a cell density of 2x10
6
 cells/ml per 
well in a 6 well plate. After 24 hours incubation at 37
o
C in 5% CO2, the 
tumour-conditioned media (CM) was collected after centrifugation and filtered 
through a 0.22µm syringe filter. MDA-MB-231 CM was used immediately for 
subsequent experiments.  
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2.2 Endothelial Cells Culture 
2.2.1 Preparation of gelatin coated dishes 
0.5% gelatin solution was prepared from pre-warmed 2% gelatin solution 
(Sigma Aldrich) with miliQ H20. The coating of dishes was carried out weekly 
in a sterile tissue culture hood. 3ml of 0.5% gelatin solution was used to cover 
the growth area of 100mm dish (Corning Costar) and left for 15 minutes 
before aspiration. The dishes were then left to dry for 4 hours and stored for 
future use.  
 
Similar coating steps were done on 8µm pore size transwell inserts (Corning 
Costar) and 96-well culture plates (Corning Costar) for various experiments. 
In both cases, 50μl of 0.5% gelatin solution was added to the insert or wells. 
The subsequent steps are as described above.  
 
2.2.2 Isolation of Human Umbilical Cord Vein Endothelial cells 
Human umbilical cord vein endothelial cells (HUVEC) were isolated from 
human umbilical cords from consented donors (National University Hospital, 
Singapore). The isolation protocol was adapted and modified from original 
work of Lim et al 
336
. The umbilical cord vein was first cannulated at both 
ends with two-way stopcocks. The vein was flushed with HBSS to remove 
blood clots using a syringe attached to one end of the stopcocks. Next, the vein 
was filled with collagenase (1mg/ml) (Sigma Aldrich). The stopcocks were 
closed at both ends and the vein was placed in an enclosed sterile jar. The jar 
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was then placed in a 37°C water bath for 8 minutes. After that, the umbilical 
cord vein was attached to a 20ml syringe containing 10ml of HBSS at one end, 
and an empty 20ml syringe at the other end. The HBSS was transferred back 
and forth between the syringes for 10-15 times to dislodge the endothelial cell 
layer. The detached endothelial cells in the collagenase/HBSS vein were 
collected and centrifuged at 350 x g for 8 minutes at 4°C. After centrifuging, 
the supernatant was removed. The cell pellet was resuspended in the 
Endothelial Cell Growth Medium-2 (EGM™-2, supplemented with human 
endothelial growth factor, hydrocortisone, Gentamicin/Amphotericin-B, 
vascular endothelial growth factor, basic fibroblast growth factor, R3 insulin-
like growth factor 1, ascorbic acid, heparin and 10% FCS) (Clonetics, LONZA) 
culture media and seeded in a 100mm gelatin-coated culture dish.  
 
On reaching 100% confluence, HUVEC monolayer was washed twice with 
HBSS before being detached with 0.02% trypsin. The trypsin was neutralized 
with M199 wash buffer (M199 media (Gibco) supplemented with 10% FCS 
(Gibco), 25mM Hepes (Sigma Aldrich), 2mM of L-glutamine (Gibco), 
100U/ml of Penicillin and 100μg/ml of Streptomycin (Gibco)) and centrifuged 
at 350 x g for 8 minutes at 4°C. After centrifugation, the supernatant was 
discarded and the pellet was resuspended in EGM-2 media to be re-plated in 
new 100mm gelatin-coated culture dishes at a split ratio of 1:3. For 




2.2.3 Isolation of Saphenous Vein Endothelial Cells (SVEC) 
Saphenous vein were harvested from consented patients undergoing bypass 
surgery (National University Hospital, Singapore). Saphenous Vein 
endothelial cells (SVEC) were isolated from segments of saphenous veins by a 
combination of enzymatic and mechanical technique adapted and modified 




Saphenous vein was flushed with HBBS to remove blood clots and cell debris. 
The vein was then carefully cut open longitudinally with a pair of scissors and 
washed again with PBS to remove the remaining blood and debris. The open 
vein was incubated in 2ml of collagenase (1mg/ml) at 37
o
C for 8 minutes. 
After that, the vein was placed on a sterile petri dish. The exposed luminal 
surface of the vein was gently scraped longitudinally with a 2ml syringe 
plunger. The luminal surface was then flushed with PBS to remove the 
detached cells. The cells mixture was added to the collagenase solution and 
was centrifuged at 350 x g for 8 minutes at 4°C. After centrifuging, the 
supernatant was removed. The cell pellet was resuspended in SVEC complete 
culture medium (M199 media (Gibco) supplemented with 10% human serum 
(Sigma Aldrich), 100U/ml of Penicillin and 100μg/ml of Streptomycin) and 
seeded in a 100mm gelatin-coated culture dish. The medium was changed 
after 24 hours to remove non-adhered cells. Cells were sorted with CD-31 
coated beads as described in section 2.2.4 to purify the endothelial cells 
population when necessary.  
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On reaching 100% confluence, SVEC was trypsinized and split in the same 
manner as HUVEC as described in section 2.2.2. For experiments, SVEC up 
to passage 6 were used.  
 
2.2.4 Isolation of Fetal Lung Endothelial Cells (FLEC) and Adult Lung 
Endothelial Cells (ALEC) 
Fetal lung endothelial cells (FLEC) were isolated from fetal lung from 
consented donors (KK Women's and Children's Hospital, Singapore and 
National University Hospital, Singapore) while adult lung endothelial cells 
(ALEC) were isolated from adult lung from consented pneumothorax patients 
(National University Hospital, Singapore). The isolation protocol was adapted 
and modified from original work of Lim et al 
19
. Sheep anti-mouse-IgG Dynal 
Beads (Gibco) were coated with anti-CD31 monoclonal antibody (0.1mg/ml) 
(BD Pharmingen, BD Bioscience) according to the manufacturer protocol. The 
CD-31 beads were pre-coated, resuspended in phosphate-buffered saline (PBS) 
with 0.1% bovine serum albumin (BSA) and stored at 4
o
C prior to use.  
 
Lung lobes were washed in 20ml of RPMI 1640 medium to remove excess 
blood and visible bronchi were dissected out. The lung lobes were then 
minced finely with scissors and digested in a mixture of enzyme solutions 
from Tumour Dissociation Kit (Miltenyi Biotec) according to the 
manufacturer’s recommendation. The tissues were digested for 7 minutes in a 
37°C waterbath. The digested tissues were then mechanically broken down by 
triturating through a 16G cannula. 20ml of RPMI 1640 medium was added to 
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the digested tissues to stop the digestion. The mixture was filtered through a 
70µm cell strainer (BD Falcon) and centrifuged at 350 x g for 8 minutes at 4°C. 
After centrifuging, the supernatant was removed. The cell pellet was 
resuspended in M199 wash buffer and incubated with CD-31-coated beads 
(1.25µl/ml of cells) at room temperature for 10 minutes on a MACSmix tube 
rotator (Miltenyi Biotec). CD-31-bead-bound cells were retrieved using a 
magnetic separator and washed 3 times with M199 wash buffer. The isolated 
cells were resuspended in EGM-2 (Clonetics, LONZA) culture media and 
seeded in a 100mm gelatin-coated culture dish. After overnight incubation, the 
non-adherent cells were removed and the fresh medium was added. When the 
cells reached 70% confluence, they were detached with 0.02% trypsin to 
generate a single cell suspension. The cells were pelleted and then 
resuspended in M199 wash buffer for second sorting with CD31-beads to 
further purify the endothelial cells population. After sorting, the bead-bound 
cells were resuspended in EGM-2 (Clonetics, LONZA) culture media and re-
plated in new 100mm gelatin-coated culture dishes at a split ratio of 1:2. On 
reaching 100% confluence, FLEC/ALEC was trypsinized and split in the same 
manner as HUVEC as described in section 2.2.2. If further purification is 
required, the sorting process described above will be repeated. The resultant 
FLEC/ALEC cultures were generally pure with 80-90% of the cells showing 
CD-31 expression after 2-3 rounds of CD-31 beads sorting. For experiments, 
FLEC and ALEC up to passage 5 were used. Endothelial cells isolated from 
the fetal lung/adult lung include endothelial cells from the pulmonary artery, 
veins and capillaries. As such, the size of the endothelial cells varies among 
the different donors.  
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2.3 Monocytes, Macrophages, Dendritic Cells and Tumour-conditioned 
Macrophages culture 
2.3.1 Monocytes isolation 
Monocytes were isolated from buffy coats of healthy donors (National 
University Hospital, Singapore). First, buffy coat was diluted 7X with HBSS. 
The mixture was carefully layered over 10ml of Ficoll-Paque (GE Heatlhcare) 
in a 50ml conical tube and centrifuge at 450 x g for 30 minutes at room 
temperature. The PBMC (peripheral blood mononuclear cell) layer at the 
Ficoll-Paque/plasma interface was carefully aspirated to a new 50ml conical 
tube. The PBMC suspension was centrifuged at 350 x g for 8 minutes at 4
o
C. 
After centrifuging, the supernatant was removed. The cell pellet was 
resuspended 10ml of MACS buffer (PBS + 5% BSA + 2mM EDTA) and 
subjected to centrifugation again to wash out the ficoll. The cell number was 
then counted using the trypan blue exclusion method. CD14
+
 monocytes were 
isolated from the PBMC by positive selection using Whole Blood CD14 
microbeads (Miltenyi Biotec) according to manufacturer protocol. CD14 
microbeads were added to the cell suspension in a 1:20 ratio (5μl of 
microbeads to 95μl of MACS buffer for 12x107 PBMC). The mixture was 
mixed well and incubated for 15 minutes at 4
o
C. Next, 20ml MAC buffer was 
added and the mixture was centrifuged at 350 x g for 8 minutes at 4
o
C. After 
centrifuging, the supernatant was removed. Subsequently, the cell pellet was 
resuspended in MACS buffer (2.4x10
7
 PBMC/ml) and applied to LS columns 
(Miltenyi Biotec) attached on a magnetic separator (Miltenyi Biotec). After 
the unlabelled cells had passed through the column, the LS column was 
washed three times with MACS buffer. Column was then removed from the 
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magnetic separator and placed on a 15ml conical tube. 4ml of MACS buffer 
was added to the column and the CD14
+
 labelled cells were flushed out using 
a plunger. The number of CD14
+
 monocytes obtained is approximately 20% of 
the number of PBMC used for the isolation process.  
 
2.3.2 Macrophages and Tumour- conditioned Macrophages 
differentiation 
MCSF-derived Macrophages (MCSF-mϕ) and MDA-MB-231 (tumour)-
conditioned macrophages (MDA-mϕ) were differentiated from peripheral 
blood monocytes. Briefly, CD14+ monocytes was cultured in RPMI 1640 
medium (Gibco) supplemented with 10% human serum (Sigma Aldrich), 
2mM L-glutamine (Gibco), 100 U/ml penicillin and 100μg/ml streptomycin 
(Gibco) and 20ng/ml of recombinant human MCSF (Peprotech) at a density of 
1.2x10
6
 CD14+  monocytes/ml for 4 days. For MCSF-mϕ differentiation, 
additional dose of 20ng/ml MCSF was added and 50% of the medium was 
replaced with fresh medium on day 4. For MDA-mϕ differentiation, 50% of 
the medium was replaced with MDA-MB-231 CM on day 4. On day 8, both 
MCSF-mϕ and MDA-mϕ were harvested using a cell scraper (CellTreat) for 
preparation of respective conditioned media in the same manner as described 
above in section 2.1.1. The conditioned media are designated respectively as 
MCSF-mϕ CM and MDA-mϕ CM. 
 
M1 macrophages (M1-mϕ) were polarized by stimulating MCSF-mϕ on day 7 
overnight with 100ng/ml LPS (Peprotech) and 500U/ml IFN-γ (Peprotech). 
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M2 macrophages (M2-mϕ) were polarized by stimulating MCSF-mϕ on day 7 
overnight with 20ng/ml IL-4 (R&D).  
 
The phenotype of MCSF-mϕ and MDA-mϕ were characterised and compared 
with M1-mϕ, M2-mϕ and DC using flow cytometry as described below in 
section 2.4.  
 
2.3.3 Dendritic cells differentiation 
Dendritic cells (DC) were obtained by culturing CD14
+ 
monocytes in RPMI 
1640 medium (Gibco) supplemented with 10% human serum (Sigma Aldrich), 
2mM L-glutamine (Gibco), 100 U/ml penicillin and 100μg/ml streptomycin 
(Gibco), 50ng/ml of recombinant human granulocyte macrophage colony-





monocytes/ml for 8 days. On day 4, the cells were 
supplemented with an additional dose of GMCSF (50ng/ml) and IL-4 
(50ng/ml) and 50% of the medium was replaced with fresh medium. On day 7, 
100ng/ml LPS and 500U/ml IFN-γ were added to the cells. On day 8, the DC 
were harvested and used for subsequent experiments. DC was characterised 





2.4 Flow cytometry  
Flow cytometric analysis was performed to characterise or examine the 
expression of various markers on the breast cell lines (MDA-MB-231, MCF-7 
and MCF-10A), the endothelial cells, the MCSF-mϕ, MDA-mϕ, M1-mϕ, M2-
mϕ and DC. In general, cells were resuspended in flow cytometry buffer (PBS 
+ 0.1% BSA) to a cell density of 2-5x10
6
 cell/ml. Subsequently, 100µl of the 
cell suspension was aliquot into 5ml polystyrene round bottom tubes (BD 
Bioscience) and incubated with optimally diluted primary antibodies for 30 
minutes at 4°C. Next, cells were washed once with 1ml of flow cytometry 
buffer and pelleted by centrifuging at 350 x g for 8 minutes at 4°C. Then, the 
supernatant was discarded and the cells were incubated with corresponding 
optimally diluted fluorescence-conjugated secondary antibody in the dark for 
30 minutes at 4°C. Next, cells were washed twice as described above; with 
flow cytometry buffer and PBS respectively. Lastly, the cells were fixed with 
350μl of 1% Formalin in PBS and kept in the dark at 4°C until data acquisition 
(within 48 hours). Cell acquisition (at least 10,000 cells per sample) was 
carried out on the FACS Calibur cytometer (Becton Dickinson) and analysed 
using the CellQuest Software (Becton Dickinson).  
 
Antibodies used for flow cytometry analysis were purchased from commercial 
sources. Each new antibody was titrated in the laboratory to determine its 
optimal working concentration which was adhered to throughout the study. 
Table 2.1 below lists the common isotype controls and fluorescence-
conjugated secondary antibody used throughout this project, their sources, 
working concentrations and stock concentration (where available). 
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Table 2.1: Source and working concentration of common antibodies 
for flow cytometry 








Purified MuIgG1 Life 
technologies 
1.0 0.1 
Purified RatIgG1 0.6 3.0 
MuIgG1 – PE  BD Pharmingen 4.0 0.2 

















 2.4.1 Cell surface markers and adhesion molecules expression 
Flow cytometric analysis was performed to examine the expression of cell 
surface markers and adhesion molecules on different endothelial cells (FLEC, 
HUVEC and SVEC) and breast cells (MDA-MB-231 and MCF-7). Confluent 
endothelial monolayer was either stimulated with TNF-α (10ng/ml), MDA-
MB-231 CM, MCSF-mϕ and MDA-mϕ CM or left untreated for 24 hours at 
37°C. After stimulation, endothelial cells were detached from the culture 
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dishes as described in section 2.2.2. The harvested cells were resuspended in 
flow cytometry buffer and staining was carried out as described above.  
 
Table 2.2 below lists the various antibodies used, their sources, final working 
concentrations (where available) and stock concentration. 
Table 2.2: Source and working concentration of cell surface markers 
and adhesion molecules antibodies for flow cytometry 





























































































2.4.2 MCSF-mϕ, MDA-mϕ, M1-mϕ, M2-mϕ and DC characterisation 
Flow cytometric analysis was performed to characterise MCSF-mϕ, MDA-mϕ, 
M1-mϕ, M2-mϕ and DC obtained in section 2.3. The cells were harvested on 
day 8 of differentiation or day 9 after the collection of conditioned media. 
Surface markers were stained as described above. Secretory factors of these 
cells were stained through intra-cytoplasmic staining. Briefly, cells were pre-
treated with Golgi plug (BD bioscience) for six hours before staining 
according to the manufacturer protocol. After six hours, cells were harvested 
and resuspended in Fixation/Permeabilization solution (250μl) (BD 
Biosciences) for 20 minutes at 4°C. Then, the cells were washed twice with 
1X BD Perm/Wash buffer (BD Biosciences) by centrifuging at 350 x g for 8 
minutes at 4°C. After the washing step, the cells were incubated with 
optimally diluted primary antibodies or fluorescent-conjugated antibodies or 
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corresponding isotype controls (Table 2.2) in 50μl of BD Perm/Wash buffer 
for 30 minutes at 4°C. Next, cells were washed twice as described above and 
subsequently incubated with corresponding optimally diluted fluorescence-
conjugated secondary antibody if applicable in 50μl of BD Perm/Wash buffer 
in the dark for 30 minutes at 4°C. After incubation, cells were washed thrice 
as described above; twice with BD Perm/Wash buffer and once with PBS. 
Lastly, the cells were fixed with 350μl of 1% Formalin in PBS and kept in the 
dark at 4°C until the day of data acquisition. Data acquisition and analysis was 
carried out as described previously.    
 
Table 2.3 below lists the various antibodies used, their sources, working 
concentrations and stock concentration (where available). 
Table 2.3: Source and working concentration of cell surface markers 
and cytokines antibodies for flow cytometry 












1:10 dilution NA 
Anti-Human 
CD68-FITC 
Biolegend 2.5 0.025 
Anti-human 
CD80 










Biolegend 5 0.5 
Anti-Human 
CD163 






































2.5 Tumour cell-endothelial cell interaction study 
2.5.1 Tumour cell binding assay  
25% of a confluent 100mm dish of endothelial cells (ECs) was trypsinized and 
seeded onto one gelatin coated 96-well plate. The ECs were maintained in 
culture for 4 days to form a tight confluent monolayer. Confluent EC 
monolayers were either stimulated with TNF-α (10ng/ml), IL6 (10ng/ml), 
MDA-MB-231 CM, MCSF-mϕ CM, MDA-mϕ CM or left untreated for 24 
hours at 37°C prior to the binding assay. Tumour cells (MDA-MB-231 and 
MCF-7) were detached using pre-warmed cell dissociation buffer (Sigma 
Aldrich) after washing twice with HBSS. The cells were pelleted down, 
supernatant discarded and resuspended in HBSS to a final concentration of 
2x10
6
 cells/ml. Tracker Dye Orange (TDO, 10mM) (Molecular Probes) was 
added to the cell suspension (1μl per ml of cell suspension) which was then 
incubated for 30 minutes at 37
o
C with vortexing at 5 minutes interval during 
the incubation period. Excess TDO was washed off by centrifuging at 350 x g 
for 8 minutes and cells were resuspended in TBA buffer (RPMI supplemented 
with 1% FCS) to a cell density of 0.5x10
5
 cells/ml. The culture medium in the 
96-well plate were discarded (without washing) prior to the addition of the 
TDO labelled cells 100μl per well in triplicate wells for each condition. Plate 
was incubated at 37
o
C and the tumour cell-EC interactions were allowed to 
take place for 2 hours. At the end of the incubation, the cell suspension in 
wells was discarded. The wells were filled to the brim with TBA buffer, sealed 
and inverted for 10 minutes to allow the unbound cells to settle before the 
unbound cell suspension in wells were discarded. The wash with TBA buffer 
was repeated twice for 5 minutes per wash. Finally, TBA buffer (100μl) was 
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added to each well and cell fluorescence was acquired at excitation 
wavelength 535nm and emission wavelength 595nm using Tecan 
SPECTRAFluor Plus. Number of bound cells was calculated by comparing the 
fluorescence intensity per well against a fluorescent intensity standard curve. 
Standard curve was generated using respective TDO labelled MDA-MB-231 
and MCF-7 cells. The highest cell density used was 3x10
4
 cells/ 100μl/well 
which was serially diluted 1:2 in subsequent wells. Cell numbers in the 




For function blocking assays, either the FLEC monolayers or the tumour cells 
were treated with function blocking antibodies prior to use. To block the 
function of adhesion molecules expressed on FLEC and tumour cells surface, 
the panel of adhesion molecules antibodies at their respective working 
concentration stated in table 2.3 were added to FLEC monolayer in respective 
wells or tumour cells and incubated for 30 minutes at 37
o
C. TDO cells were 
then added to each well following the procedures as mentioned above. The 
binding interactions after function blocking were compared with the 
interaction of the untreated control. Treatment with anti-MHC class 1 (W6/32) 
was used as the binding, non-blocking control.  
 
For inhibitors treatments, FLEC monolayer was pre-treated for 4 hours with 
the various inhibitors at their respective working concentration stated in table 
2.5 and an addition dose of the inhibitors was added when FLEC was 
stimulated with the respective stimulations mentioned above for 24hours. The 
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amount of vehicle control, dimethyl sulfoxide (DMSO) used was matched to 
the highest volume of inhibitor used for each experiment.  The binding 
interactions after inhibitor treatments were compared with the interactions of 
the untreated control.  
 
Table 2.4 below lists the inhibitors used, their sources, final working 
concentrations (where available) and stock concentration. 
Table 2.4: Source and working concentration of inhibitors 







80 μM 90.83mM in DMSO 
STAT3 inhibitor, 
WP1066 
Santa Cruz 3µM 10mM in DMSO 
 
2.5.2 Trans-endothelial migration assay  
2-2.5 x10
5
 ECs were seeded on each gelatin coated transwell insert with 
8.0μm pore size membrane and grown for 4 days to form a tight confluent EC 
monolayer. The confluent EC monolayers were subjected to similar 
stimulations as described in section 2.5.1. MDA-MB-231, MCF-7 and MCF-
10A were harvested and 5x10
5
 cells were resuspended in 300μl of EBM-
2/respective culture media (1:1 ratio) and added to insert with EC monolayer 
as shown in Figure 2.1. 700μl of EBM-2/respective culture medium (1:1 ratio) 
was added to the lower chamber. The transwells were incubated at 37°C for 24 
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hours. EC monolayer control was set up to monitor the migration of the 
endothelial cells in the absence of tumour cells. 
 
At the end of the experiment, the upper chamber was flushed with 700μl of 
PBS to wash away unbound cells. The bound cells and the endothelial 
monolayer on the upper surface of the membrane were removed using a cotton 
swab. The migrated cells on the underside of the membrane were fixed with 
cold methanol for 20 minutes and left to air-dry overnight. The migrated cells 
were stained with Giemsa (1:20 dilution in Sorensen’s Phosphate Buffer) for 
30 minutes and subsequently washed with Sorensen’s phosphate buffer. 
Membrane was then carefully cut out and mounted on microscope glass slide 
with DPX mounting medium. Images of the migrated cells from 21 fields 
distributed regularly across the whole membrane surface (as mapped in Figure 
2.2) were captured using Olympus inverted microscope, JVC colour video 
camera TK-C921EG and JVC Digital video recorder VR-509E recording 
system. Total number of migrated cells in the 21 fields was counted.  
 
Figure 2.2: Map of the 21 fields’ 






Figure 2.1: Static transwell 
system used in the trans-
endothelial migration assay.  
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A series of experiments were first carried out to visualize EC that may 
havetransmigrated across the 8.0 μm pore size membrane together with the 
breast cancer cells. To observe if any EC has migrated, inserts without breast 
cancer cells was set up. Similarly, after 24 hours, membranes were cleaned, 
fixed and the underside of the membrane was stained with Giemsa and 
mounted on glass slide as described above. Total number of migrated cells 
from 21 fields was quantified. To visualise whether EC monolayer on the 
membrane remained intact, the underside of membrane was cleaned and 
upperside of membrane was immunostained with anti-CD31 antibody 
followed by goat-anti-mouse IgG conjugated to FITC as described in section 
2.6.1 after 8 hours. The underside of the membrane of another insert with the 
same setup was immunostained in the same manner for visualization of 
transmigrated EC. The stained membrane was then cut out and mounted on 
glass microscope slide with Prolong Gold Plus (Molecular Probes) containing 
DAPI which would enable nuclear visualization. In a different set of set-up 
with breast cells, MDA-MB-231, MCF-7 and MCF-10A were tracker dye 
labelled as described in section 2.5.1 before addition to EC monolayers in the 
transwell inserts. After 24 hours of incubation under standard culture 
conditions, the inserts were washed, cleaned and fixed as described above. 
Membrane was then also mounted with Prolong Gold Plus for nuclear 
visualization. Fluorescence images were captured using Nikon Eclipse 




2.6 Immunofluorescence staining  
2.6.1 Tumour endothelial interactions  
Approximately 2-2.5 x10
5 
EC were seeded on each matrigel coated glass 
coverslip (25mm diameter) and grown for 4 days to form a tight confluent EC 
monolayer. MDA-MB-231, MCF-7 and MCF-10A were harvested and 
labelled with TDO for 45 minutes (for brighter signals) as described in section 
2.5.1. Stained cells were resuspended in EBM-2/respective culture medium 
(1:1 ratio). 2ml of TDO-labelled cell suspension (5x10
4
 cells) were added to 
each coverslip (in a 6-well plate) and incubated at 37°C for 1 hour. Next, the 
coverslip was removed from the cell suspension and dipped into M199 wash 
buffer 5 times to remove unbound cells. The monolayer and bound cells on the 
coverslip were fixed in cold methanol (2ml) for 20 minutes and left to air dry 
for 15 minutes. The cells was then incubated with diluted anti-CD31 antibody 
for 90 minutes at room temperature and subsequently washed by dipping into 
wash buffer 5 times. Next, the cells were incubated with goat anti-Mu IgG-
FITC for 90 minutes at room temperature in the dark. The coverslip was then 
washed twice as described earlier with M199 wash buffer and PBS 
respectively before mounting onto a microscope glass slide with aqueous 
mounting media. The cells were viewed under 20X magnification using an 
inverted fluorescence microscope (Nikon Eclipse TE2000-U). Bound tumour 
cells on the EC monolayer and “holes” in endothelial monolayer created by 
bound cells were counted. At least 200 bound cells per coverslip were counted 
and the percentage of “holes” in the monolayer associated with bound cells 
was determined. Fluorescence images of the EC monolayer and bound cells 
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were captured using Nikon Eclipse TE2000-U and the Metamorph imaging 
software.  
 
2.6.1.1 Matrix Metalloproteinases (MMPs) inhibition 
MDA-MB-231 and FLEC’s MMPs inhibitions were done prior to 
immunofluorescence visualisation of tumour-endothelial interactions and 
trans-endothelial migration assay.  
 
 For visualisation of tumour-endothelial interactions, TDO labelled MDA-
MB-231 and FLEC were treated with broad spectrum MMPs inhibitor 
(GM6001), MMP2/9 inhibitor (SB-3CT) and MMP2 inhibitor (OA-HY) for 
30 minutes at 37
o
C at their respective working concentration stated in table 2.6 
Control cells were treated with vehicle DMSO (1:1000 dilution). Tumour-
endothelial cells interaction assay was then carried out as described above. 
Whereas for trans-endothelial migration assays, MDA-MB-231 and FLEC 
were treated with broad spectrum MMPs inhibitor (GM6001), MMP2/9 
inhibitor (SB-3CT), MMP2 inhibitor (OA-HY), MMP3 inhibitor and MMP8 
inhibitor for 30 minutes at 37
o
C. Fresh inhibitors were added again during the 
trans-endothelial migration assay. The respective working concentration used 
is as stated in table 2.6. For control setup, cells were also treated with vehicle 
DMSO (1:1000 dilution). Transmigration assays were then carried out as 




Inhibitors were purchased from commercial sources. Each inhibitor was 
titrated to determine its optimal working concentration for the assays. The 
source and final working concentration for each inhibitor is as listed in Table 
2.5 below.  
Table 2.5: Source and working concentration of MMPs inhibitors 



























2.6.2 Fibronectin staining 
Approximately 1-1.5 x10
5 
FLEC were seeded on each matrigel coated glass 
coverslip (15mm diameter) and grown for 4 days to form a tight confluent 
FLEC monolayer. After 24 hours stimulation with the different CM as 
described in section 2.5.1, the FLEC monolayer on the coverslip were fixed in 
cold methanol (intra-cytoplasmic staining) or 4% paraformaldehyde (surface 
membrane staining) for 20 minutes and left to air dry for 15 minutes. The cells 
was then incubated with diluted anti-fibronectin antibody (20μg/ml) (Abcam) 
overnight at room temperature and subsequently washed by dipping into wash 
buffer 5 times. Next, the cells were incubated with goat anti-rabbit IgG-FITC 
for 4 hours at room temperature in the dark. The coverslip was then washed in 
wash buffer and then incubated with diluted anti-CD31-PE antibody (1:20 
dilution) (Miltenyi Biotech) overnight at room temperature. The cells were 
washed with wash buffer to remove unbound antibodies, prior to incubation 
with DAPI (10μg/ml) (Santa Cruz) for 15 minutes. This was followed by more 
washing before mounting the coverslips onto a microscope glass slide with 
aqueous mounting media. Fluorescence images of fibronectin were captured 
using Olympus BX43 and the cellSens imaging software (Olympus). The 
fibronectin expression was quantified using ImageJ software.  
 
For inhibitors treatments, FLEC monolayer was treated in the manner as 
described in section 2.5.1. The amount of vehicle controls used was matched 
to the highest volume of inhibitor used for each experiment. For function 
blocking and neutralisation protocols, human recombinant IL6 (10ng/ml) and 
MDA-m  CM were treated with IL6 antibody (3μg/ml) while FLEC 
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monolayer was treated with IL6R antibody (3μg/ml) for 30 minutes at 37oC 
prior to stimulation. After stimulation, immunofluorescence staining of 
fibronectin was carried out as described above.   
 
2.7 Western blot 
Mechanistic study was carried out using Western blotting analysis. CM-
stimulated FLECs were harvested as described in section 2.2.4. Protein lysate 
was extracted by first incubating the cells with 30μl of RIPA buffer (Sigma 
Aldrich) supplemented with 1% PMSF, 1% protease inhibitor, and 0.1mM 
DTT for 15 minutes on ice. The cells were then mechanically broken down by 
triturating and incubated on ice for another 15 minutes. Next, the mixture was 
centrifuged at 12.5 x g for 15 minutes at 4°C. The supernatant was collected as 
total cell protein and was quantified using Bradford Reagent (Bio-rad, USA) 
according to manufacturer’s protocol. A total of 25μg of proteins was loaded 
and separated on 8% or 9% SDS-Page gel. Then, the separated protein was 
transferred to a polyvinylidene fluoride (PVDF) microporous membrane 
(Millipore) and the membrane was blocked with 5% (w/v) non-fat milk in 0.1% 
(Tris-Buffered Saline + 1% Tween 20) TBST for one hour at room 
temperature. The membranes were incubated with diluted primary antibodies 
overnight at 4°C and washed with TBST 3 times for 15 minutes each. After 
that membrane was incubated with secondary antibodies (for one hour at room 
temperature) and washed again with TBST before chemiluminescent substrate 
detection. The western bands were quantified using ImageJ software.  
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Western blot analysis was also done to FLEC subjected to the various 
stimulations (IL6, TNF-α, MCSF-mϕ CM, MDA-mϕ CM) to study the 
signaling pathways activated in FLEC. To validate the pathways, FLEC was 
treated with inhibitors/function blocking antibodies/neutralisation antibodies 
prior to protein extraction and western blot analysis. The working 
concentrations of the primary and secondary antibodies used are as listed in 
Table 2.6.    
Table 2.6: Source and working concentration of antibodies for western 
blot 
Antibody Source Dilution Origin 






Fibronectin Abcam 1:5000 Rabbit 
Beta actin- Horseradish 
peroxidase (HRP) 
Conjugated 
Santa Cruz 1:30000 Mouse 
Goat anti Mouse IgG 
HRP 
1:5000 Goat 






2.8 Enzyme-linked immunosorbent assay (ELISA)   
The IL-6 concentration in MCSF-m  and MDA-m  was determined using 
Human IL-6 ELISA Ready-Set-Go! kit from eBioscience (eBioscience) 
according to the manufacturer protocol. The 96-well ELISA plate (Corning 
Costar) was coated with 1X capture antibody (100µl/well) and incubate 
overnight at 4
o
C and washed 3 times with wash buffer (1X PBS with 0.05% 
Tween-20) to remove residual coating buffer. After which, the wells were 
blocked with ELISA diluent (200µl/well) at room temperature for 1 hour and 
subsequently washed once with wash buffer. MCSF-mϕ CM and MDA-mϕ 
CM were diluted before adding to appropriate wells (100µl/well and triplicates 
per condition). Plate was sealed and incubated for 2 hours at room temperature. 
After incubation, plate was washed 3-5 times before detection antibody (1X 
anti-human IL-6 biotin) (100µl/well) was added for 1 hour incubation at room 
temperature. Plate was then for 3-5 times prior to incubation with 1X Avidin-
HRP (100µl/well) for 30 minutes at room temperature. After that, plate was 
washed for 5-7 times before TMB substrate solution (100µl/well) was added 
for 15 minutes incubation at room temperature. 50µl of 2N sulphuric acid was 
added to stop the colorimetric reaction. Absorbance reading at 450nm was 
determined using a Tecan plate reader. IL-6 concentration was calculated by 
comparing the absorbance per well against a standard curve. Standard curve 
was acquired 8 decreasing concentrations of recombinant human IL-6 
(triplicates for each concentration). The highest concentration used was 
200pg/ml which was serially diluted 1:2 in subsequent concentrations. IL-6 




For neutralisation treatments, MDA-m  CM were treated with IL6 antibody 
(3μg/ml) for 30 minutes at 37oC prior to ELISA.  
 
 
2.9 PCR array 
Expression of adhesion molecules on FLEC was examined using the RT² 
Profiler PCR Array (Qiagen, SAbioscience) according to the manufacturer 
protocol. FLEC was subject to similar stimulations as described in section 
2.5.1 and was harvested as described in section 2.2.4 prior to RNA extraction 
using the RNeasy mini kit (Qiagen SAbioscience) according to the 
manufacturer protocol. Cells were harvested and lysis with buffer RLT. Lysate 
was homogenized by passing the lysate through a blunt 20-gauge needle fitted 
to an RNase-free syringe at least 5 times. After that, 70% ethanol (same 
volume as buffer RLT added) was added to the homogenized lysate and mixed 
well by pipetting. Mixture was transferred to an RNeasy spin column with a 
2ml collection tube and centrifuged at 8000 x g for 15 seconds. Flow through 
was discarded after centrifugation. 700µl of Buffer RW1 was added to the 
RNeasy spin column and subjected to centrifugation at the same setting. Flow 
through was discarded again and 500µl of buffer RPE was added. After which, 
column was centrifuged again at the same setting. 500µl of buffer RPE was 
added again after flow through was discarded. The column was centrifuged at 
8000 x g for 2 minutes to wash the spin column membrane. Next, a new 1.5ml 
collection tube was replaced and 30µl of RNase-free water was added directly 
to the spin column membrane. The column was centrifuged at 8000 x g for 1 
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minute to elute the RNA. Subsequently, RNA yield concentration and purity 
was determined by measuring the absorbance with NanoDrop 
spectrophotometer ND1000 (NanoDrop Thermo Scientific). Next, cDNA was 
synthesized using the RT
2
 First Strand Kit (Qiagen SAbioscience) according 
to the manufacturer protocol. First, genomic DNA was eliminated by 
incubating the each RNA sample with the genomic DNA elimination mix for 5 
minutes at 42
o
C and on ice immediately for 1 minute. Next, the reverse-
transcription mix was added to each tube and incubated for 15 minutes at 42
o
C. 
Reaction was stopped by incubating mixture at 95
o
C for 5 minutes. RT
2
 SYBR 
Green Mastermix was added to the cDNA synthesis reaction and mixed before 
dispensing into the RT
2
 Profiler PCR array. Array plate was tightly sealed 
with an optical adhesive film and centrifuged for 1 minute at 1000 x g to 
remove bubbles. Lastly, real-time PCR was carried out in AB7500 fast real 
time PCR system (Applied Biosystems) for 1 cycle of 10minutes at 95
o
C 
followed by 40 cycles of 15 seconds at 95
o
C and 1 minute of 60
o
C. Data 
analysis was done on the PCR array data analysis web portal (SAbioscience).  
 
 
2.10 SiRNA Transfection 
FLEC was grown to 80% confluent prior to transfection.  Transfections of 
various siRNA (stated in table 2.8) with FuGENE
®
 HD Transfection Reagent 
(Promega) were performed according to the manufacturer's protocols. In brief, 
the various siRNAs were first diluted in Opti-MEM® I Reduced Serum 
Media (Gibco) before the FuGENE
®
 HD Transfection Reagent (3 µl FuGENE : 
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1 µg siRNA ratio) was added to it. The mixture was mixed gently and 
incubated at room temperature for 10 minutes. Next, the mixture was added to 
the cells in EGM-2 and incubated for 24 hours at normal culture conditions. 
Transfection mixture was replaced with fresh media for another overnight 
incubation. Validation of transfection was done via western blot analysis. 
FLEC that had undergone transfection were also subjected to the various 
stimulations (IL6, TNF-α, MCSF-mϕ CM, MDA-mϕ CM) prior to western 
blot analysis for signaling pathways verification. 
 
siRNAs were purchased from commercial sources. Each siRNA transfection 
was titrated to determine its optimal working concentration and FuGENE
®
 HD 
Transfection reagent ratio for the assays. The source and final working 
concentration for each siRNA is as listed below in table 2.7.  
Table 2.7: Source and working concentration of siRNA for 
transfection 











Silencer Select JUN 
siRNA s7659 
970.8 





Silencer Select STAT3 
siRNA s745 
717.1 
Silencer Select negative 




2.11 Statistical analysis 
Statistical significance was determined by two-tailed paired Student’s T-test or 
unequal variance T-test when appropriate. A p-value of ≤ 0.05 was considered 
to represent significant difference between the different cell types used or 






CHAPTER 3:  
Interactions of breast cancer cells with endothelial cells 
from metastatic sites and non-metastatic sites 
3.1 Introduction 
Metastasis is the widespread of tumour cells from their primary site to distant 
organs. It is a process involving a series of interrelated steps where each step 
is arduous for the tumour cells to overcome. Theoretically, once the tumour 
cells enter circulation, they would be disseminated to every organ in the body 
and malignant colonisation could occur anywhere. However, metastasis is 
only observed in specific organs. Different cancers have different organ 
preference for metastasis and apart from the lymph nodes. For instance, breast 
cancer preferentially metastasizes to bone, lungs, liver and brain 
322
. Stephen 
Paget’s “seed and soil” hypothesis states that the tumour cells thrive in organs 
that have a supportive microenvironment for their survival and colonization 
7
. 
This implies that the outcome of metastasis is dependent on the interactions 
between newly arrived tumour cells with the host organ environment. Thus, 
differences in functional and physical ‘barriers’ present at each different organ 




Through genetic aberrations, tumour cells acquire the abilities to detach from 
the primary tumour, survive in circulation, eventually adhere to the vascular 
endothelial cells at a distant site and invade the organ. The vascular 
endothelium is the first barrier that tumour cells encounter during the exit from 
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circulation at the host organ. It is well known that endothelial cells from 
different vascular beds and at organ sites are functionally different. 
Endothelial cells in different organs may express different cell surface 
glycoproteins, adhesion molecules, growth factor receptors and secrete 
different growth factors 
19,339,340
. This heterogeneity could be the combined 
outcome of genetic variations together with chemical and molecular cues 
present in the local microenvironment 
19,339
. Thus, this functional difference 





Extravasation of the tumour cells at the target organ involves the binding and 
arrest of the tumour cells to the endothelium prior to trans-endothelial 
migration. These interactions are hypothesized to be similar to the leukocyte 
recruitment during inflammation 
12
. Transient adhesion of the tumour cells 
could result in rolling of the tumour cells on the endothelium which brings the 
tumour cells in closer proximity with the endothelium. This is followed by 
firm adhesion (arrest) of the tumour cell prior to transmigration across the 
endothelium and the underlying basement membrane 
12
. It is hypothesized that 
the trans-endothelial migration of the tumour cells can be paracellular or 
transcellular, similar to leukocyte transmigration 
91
. However, tumour cells are 
larger in size and their transit across the endothelium monolayer could disrupt 
the endothelial integrity by inducing morphological changes or apoptosis 
93
. 
Studies have shown that transmigration of different types of tumour cells can 
lead to either reversible or irreversible retraction of the endothelial monolayer 
92,102,103
. Some mechanisms have been suggested to explain the observation of 
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the endothelial retraction of apoptosis during extravasation. As reviewed 
earlier, various soluble factors such as VEGF, 12(S)-HETE and MMPs have 
been reported to induce the retraction of endothelial monolayer to facilitate the 




To date, the “seed and soil” hypothesis remains as the basis for organ-specific 
metastasis observed in cancer. However, it is not known whether the 
disseminated tumour cells in circulation indeed have a preference for some 
organs over others and thus leading to metastasis in the preferred organs. It is 
also not known whether endothelial heterogeneity also contributes towards 
this phenomenon. In breast cancer, lung is one of the preferred metastatic sites. 
With that, I aim to determine whether breast tumour cells can preferentially 
interact with lung endothelial cells compared to endothelial cells from non-
metastatic sites in this chapter. Furthermore, I sought to elucidate the 
mechanisms underlying the extravasation of the breast tumour cells across the 






I first studied the interactions between the breast cells and endothelial cells to 
determine whether the invasive potential of the tumour cells or the organ 
source of the endothelial cells regulate the interactions. Endothelial cells from 
fetal and adult lung (FLEC and ALEC respectively) were used to represent 
endothelial cells from the metastatic sites; and those from the human umbilical 
cord vein (HUVEC) and human saphenous vein (SVEC) were used to 
represent endothelial cells from non-metastatic sites. MDA-MB-231 and 
MCF-7 were used to represent invasive and less-invasive breast tumour cells 
respectively while MCF-10A was used to represent normal breast epithelial 
cells.  
 
3.2.1 Endothelial cells from various organ sites were able to support the 
adhesion of breast cells 
The extravasation of tumour cells in the circulation to the target organ sites 
requires successive adhesive interactions between the endothelial cells. Thus, I 
first examined the static adhesion of the breast cell lines (MDA-MB-231, 
MCF-7 and MCF-10A) and endothelial cells of various organs sites (FLEC, 
ALEC, HUVEC and SVEC) using the static binding assay as described in 
section 2.5.1. All 3 breast cell lines were able to bind to the various 
endothelial monolayers efficiently despite the differences in their invasive 
potential (Fig. 3.1). There were no significant differences in the absolute 
number of bound breast cells across the different endothelial cells. Likewise, 
the endothelial cells, whether from the metastatic site (lung) or the non-
metastatic sites (umbilical cord and saphenous vein), were equally receptive to 
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the breast cells. The data thus suggest that disseminated breast cancer cells and 
non-malignant breast epithelial cells can bind to endothelium from both 






Figure 3.1: Endothelial cells from various organs were able to bind both 
malignant and non-malignant breast cells 
Both malignant cells (MDA-MB-231 and MCF-7) and non-malignant cells 
(MCF-10A) were able to adhere to the endothelial cells from various organs 
(FLEC, ALEC, HUVEC and SVEC) after 2 hours incubation. There was no 
significant difference in the number of adhered cells. Data shown is the mean 




3.2.2 Invasive MDA-MB-231 most readily transmigrated across lung 
endothelial monolayer 
Since all breast cells were able to bind to the various endothelial cells 
efficiently, I next examined their ability to transmigrate across the endothelial 
monolayer using the transwell system. As described in materials and methods 
(section 2.5.2), an intact monolayer of endothelial cells were first grown in the 
transwell insert before addition of breast cells. The breast cells were allowed 
to transmigrate across the endothelial monolayers for 24 hours.  
 
3.2.2.1 Endothelial cells from different organ sites exhibit different 
spontaneous migratory behaviour 
Prior to the trans-endothelial migration assay, a series of preliminary 
experiments was carried out to examine whether the endothelial monolayer 
grown on the insert is intact at the start of the experiment and whether  the 
cells also migrate across the 8µm pores to the underside the membrane of the 
transwell inserts.  
 
Immunofluorescence staining of the control wells containing FLEC monolayer 
only with anti-CD31 antibody confirmed that the monolayer in the inner 
surface is intact (Fig.3.2A) at the start of each experiment. CD31 is a 
junctional protein and its expression is often used as a lineage marker for 
endothelial cells. In every trans-endothelial migration assay, a control insert 
with only endothelial cells and no breast cells added was set up to monitor 
spontaneous endothelial cell migration across the transwell membrane. There 
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were significantly more HUVEC and SVEC migrated across the transwell 
membrane after 24 hours compared to lung endothelial cells (FLEC and 
ALEC) (Fig. 3.2 B & C). This indicated that the migrated cells observed for 
inserts coated with HUVEC and SVEC could be a mixture of breast cells and 
endothelial cells. On an average 64.87 ± 4.89 HUVEC per field and 55.69 ± 
9.21 SVEC per field migrated across the transwell membrane in 24 hours.  
Therefore, to account for the presence of migrated endothelial cells on the 
underside of the membrane, I decided to treat this as the baseline migration of 
each endothelial cell type in 24 hours. This baseline was subtracted from the 
total number of migrated cells for each respective condition and only the 
difference was inferred as the number of trans-endothelial migrated breast 





Figure 3.2: Fewer FLEC and ALEC spontaneously transmigrate across 
transwell membrane compared to HUVEC and SVEC 
(A) The FLEC monolayer in the transwell insert was stained with DAPI and 
anti-CD31-FITC (Left and middle panel). The last panel shows the overlay of 
the two staining. Images shown are representative of two independent 
experiments. Magnification: 40x (B) Left to right: FLEC, ALEC, HUVEC, 
SVEC. Migrated cells on the underside of the membrane were stained with 
Giemsa. Images shown are representative of four to eight independent 
experiments. Magnification: 10x (C) Negligible number of FLEC and ALEC 
were observed on the underside of the membrane after 24 hours. However, 
significantly more HUVEC and SVEC were observed on the underside of the 
membrane after 24 hours. Data shown is the mean ± SEM from four to eight 
independent experiments.  
50μm Magnification: 40x 
FLEC monolayer (insert) 
DAPI CD31-FITC  Overlay 
A 
FLEC ALEC HUVEC SVEC 







3.2.2.2 MDA-MB-231 transmigrated across lung endothelial monolayer 
more efficiently compared to other endothelial monolayers 
After establishing the baseline migration of endothelial cells, I proceeded with 
the transmigration assay. The data showed that the invasive breast cancer cells, 
MDA-MB-231, were most efficient at transmigrating across endothelial 
monolayers, followed by MCF-7 and lastly MCF-10A (Fig.3.3).  MDA-MB-
231 cells were able to transmigrate most readily across the lung endothelial 
monolayers (FLEC). There was a significant lower number of transmigrated 




Figure 3.3: MDA-MB-231 transmigrated most efficiently across FLEC 
and ALEC monolayers.  
Comparing the number of transmigrated MDA-MB-231 across the different 
endothelial monolayers, there was a significant reduction in transmigrated 
MDA-MB-231 across ALEC, HUVEC and SVEC compared to FLEC. There 
was no significant difference in the transmigration of MCF-10A across the 
different endothelial monolayers. Data shown is the mean ± SEM from three 
to six independent experiments. * indicates statistical significant compared to 
transmigrated cells across FLEC at p≤0.05. ^ indicates statistical significant 





3.2.3 FLEC is most susceptible to invasion by invasive breast tumour cells, 
MDA-MB-231 
I observed that despite the differences in the invasive potential of the 
malignant breast cells, both non-malignant and malignant breast cells had 
similar efficiency in adhering to endothelial cells from various organs. 
However, the adhesion of these tumour cells did not translate into successful 
trans-endothelial migration. Therefore, I decided to examine the interactions 
more closely to determine the mechanism that facilitates transmigration. It has 
long been suggested that tumour cell extrvasation disrupts endothelial junctions 
causing endothelium to retract thus exposing the underlying basement membrane 
343. I speculated that prior to transmigration, MDA-MB-231 and MCF-7 would 
be able to disrupt the endothelial monolayer by creating ‘gaps’ along the 
bicellular or tricellular junctions to allow their transit across the monolayer. 
Since the normal breast epithelial cell line MCF-10A was the least efficient in 
transmigrating across the endothelial monolayer (Fig. 3.3), it should not 
disrupt the endothelial monolayer. 
 
Tracker dye orange labelled breast cells were added on endothelial monolayer 
plated on coverslips for 1 hour to allow interactions to occur. The monolayer 
was then stained with anti-CD31 antibody conjugated to FITC for the 
visualization of the endothelial cell junctions. I then proceeded to examine the 
endothelial monolayers for ‘gaps’ i.e. disruptions in the junctional staining for 




From the immunofluorescence images, it was observed that there was 
uninterrupted CD31+ staining at the cellular junctions and the FLEC 
monolayer remained intact when no cells were added (Fig 3.4 A) or on areas 
not associated with bound cells (Fig 3.4 B-D). In contrast, bound MDA-MB-
231 (Fig. 3.4 B, white arrows) and MCF-7 (Fig. 3.4 C, white arrows) were 
associated with disruptions in the monolayer as indicated by the loss of 
junctional CD31 staining around the tumour cells. Some of the bound MCF-7 
did not disrupt the FLEC monolayer (Fig. 3.4C, red arrows). Most of the 
bound MCF-10A cells were also not associated with gaps or disruption of 
CD31 staining in the FLEC monolayer (Fig. 3.4 D, red arrow). 
 
The same assay was carried out with other endothelial cells (ALEC, HUVEC 
and SVEC) and I quantified the percentage of bound cells associated with gaps. 
Figure 3.5 A-D showed the percentage of bound cells that were associated 
with gaps for each endothelial monolayer. As expected, 72.94% ± 1.84% of 
MDA-MD-231 bound to FLEC were associated with gaps compared to bound 
MCF-7 (55.36% ± 1.84%) and bound MCF-10A (18.52% ± 4.93%) (Fig 3.5A). 
A similar profile was observed for ALEC, where 42.49% ± 2.78% of bound 
MDA-MB-231 were associated with gaps followed by MCF-7 (23.47% ± 
5.16%) and MCF-10A (9.41% ± 5.82%) (Fig 3.5B). However, such profile 
was not observed for breast cells bound on endothelial cells from non-
metastatic sites (HUVEC and SVEC). Percentage of MDA-MB-231 bound to 
HUVEC and SVEC that were associated with gaps were 44.84% ± 3.09% and 
44.48% ± 4.36% respectively. Similarly, the percentage of MCF-7 associated 
with gaps was 48.50% ± 2.64% for HUVEC and 42.76% ± 9.51% for SVEC. 
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Surprisingly, approximately 31.48% ± 2.64% and 29.67% ± 2.04% of bound 
MCF-10A on HUVEC and SVEC respectively were also associated with gaps 
(Fig 3.5 C and D). 
 
For the lung endothelium (FLEC and ALEC), invasive breast tumour cell line 
MDA-MB-231 was able to disrupt the monolayer most efficiently followed by 
the less invasive MCF-7 and the benign breast epithelial cell line MCF-10A. 
This difference in the disruption of the lung endothelial monolayer was 
consistent with the transmigration profile of the breast cells across the lung 
endothelium (Fig. 3.3). Furthermore, the percentage of gaps associated with 
bound MDA-MB-231 on FLEC was significantly more than that seen with the 
other endothelial monolayers. This suggests that binding of MDA-MB-231 to 
FLEC would lead to greater disruption to the FLEC monolayer compared to 
other endothelial monolayer thus enable this invasive cell to transmigrate 
FLEC monolayer much more efficiently. 
 
The difference in the ability to disruption the endothelial monolayer by the 
different breast cells was less evident for endothelial cells from non-metastatic 
sites. There was no significant difference in the ‘gaps’ associated with bound 
MDA-MB-231, MCF-7 and MCF-10A on HUVEC and SVEC. Although 
bound MCF-10A were able to disrupt the HUVEC and SVEC monolayer as 
efficiently as MDA-MB-231 and MCF-7, the cells were still unable to 
transmigrate across HUVEC and SVEC monolayer as observed in section 
3.2.2.2. Interestingly, bound MDA-MB-231 on ALEC, HUVEC and SVEC 
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were able to disrupt the monolayer equally well, yet more MDA-MB-231 
transmigrated across ALEC monolayer compared to HUVEC and SVEC 
monolayers. This suggests that ALEC is able to support the transmigration of 
MDA-MB-231 better than HUVEC and SVEC. Together, the data from 
section 3.2.2.2 and 3.2.3 showed that the transmigration of the tumour cells 
across the endothelial cells depends on the invasiveness of the tumour cells to 
disrupt the monolayer as well as the endothelial receptiveness to the tumour by 





Figure 3.4 MDA-MB-231 disrupted the FLEC endothelial monolayer 
most efficiently compared to MCF-7 and MCF-10A 
(A) Continuous junctional CD31 staining was observed in the FLEC control 
monolayer where tumour cells were not added to the monolayer. (B) Addition 
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Gaps – White arrows 







junctional staining at sites of adhesion (white arrows) (C) Addition of MCF-7 
to FLEC also resulted in disruption of the monolayer. While gaps were 
associated with some of the bound MCF-7 cells (white arrow), many were not 
associated of gaps (red arrows) (D). Many of the MCF-10A cells that were 
bound to FLEC monolayer did not disrupt the CD31 staining in the monolayer 
(red arrow). Images shown are representative of three to five independent 





Figure 3.5: More MDA-MB-231 cells bound to lung endothelium were 
associated with gaps when compared to MCF-7 and MCF-10A bound to 
lung endothelium under similar conditions. 
 
Approximately 200 bound cells were counted for each experiment to 
determine the percentage of bound cells there were associated with gaps. (A) 
More MDA-MB-231 bound to FLEC were associated with gaps than MCF-7 
and MCF-10A. (B) For ALEC, A similar profile of gaps associated bound 
cells was observed for ALEC. Most bound MDA-MB-231 were associated 
with gaps, followed by MCF-7 and then MCF-10A. (C, D) For endothelial 
cells of the non-preferred metastatic sites (HUVEC and SVEC), percentage of 
bound MDA-MB-231 and MCF-7 associated with gaps were similar. Data 
shown is the mean ± SEM from three to seven independent experiments. * 






3.2.4 Matrix metalloproteinases (MMPs) 2, MMP3 and MMP8 are 
involved in facilitating trans-endothelial migration of MDA-MB-231 
After establishing that the transmigration of MDA-MB-231 across the FLEC 
monolayer is associated with disruptions of the cellular junctions by the bound 
cells, I sought to identify the mediators involved. MMPs play a role in 
invasive cancer cells metastasis as they act by degrading extra cellular matrix 
and basement membrane to facilitate tumour cell invasion 
108
. As such, MMPs 
might play a role in the creation of the gaps at the endothelial junctions by 
bound breast tumour cells. I also attempted to elucidate the source of MMPs 
involved, i.e. to determine whether they are tumour-derived, FLEC-derived or 
from both.  
 
3.2.4.1 FLEC-derived MMP2 facilitates endothelial junction disruption 
upon MDA-MB-231 adhesion 
To establish whether MDA-MB-231 is the main source of MMPs, tracker dye 
orange labelled MDA-MB-231 were incubated with pan-MMP inhibitor 
(GM6001 12.5μM), MMP2/9 inhibitor (SB-3CT, 4μM) and MMP2 inhibitor 
(OA-HY, 5μM) prior to use in the interaction assay (and subsequent anti-
CD31-FITC staining) as described in section 3.2.3. Next, to establish whether 
the FLEC could also be a source for MMPs, both MDA-MB-231and FLEC 
monolayer was also subjected to the same treatment regimen before the 
interaction assay. MDA-MB-231 and FLEC were also treated with DMSO 
alone, used here as the vehicle control. Data from the first set of experiments, 
will infer that MMPs secreted by MDA-MB-231 are involved in the creation 
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of gaps while any additional reduction of gaps detected in the second set of 
experiments will provide evidence to support FLEC involvement.  
 
Treatment of MDA-MB-231 alone or together with FLEC with DMSO did not 
affect the binding and creation of gaps by MDA-MB-231. The inhibition of all 
MMPs produced by MDA-MB-231 resulted in approximately 11.84% ± 2.09% 
reduction in gaps associated with bound MDA-MB-231. However, treatment 
of MDA-MB-231 with MMP2 and MMP9 inhibitors did not result in any 
reduction in gaps formation (Fig. 3.6). Therefore, it can be inferred that other 
MMP(s) derived from MDA-MB-231 besides MMP2 and MMP9 is (are) 
involved in the production of gaps in the FLEC monolayer. Treatment of both 
MDA-MB-231 and FLEC with the pan-MMP inhibitor resulted in a further 10% 
reduction in the percentage of gaps associated with bound MDA-MB-231 as 
compared to treatment of MDA-MB-231 alone. This suggested that MMPs 
derived from FLEC are also involving the in the production of gaps associated 
with MDA-MB-231 binding. Furthermore, our data showed that inhibition of 
both MMP2 and MMP9 or inhibition of MMP2 only resulted in a similar level 
of reduction as that seen with inhibiting all MMPs (pan-MMP inhibitor: 21.63% 
± 3.25%, MMP2/9 inhibitor: 17.63% ± 2.42%, MMP2 inhibitor: 18.52% ± 
4.02%) (Fig. 3.6). Therefore, it can be inferred that MMP2 produced by FLEC 
upon the interaction with MDA-MB-231 contributes in part to the disruption 
of the endothelial monolayer by the bound tumour cells. This role of 
endothelial-derived MMP2 in trans-endothelial migration by MDA-MB-231 






Figure 3.6: MMP2 produced by FLEC contributes to endothelial 
monolayer disruption to facilitate invasion by MDA-MB-231 
The percentage of bound cells associated with gaps for each condition was 
normalized to that of the untreated control. Broad spectrum inhibition of all 
MMPs produced by MDA-MB-231 resulted in a reduction in gaps as 
compared to the untreated cells. There was no inhibition detected when MDA-
MB-231 cells were treated with MMP2/9 inhibitor and MMP2 inhibitor. 
Broad spectrum inhibition of all MMPs produced by both MDA-MB-231 and 
FLEC resulted in a further 10% reduction in gaps as compared to pan-MMP 
inhibitor treatment of MDA-MB-231 alone. Similarly, treatment of both cell 
types with MMP2/9 and MMP2 inhibitors resulted in about 19% reduction in 
gaps detected. Data shown is the mean ± SEM from three independent 





3.2.4.2 MMP2, MMP3 and MMP8 facilitate MDA-MB-231 
transmigration across FLEC monolayer 
After observing that the MMP2 was involved in disrupting the monolayer 
integrity, I speculated that prevention of the formation of gaps through MMP 
inhibition will reduce transmigration of MDA-MB-231 across FLEC. Since 
the pan MMP inhibitor, GM6001, also inhibits MMP3 and MMP8 
345
, I 
included MMP3 and MMP8 in the panel of MMPs inhibitors used in this 
series of experiments. GM6001 also inhibits MMP1; however no specific 
MMP1 inhibitor is commercially available. Therefore the role of MMP1 could 
not be specifically examined. Both MDA-MB-231 and FLEC monolayer were 
treated with different MMPs inhibitors (Pan MMP inhibitor, MMP2 inhibitor, 
MMP2/9 inhibitor, MMP 3 inhibitor and MMP 8 inhibitor) before the 
transmigration assay for 8 hours. MDA-MB-231 and FLEC were also treated 
with DMSO as the vehicle control. 
 
Treatment of MDA-MB-231 and FLEC with DMSO did not affect the trans-
endothelial migration of MDA-MB-231. The inhibition of all MMPs resulted 
in approximately 35.44% ± 8.49% reduction in MDA-MB-231 transmigration. 
Inhibition of both MMP2 resulted in 29.22% ± 2.00% reduction while 
inhibition of both MMP2 and MMP9 resulted in 22.39% ± 6.14% reduction. 
Compared to the treatment by MMP2 inhibitor, the inhibition of MMP3 
resulted in 49.12% ± 10.17% reduction in transmigration, while inhibition of 
MMP8 resulted in 31.46% ± 8.41% reduction (Fig 3.7). As the inhibition of 
MMPs only resulted in a partial reduction in MDA-MB-231 trans-endothelial 
migration, there could be other factors involved in facilitating transmigration.  
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Inhibition of MMPs reduced the disruption of the FLEC monolayer upon 
MDA-MB-231 adhesion (section 3.4.1) as well as MDA-MB-231 trans-





Figure 3.7: MMP2, MMP3 and MMP8 are involved in facilitating MDA-
MB-231 trans-endothelial migration 
The percentage of transmigrated cells per field for each condition was 
normalized to that of the untreated control. Treatment of both MDA-MB-231 
and FLEC with pan-MMP inhibitor, MMP2, MMP2/9, MMP3 and MMP8 
resulted in a reduction in the number of transmigrated MDA-MB-231 as 
compared to the untreated cells. Data shown is the mean ± SEM from three to 
six independent experiments. * indicates statistical significant compared to 





During metastasis, circulating tumour cells in the lymphatics or the 
vasculature are carried to distant sites and eventually extravasate to establish a 
secondary growth. The extravasation step involves the adhesion of the tumour 
cells to the endothelium, transmigration across the endothelium and 
subsequent migration into the interstitium of the organ. The mechanism 
underlying these steps is not well characterised. The endothelial cells in the 
vasculature of different organs express different surface adhesion receptors 
and secrete different growth factors that will influence the recruitment and 
survival of the tumour cells. Both the invasiveness of the tumour and the 
microenvironment of the target organ contribute to the organ-specific 
metastasis observed in most cancers. It is well known that human breast 
cancer exhibits organ-specific metastasis with lung being the most common 
metastatic site 
322
. In this study, I used two breast tumour cells lines (MDA-
MB-231 and MCF-7), one breast epithelial cell line (MCF-10A) and 
endothelial cells from three different organs, (Lung: FLEC and ALEC, 
Umbilical Cord Vein: HUVEC and Saphenous Vein: SVEC) to examine and 
compare the ability of breast tumour cells to adhere to and transmigrate across 
the endothelial cell (EC) monolayer in-vitro. I also attempted to elucidate the 
mechanism underlying the transmigration of MDA-MB-231 and MCF-7 
across the lung EC monolayer. 
 
Adhesion to the endothelium is the first step during tumour exit from 
circulation. Therefore I examined the adhesion of the breast cells (MDA-MB-
231, MCF-7 and MCF-10A) to ECs (FLEC, ALEC, HUVEC and SVEC) and 
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observed that all breast cells bound equally well to all endothelial cells. MDA-
MB-231, belonging to the basal breast cancer subtype, is mesenchymal-like 
and is highly invasive. In contrast, MCF-7, which belongs to the luminal 
breast cancer subtype, is luminal epithelial-like and is weakly invasive 
346,347
. 
MCF-10A is a representative of a normal human mammary epithelial cell of 
non-malignant origin and is non-invasive 
346,348
. Despite the difference in 
invasiveness, my data showed that MDA-MB-231, MCF-7 and even MCF-
10A bound equally well to all endothelial monolayer. Two hypotheses have 
been proposed for the arrest of cancer cells in the vessel. The first hypothesis 
was proposed by Stephen Paget in 1889. His “seed and soil hypothesis” stated 
that tumour cells (seed) are circulating in the body and form metastases only 
in specific organs (soil) that are suitable 
7
. The second hypothesis is the 
“anatomical hypothesis” by James Ewing which stated that following the 
circulatory route from the primary tumour, dislodged tumour cells is able to 
arrest at a secondary site due to mechanical or anatomical trapping 
9
, 
especially in pulmonary circulation where the microvasculature might be 
narrow for tumour cells passage 
91
. Lung is one of the common sites of 
metastasis in breast cancer and as expected, ECs from metastatic site (FLEC 
and ALEC) were able to support the adhesion of MDA-MB-231, MCF-7 and 
MCF-10A in-vitro. Surprisingly, even ECs from other vascular beds, namely 
HUVEC and SVEC, were also able to support the adhesion of the three breast 
cell lines. The adhesion of the breast cells to all these EC monolayers did not 
exhibit any organ preference and thus does not fit the “seed and soil 
hypothesis”. In the tumour binding assay (TBA) carried out, there was no 
mechanical or anatomical trapping that could force the adhesion of the tumour 
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cells to the endothelium. The result was also not supported by the “anatomical 
hypothesis”.  It could be argued that TBA was carried out under static 
conditions and the effects of gravity could have contributed to the initiation of 
binding. As such, no significant difference in adhesion was observed across 
different endothelial cells. Different organ endothelium have different cell 
surface adhesion molecules and growth factor receptors, secrete different 
growth factors and respond differently to the cue or cells present in the 
microenvironment 
3,340,349
. For example, lung endothelial cell adhesion 
molecule-1 is only expressed on lung endothelium 
350
 and P-selectin is highly 
expressed on lung endothelium but not on brain endothelium 
351
. Different 
adhesion molecules from the various endothelium can mediate the same cell 
adhesion. For leukocyte trafficking in the skin, P-selectin and E-selectin 
mediate rolling and ICAM-1 mediates adhesion. Whereas in the lung and liver, 
leukocyte trafficking depends on ICAM-1 but not E-selectin or P-selectin 
352
. 
Therefore, it is unclear at this juncture whether the breast tumour cells 
adhesion on the different endothelial cells is mediated by the same or different 
adhesion molecules.  
 
A characteristic of metastatic tumour cells is the ability to invade and traverse 
the endothelium and underlying basement membrane. My data correlates with 
others showing that MDA-MB-231 is the most invasive 
346,353,354
.  The 
difference in the transmigration observed could be attributed to the different 
characteristics of MDA-MB-231 and MCF-7. MDA-MB-231, being 
mesenchymal-like, has strong migratory and invasive abilities similar to cells 
of mesenchymal origin, whereas MCF-7, being epithelial-like, exhibit 
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epithelial characteristics such as presence of tight junctions 
346
. Tumour cells 
have to undergo epithelial-mesenchymal-transition (EMT) which is mediated 
by specific transcription factors such as Snail, Slug, SIP-1, δEF1, E12/E47 and 
Twist. These transcription factors repress epithelial markers, such as E-
cadherin, ZO proteins and cytokeratins, and induce the expression of 
mesenchymal markers such as N-cadherin, vimentin, α-smooth muscle actin 
(α-SMA), fibroblast-specific protein 1 (FSP1) and desmin 355. For example, 
slug induced EMT via expression of vimentin in breast cancer 
356
. The 
expression of vimentin in the cells promotes cell adhesion and migration 
which leads to the detachment from their primary lesion and metastasis 
357
. 
EMT markers (i.e. vimentin, α-SMA, N-cadherin and cadherin-11) in breast 
cancer are correlated with breast carcinoma cells that are basal-like 
358
 and 
MDA-MB-231 belongs to the basal subtype.  
 
Although MDA-MB-231 is highly invasive, the number of trans-endothelial 
migrations across EC monolayers of non-metastatic sites was significantly 
lower compared to the migration across lung EC monolayers (metastatic site). 
To the best of my knowledge, few studies have been done to compare the 
trans-endothelial migration of tumour cells across endothelial monolayers 
from different organ sources. In my model, I studied the basal motility of the 
breast cells and compared their interactions with ECs isolated from different 
organs without any chemoattractants or difference in serum concentration 
between the upper and lower chambers. Untreated lung endothelium allowed 
the migration of the invasive MDA-MB-231 more easily than the endothelium 
of non-metastatic sites (HUVEC and SVEC). This finding suggests that lung 
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endothelium is more supportive of the extravasation of the invasive breast 
cells MDA-MB-231 which could lead to the lung being more susceptible to 
metastases colonization.  
 
The mechanisms of underlying tumour trans-endothelial migration are unclear. 
Some studies showed that tumour migration can disrupt endothelium integrity 
in contrast to leukocyte interactions 
91,359. Li et al showed ‘gaps’ in bovine 
aortic endothelial monolayer upon adhesion of Calu-1 cells (lung epidermoid 
carcinoma cells), HT1080 cells (fibrosarcoma cells) and HT-29 cells (colon 
carcinoma cells) after 12 hours 
359
. Heyder et al showed that human bladder 
carcinoma cells T24 disrupted HUVEC junctions after 3 hours 
92
. Interestingly, 
in my study, EC junction disruptions was observed as early as 1 hour, 
suggesting that disruption of the endothelial cell junctions by breast tumour 
cells is an early event. My data also suggest that lung endothelium is more 
susceptible to invasion than ECs isolated from non-metastatic sites. When 
compared to HUVEC and SVEC, disruption of FLEC endothelium integrity 
by bound MDA-MB-231 was significantly more efficient. In addition, extent 
of disruption by the all three breast cell lines to HUVEC and SVEC was 
similar regardless of their difference in invasiveness. This suggests that there 
is heterogeneity between endothelium at different sites and they respond 
differently to the presence of bound tumour cells.  
 
It is recognized that the endothelium in different organs differ in terms of 
structure and functions. In some vascular beds (e.g. skin, lung, brain and heart), 
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the ECs are connected in a continuous manner. However in others, the ECs are 
continuous but permeated with fenestrae (e.g. endocrine glands, 
gastrointestinal organs and kidney) or are discontinuous with frank gaps (e.g. 
liver) 
352
. This structural difference affects the basal permeability of the 
different endothelium. The presence of the endothelium tight junctions is 
inversely proportionate to the permeability and disruption of the tight 
junctions affects the endothelium integrity. For example, the continuous tight 
junctions of the endothelium are maintained by the vascular endothelial (VE)-
cadherin and studies showed that blocking of the VE-cadherin with antibodies 
in mice only increases vascular permeability in lung and heart but not in other 
organs. This observed increase in vascular permeability is due to endothelial 
cell retraction and detachment from the basement membrane 
360,361
. Studies 
have also shown that an increase in vascular permeability is associated with 
higher tumour invasion and metastasis 
362,363
. Hence, the disruption of FLEC 
monolayer integrity by MDA-MB-231 in my study is probably also associated 
with increased vascular permeability which further facilitated efficient trans-
endothelial migration of the tumour cells. 
 
Matrix metalloproteinases (MMPs) that degrades extra cellular matrix are 
often associated with cancer progression. As such, roles of MMPs in the 
disruption of endothelial junction and in tumour trans-endothelial migration 
were explored. I found that MDA-MB-231 secreted a yet unidentified MMP(s) 
that mediated the EC junction disruption. Studies had also revealed the role of 
other tumour-derived MMPs (MMP1, MMP3, MMP12, MMP17, MMP19, 
and MMP23) in promoting invasiveness 
364,365
. Whether these additional 
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MMPs are involved specifically in the disruption of the FLEC monolayer 
during extravasation, as indicated by the presence of the unidentified MDA-
MB-231-derived MMP(s) in my study, needs to be further studied.  
 
My data also showed that FLEC-derived MMP2 contributed to the observed 
cell junction disruption as well as the subsequent trans-endothelial migration. 
Other than MMP2, MMP3 and MMP8 were also shown to mediate MDA-
MB-231 trans-endothelial migration across FLEC monolayer. This role of 
endothelial-derived MMP2 in mediating transmigration of MDA-MB-231 
across lung endothelial monolayer was previously reported by Kargozaran et 
al 
344
. The lung endothelial cells were shown to secrete more MMP2 than 
MDA-MB-231 and that siRNA knockdown of MMP2 in the lung endothelial 
cells significantly reduced the trans-endothelial migration of MDA-MB-231. 
Karogozaran and colleagues also showed that co-culture of MDA-MB-231 
and lung endothelium is required for the activation of the MMP2 from the 
latent form to the active form. This suggests that the cell-cell interaction 
between the tumour and the lung endothelial cells is essential in promoting the 
MMP2 activity to facilitate the tumour invasion. Studies have shown that other 
MMPs such as, MMP7 
366




 and MMP 14 
369
, 
have been associated with either MDA-MB-231 invasiveness or breast cancer 
metastasis and poor prognosis. Furthermore, Minn and colleagues showed that 
genes encoding MMP1 and MMP2 in metastatic breast cells are important for 
lung metastasis 
322
. In that study, Minn et al. compared the gene expression of 
parental MDA-MB-231 and lung metastatic MDA-MB-231 population and 
observed that MMP2 is expressed solely in the metastatic population while 
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MMP1 expression increased with increasing lung metastatic ability 
322
. 
However, compared to the above mentioned MMPs, little is known about 
MMP3 and MMP8 and their role in mediating tumour-endothelial invasion 
and transmigration.  
 
At this juncture, I do not know how MMPs contribute to the observed 
endothelial monolayer disruption. MMPs could probably degrade the 
component of the basement membrane component laid down by the ECs, thus 
resulting in the disengagement of the endothelial adhesion receptors from the 
matrix material. Alternatively, the degradation of intercellular contacts would 
result in the loss of endothelial cell-cell interactions. MMPs could also act 
directly or indirectly via signalling pathways to promote matrix degradation 
and increase permeability across the endothelial monolayer 
370
. These 
mechanisms could result in the endothelial junctional instability observed in 
my study. This leads to another question with regards to the location at which 
MMPs are secreted. Puyraimond, A et. al. showed that MMP2 is co-localised 
with caveolae at the basolateral side of the endothelial cell membrane while 
MMP9 is distributed throughout the cell 
371
. These MMPs can be secreted by 
the EC via vesicles exocytosis 
372
. Thus, it is conceivable that EC-derived 
MMPs are secreted basal-laterally to disrupt the EC-basement 
membrane/matrix contacts in my model. Meanwhile, MMPs secreted by the 
bound tumour cells will act on the intercellular contacts in the endothelial 
monolayer. These could eventually reach the underlying basement membrane 
and contribute further to the disruption of the EC-matrix contacts.  
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In this chapter, my data showed that successful extravasation of the tumour 
cells during metastasis is a coordinated effect that is dictated by the 
invasiveness of the tumour cells and the response of the target organ 
endothelium. Lung is a common metastatic site for breast cancer and this 
study suggests that the lung endothelium was more susceptible to invasion by 
MDA-MB-231 compared to the endothelium from other non-metastatic organ 
sites. This observation is consistent with Paget’s seed and soil hypothesis 7 that 
only suitable distant organ sites (soil) is able to allow the invasion of the 




CHAPTER 4:  
Primary tumour-derived factors could transform 
microenvironment of distant organs into potential sites 
of metastasis 
4.1 Introduction 
Cancer progression such as local invasion involves the interactions between 
tumour cells with resident stromal and inflammatory cells recruited to the 
primary lesion. In contrast, secondary metastases establishment requires the 
interplay between the tumour cells and the stromal cells in the distant organ. In 
the primary tumour, the inflammatory infiltrate plays a role in promoting the 
survival and proliferation of the tumour cells, driving angiogenesis and 
facilitating metastasis 
139
.  In recent years, studies have shown that prior to 
metastasis, there is the formation of a pre-metastatic niche in distant organ to 
facilitate the homing of circulating tumour cells to the ‘chosen’ site. The pre-
metastatic niche refers to a microenvironment that is modified to support the 
recruitment of circulating tumour cells and conducive for colonization of the 
tumour cells upon engraftment 
229
. Studies have suggested that this process 
could be directed by the tumour cells in the primary site 
232
; and dependent on 





The importance of the cellular composition and milieu of the tissue in 





Chronic inflammation has been associated with cancer initiation due to the 
constant tissue damage and repair, and genetic mutations that lead to 
uncontrolled cell proliferation and defective repair. Furthermore, the 
inflammatory cells infiltrating the tumour, such as macrophages and 
leukocytes, could secrete both pro-inflammatory and immunosuppressive 
factors that not only promote tumour cell growth and survival, but also 
orchestrate the metastatic progress. For example, TAMs suppress the 
inflammation in the tumour microenvironment through recruitment of anti-
inflammatory cells such as CD4
+




 and create an 
immune-suppressive microenvironment that favours tumour survival. In 
addition, the presence of TAMs in breast tumour also enhances the 
invasiveness of breast tumour cells and increases incidences of metastasis 
330,331
. Inflammatory cytokines such as TNF-α and IL-1β, are also involved in 




The microenvironment at the secondary sites that permit the colonisation of 
metastatic tumour cells is poorly understood. As mentioned earlier, the 
primary tumour has been shown to play a role in modulating the 
microenvironment in distant organs to create a pre-metastatic niche to 
facilitate metastasis. Involvement of inflammatory cytokines such as TNF-α 
and growth factors such as VEGF, PIGF and TGFβ derived from the primary 
tumour modulate distant organ which leads to in the formation of the pre-
metastatic niche to facilitate metastasis has been described 
230,231
. Studies also 
showed under the influence of the tumour-secreted factors, myeloid cells and 
bone marrow-derived cells (BMDCs) are recruited into the distant organ. 
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These myeloid cells and BMDCs alter the microenvironment by remodelling 
the ECM, creating an immune-suppressive environment, inducing 
inflammation and increasing vascular hyper-permeability 
229
 thus creating an 
environment that promotes the recruitment and survival of the newly arrived 
tumour cells. However, the exact mechanism underlying pre-metastatic niche 
formation is not well-defined. An intriguing question is why pre-metastatic 
niche is only formed in organs that are commonly known to be sites of human 
cancer when tumour-secreted factors are circulating systemically through all 
the organs in the body?  
 
The key step in metastasis is the adhesion of the tumour cells to the 
endothelium prior to trans-endothelial migration during the exit of the tumour 
cells from the vasculature into the interstitium. However, current studies 
derived from various mouse models 
230,231,265
 only documented the appearance 
of the pre-metastatic niche and the eventual metastasis establishment. They 
have not examined the molecular interactions between the circulating tumour 
cells and endothelium at pre-metastatic site. In the previous chapter, the 
success of a breast cancer cell to adhere to and to transmigrate across the 
endothelial monolayer is dependent on both the intrinsic properties of the 
tumour cells and the functional behaviour of the endothelium. Hence it is 
logical to hypothesize that the observed heterogeneity between endothelial 
cells from different organ sites will also affect their receptiveness to priming 
by tumour cell-derived factors. If so, compared to endothelium from non-
metastatic sites, endothelial cells from the lung (known metastatic site), would 
be more responsive to stimulation by tumour-associated cytokines such as 
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TNF-α and tumour cell-derived factors. As such, in this next series of my 
study, I aimed to find out whether inflammatory cytokines and tumour-derived 
soluble factors are able to modulate the behaviour of endothelial cells and 
enhance tumour-endothelial interactions. Furthermore, I sought to determine 
whether endothelial cells from the different organ source would respond 
differently to the soluble mediators and conditions used in these experiments. 
Lastly, I strived to examine the molecular mechanisms that regulate the 





In this chapter, tumour-endothelial interactions were examined after the 
various types of ECs were stimulated by the soluble mediators. Firstly, to 
study the effect of inflammation, TNF-α was used. Secondly, to study the 
effect of tumour-secreted factors, MDA-MB-231 conditioned medium was 
used. 
 
4.2.1 Enhancement of tumour interactions by TNF-α is specific to the lung 
endothelial cells 
Chronic inflammation has often been linked with cancer progression including 
metastasis. One of the key cytokine mediators implicated is TNF-α 175,373, 
which is frequently detected in breast cancer 
374,375
.  High serum level of TNF-
α is also correlated to disease progression and poor survival 376. Hence, I 
examined whether TNF-α stimulation of ECs from the various organs will 
result in differential effect on tumour-endothelial interactions.  
 
Firstly, I examined the adhesion of the tumour cells to the endothelium. I 
stimulated the various EC monolayers with TNF-α for 24 hours prior to the 
static adhesion assay as described in section 2.5.1.  I observed that TNF-α 
stimulation of FLEC significantly enhanced the adhesion of MDA-MB-231 
and MCF-7 by 97.56 ± 29.88% and 37.74 ± 10.52% respectively. Similarly, 
adhesion of MDA-MB-231 and MCF-7 to TNF-α-simulated ALEC increased 
by 76.65 ± 18.78% and 30.33 ± 12.66% respectively (Fig 4.1A). On the 
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contrary, such enhancement in adhesion was not observed with TNF-α-
stimulated ECs from non-metastatic sites, HUVEC and SVEC (Fig 4.1B).  
 
Next, I examined the trans-endothelial migration of the breast cells across the 
various TNF-α-stimulated endothelial monolayers. The data showed that there 
was significant increase in transmigration of MCF-7 across the TNF-α-
stimulated lung endothelial monolayers. Transmigrated MCF-7 across TNF-α-
stimulated FLEC per field (53.00 ± 13.02) was significantly higher than the 
untreated control (35.30 ± 15.59). Similarly, transmigration of MCF-7 across 
TNF-α-stimulated ALEC (33.37 ± 10.29) was significantly higher compared 
to untreated ALEC (9.70 ± 6.33) (Fig 4.2A). However, there was no difference 
in the transmigration of MDA-MB-231 across untreated FLEC and TNF-α-
stimulated FLEC. Due to the limitation of the transwell system, the maximum 
number of cells attached to the underside of the membrane that can be 
quantified is approximately 200 cells per field. Under untreated condition, the 
number of MDA-MB-231 transmigrated across FLEC was approximately 200 
cells per field (197.46 ± 24.27). As such any further increase in the 
transmigrated cells due to any treatment would be limited by the transwell 
membrane size and could not be observed. There was slight but not significant 
increase in transmigration of MDA-MB-231 across TNF-α-stimulated ALEC 
(173.81 ± 18.00) compared to untreated control (163.94 ± 10.63). Although 
there was also an increase in the number of transmigrated MCF-7 cells across 
HUVEC, this increase did not achieve statistical significance (Fig 4.2B). As 
for SVEC, there was no difference in the transmigration of the MDA-MB-231, 




Figure 4.1: TNF-α stimulation of the lung endothelium, FLEC and ALEC, 
significantly enhanced the adhesion of MDA-MB-231 and MCF-7. 
 (A) There was significant increase in adhesion of malignant cells (MDA-MB-
231 and MCF-7) to both TNF-α-stimulated FLEC and ALEC after 2 hours 
incubation. There was no significant difference in the adhesion of MCF-10A 
to TNF-α-stimulated FLEC and ALEC. (B) There was no significant 
difference in the adhesion of all three breast cells to TNF-α-stimulated 
HUVEC and SVEC. Data shown is the mean ± SEM from four to eleven 
independent experiments. * indicates statistical significant compared to each 







Figure 4.2: TNF-α stimulation of the lung endothelium, FLEC and ALEC, 
significantly enhanced the transmigration of MCF-7. 
(A) 24 hours TNF-α stimulation of FLEC and ALEC resulted in a significant 
increase in MCF-7 trans-endothelial migration. While there was no significant 
increase in the transmigration of MDA-MB-231 across TNF-α-stimulated 
FLEC and ALEC, the number of transmigrated MDA-MB-231 remained 
highest among the three breast cell lines. The number of MCF-10A that had 
transmigrated across the TNF-α-stimulated lung endothelial monolayer 
remained low. (B) There was no significant increase in trans-endothelial 
migration of the three breast cell lines across TNF-α-stimulated HUVEC and 
SVEC compared to their respective untreated control. Data shown is the mean 
± SEM from two to three independent experiments. * indicates statistical 






4.2.2 Tumour secreted factors in MDA-MB-231 conditioned medium did 
not enhance tumour-endothelial interactions 
To determine whether tumour cells play a role in the process of pre-metastatic 
niche formation by modulating the receptiveness of endothelial cells to the 
tumour cells, I went on to examine whether MDA-MB-231-secreted factors 
can influence tumour-endothelial cell interactions. MDA-MB-231 conditioned 
medium (MDA-CM) was prepared by incubating the 2x10
6
 tumour cells per 
ml of fresh culture medium for 24 hours. The CM was then used to stimulate 
the ECs prior to the adhesion and transmigration assays as described in section 
2.5.  
 
Data revealed that MDA-CM did not significantly increase the adhesion of all 
three breast cells (MDA-MB-231, MCF-7 and MCF-10A) to 24 hours 
stimulated ECs (FLEC, ALEC, HUVEC and SVEC) (Fig 4.3 A and B). 
Similarly, for tumour trans-endothelial migration, stimulation of the various 
ECs with MDA-CM for 24 hours did not result in any significant increase in 
tumour trans-endothelial migration (Fig 4.4 A and B). My data suggest that 
MDA-MB-231-derived soluble factors could not directly stimulate endothelial 
cells to enhance tumour-endothelial interactions. Since there are many 
different cell types present in the distant organ, it is possible that the MDA-
CM could act on other targets to prime the organ microenvironment to 





Figure 4.3: MDA-MB-231 conditioned medium did not enhance the 
adhesion of breast cells to FLEC, ALEC, HUVEC and SVEC. 
(A) MDA-CM stimulation of both FLEC and ALEC did not result in any 
significant effect on adhesion of both breast tumour cells MDA-MB-231 and 
MCF-7 to FLEC. (B) Similarly, there was no significant difference in the 
adhesion of all three breast cells to both MDA-CM-stimulated HUVEC and 








Figure 4.4: MDA-MB-231 conditioned medium also did not enhance the 
migration of breast cells across FLEC, ALEC, HUVEC and SVEC. 
(A) MDA-CM stimulation of both FLEC and ALEC did not result in any 
significant effect on trans-endothelial migration of all breast tumour cells 
MDA-MB-231, MCF-7 and MCF-10A. (E) Similarly, there was no significant 
difference in the trans-endothelial migration of all three breast cells to both 
MDA-CM-stimulated HUVEC and SVEC. Data shown is the mean ± SEM 






4.2.3 Tumour-conditioned macrophages play a key role in enhancing 
tumour cell interactions specifically to lung endothelium 
Hirastuka and colleagues found that primary tumour cells secrete factors such 
as TNF-α, VEGF or TGFβ which can induce the expression of pro-
inflammatory chemokines, S100A8 and S100A9, in the pre-metastatic lung 
microenvironment. These secreted factors can also condition myeloid cells at 
the pre-metastatic microenvironment 
232,377
. Hence I decided to determine 
whether these tumour-secreted factors can condition other resident cells in the 
organ such as lung macrophages, and in turn these tumour-conditioned 
macrophages can modulate EC function to create an environment suitable for 
tumour cell adhesion and transmigration. To address this, I created MCSF-
derived macrophages (MCSF-mϕ) and MDA-MB-231-conditioned 
macrophages (MDA-mϕ) as described in section 2.3 and used their respective 
CM to stimulate endothelial cells prior to the adhesion and transmigration 
assays as described in section 2.5.  
 
Tumour-associated macrophages (TAMs) found in the tumour 
microenvironment are known to have a M2 macrophages (mϕ) phenotype 
377,378
. Therefore, I predicted that the MDA-mϕ would also exhibit a M2 
phenotype. The controls for the in-vitro differentiation process are M1-mϕ, 
M2-mϕ, and dendritic cells (DC) differentiated from the same monocytes 
isolated as described in section 2.3. To characterise the phenotype of the 
MCSF-mϕ and MDA-mϕ, I compared the expression of the M1, M2 
macrophage and DC surface marker expression with these in-vitro 
differentiated cells.   
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4.2.3.1 MDA-mϕ are M2-macrophages 
MCSF-mϕ and MDA-mϕ were derived from monocytes after 8 days of culture 
with MCSF and MDA CM respectively. Following the 8 days of culture, both 
MCSF-mϕ and MDA-mϕ, which were adhered to the bottom of the plastic 
culture flask, exhibit similar morphological appearance as shown in figure 4.5.  
M1 mϕ, M2 mϕ, and DC were also differentiated from the same monocyte 
isolate for comparison. The cells were harvested for flow cytometry analysis 
of surface markers expression. Studies have shown that respectively M1 and 



















As shown in Fig 4.6A, the in-vitro differentiated M1 mϕ expressed high levels 
of CD80 and CD86. M2 mϕ also expressed CD80 and CD86 but at a much 
lower level compared to the M1 mϕ. CD83 was detected on DC but not on the 
M1 and M2 macrophages. CD206 expression was highest on DC, followed by 
M2 mϕ and was lowest on M1 mϕ (Fig 4.6B). Thus, flow cytometry analysis 
showed that the M1-mϕ generated were CD14+ /CD80high /CD86high /CD206mid 
(Fig 4.6 A and B), M2-mϕ are CD14+ /CD80low /CD86mid /CD206high (Fig 4.6 











(Fig 4.6 A and B). Characterisation of the M1-mϕ, M2-mϕ and DC 










 (Fig 4.6 A and B) and CD206
high
 (Fig 4.6B). DC 
and MDA-mϕ expressed higher level of CD206 compared to M2-mϕ. MCSF-
mϕ expressed a lower level of CD206 compared to M2-mϕ but higher than 
M1-mϕ. In recent years, another M2-mϕ, marker CD163, has often been used 
in addition to CD206 to differentiate M2-mϕ from TAM 380-383. Therefore, 
CD163 expression on MCSF-mϕ and MDA-mϕ were also examined. As 
expected, both MCSF-mϕ and MDA-mϕ expressed high levels of CD163 (Fig 
4.6B). MDA-mϕ expressed higher levels of CD206 and CD163 compared to 
MCSF-mϕ (Mean fluorescent intensity of CD206 were respectively 76.86 and 
389.28 on MCSF-mϕ and MDA-mϕ; and mean fluorescent intensity of CD163 
were respectively 37.29 and 445.22 on MCSF-mϕ and MDA-mϕ). Since 
MCSF-mϕ and MDA-mϕ generated expressed signature of M2-mϕ markers 
and not dendritic cells markers, this suggests that they skewed towards the M2 
mϕ phenotype. In addition, MDA-mϕ also exhibited a high expression of 





Figure 4.5: MCSF-mϕ and MDA-mϕ exhibited similar morphology 
(A) Both MCSF-mϕ and MDA-mϕ adhered to the bottom of the cultured flask 
following 8 days of culture with MCSF and MDA CM respectively. They 
exhibit similar morphology. Images shown are representative from three 




















































Figure 4.6: MCSF-mϕ and MDA-mϕ expressed signature of M2 
macrophages markers 
(A) Expressions of CD80, CD83 and CD86 on M1-mϕ, M2-mϕ, DC, MCSF-
mϕ and MDA-mϕ. (B) Expression of CD14 and CD206 on M1-m, M2-m, 
DC, MCSF-m and MDA-m. MCSF-m and MDA-m were also analysed 
for their cell surface expression of CD163. Mean fluorescent intensity of 
expression is indicated in each individual graph in red. Data shown here is a 

















Marker Ev ents % Gated % Total Mean Geo Mean
All 9604 100.00 96.04 76.60 37.29
M1 8261 86.02 82.61 88.30 52.96
Sample ID: CD163/PE Patient ID: MSCF mo
Gate: G1 Gated Ev ents: 9604
Total Ev ents: 10000
M1
Marker Ev ents % Gated % Total Mean Geo Mean
All 9213 100.00 92.13 52.47 48.45
M1 9201 99.87 92.01 51.45 48.58
Sample ID: CD68/FITC CD206/PE Patient ID: MDA Mo
Gate: G1 Gated Ev ents: 9213
Total Ev ents: 10000
M1
Marker Ev ents % Gated % Total Mean Geo Mean
All 9213 100.00 92.13 666.04 578.99
M1 9204 99.90 92.04 666.69 581.97
Sample ID: CD68/FITC CD206/PE Patient ID: MDA Mo
Gate: G1 Gated Ev ents: 9213
Total Ev ents: 10000
M1
Marker Ev ents % Gated % Total Mean Geo Mean
All 9228 100.00 92.28 825.67 445.22
M1 9207 99.77 92.07 825.41 449.63
Sample ID: CD163/PE Patient ID: MDA Mo
Gate: G1 Gated Ev ents: 9228
























4.2.3.2 Stimulation of lung endothelium with MDA-mϕ CM significantly 
increased adhesion and trans-endothelial migration of tumour cells  
After characterising the MCSF-mϕ and MDA-mϕ, I went on to 
examine the interactions (adhesion and transmigration) of the tumour cells 
with MCSF-mϕ CM- and MDA-mϕ CM-stimulated endothelium. The EC 
monolayers isolated from lung (FLEC and ALEC) and the umbilical cord vein 
(HUVEC) were stimulated with MCSF-mϕ CM and MDA-mϕ CM for 24 
hours prior to the static adhesion and transmigration assays as described in 
sections 2.5. From this section onwards, only HUVEC was used as a 
representative of EC from the non-metastatic sites due to the low availability 
of SVEC. 
 
Data showed that MCSF-mϕ CM stimulation of all three EC types did not 
have significant effect on the adhesion of all three breast cells (MDA-MB-231, 
MCF-7 and MCF-10A) (Fig 4.7). In contrast, MDA-mϕ CM stimulation of the 
lung endothelium, FLEC and ALEC, significantly enhanced the adhesion of 
MDA-MB-231 by 51.53 ± 7.19% and 161.24 ± 35.38% respectively compared 
to adhesion to untreated FLEC and ALEC (Fig 4.5A).  MDA-mϕ CM 
stimulation also enhanced the adhesion of MCF-7 to FLEC and ALEC by 
48.91 ± 19.22% and 70.39 ± 16.51% respectively. There were also significant 
increase in the adhesion of MDA-MB-231 and MCF-7 to MDA-mϕ CM-
stimulated lung endothelium compared to the MCSF-mϕ CM-stimulated lung 
endothelium. No enhancement in adhesion was observed for interactions with 
HUVEC (Fig 4.7A). In addition, there was also no enhancement in adhesion 
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of the normal breast epithelial cell line, MCF-10A, to both MCSF-mϕ CM and 
MDA-mϕ CM-stimulated ECs (Fig 4.7B).  
 
Next, I examined the trans-endothelial migration of the breast cells across the 
various MCSF-mϕ CM- and MDA-mϕ CM-stimulated endothelial monolayers. 
As expected, there was a significant increase in transmigration across MDA-
mϕ CM stimulated lung endothelial monolayers (FLEC and ALEC) for MDA-
MB-231 compared to untreated control and MCSF-mϕ CM stimulated lung 
endothelial monolayers. More MDA-MB-231 cells transmigrated across 
MDA-mϕ CM-simulated FLEC than untreated FLEC (174.03 ± 11.02 vs 
137.54 ± 10.99 migrated cells per field); and across MDA-mϕ CM-simulated 
ALEC than untreated ALEC (163.53 ± 36.10 vs 129.77 ± 30.49 migrated cells 
per field) (Fig 4.8A).  MCF-7 transmigration across MDA-mϕ CM-stimulated 
ALEC also significantly increased when compared to both untreated control 
and MCSF-mϕ CM-stimulated ALEC (Fig 4.8B).  The absolute number of 
transmigrated MCF-7, however, remained low compared that of migrated 
MDA-MB-231 across the lung endothelium. As for HUVEC, there was no 
significant difference in the transmigration of the MDA-MB-231 and MCF-7 
across untreated HUVEC and MDA-mϕ CM-stimulated HUVEC (Fig 4.8C). 
The number of transmigrated MCF-10A across FLEC, ALEC and HUVEC 




Figure 4.7: MDA-mϕ CM stimulation of the lung endothelium, FLEC and 
ALEC, significantly enhanced the adhesion of MDA-MB-231 and MCF-7 
There was significant increase in adhesion of both (A) MDA-MB-231 and (B) 
MCF-7 to FLEC and ALEC stimulated with MDA-mϕ CM for 24 hours 
compared to untreated controls and to MCSF-mϕ CM-stimulated FLEC and 
ALEC. There was no significant difference in the adhesion of MDA-MB-231 
and MCF-7 to MCSF-mϕ CM- and MDA-mϕ CM-stimulated HUVEC. (C) 
MCSF-mϕ CM and MDA-mϕ CM simulation of the endothelial monolayers 
had no significant effect on the adhesion of MCF-10A to FLEC, ALEC and 
HUVEC. Data shown is the mean ± SEM from three to twelve independent 
experiments. * indicates statistical significant compared to each respective 







Figure 4.8: MDA-mϕ CM stimulation of the lung endothelium, FLEC and 
ALEC, significantly enhanced the transmigration of MDA-MB-231 and 
MCF-7 
There was significant increase in transmigration of (A) MDA-MB-231 across 
both MDA-mϕ CM-stimulated FLEC and ALEC compared to untreated 
control. This increase in transmigration was also statistically different from 
that seen with MCSF-mϕ CM-stimulated FLEC and ALEC. Significantly 
more (B) MCF-7 transmigrated across MDA-mϕ CM-stimulated ALEC 
compared to respective untreated and MCSF-mϕ CM controls. There was no 
significant difference in transmigration of MDA-MB-231 and MCF-7 across 
both MCSF-mϕ CM- and MDA-mϕ CM-stimulated HUVEC. (C) MCSF-mϕ 
CM and MDA-mϕ CM simulations had no significant effect on the 
transmigration of MCF-10A across FLEC, ALEC and HUVEC. Data shown is 
the mean ± SEM from three to four independent experiments. * indicates 
statistical significant compared to each individual untreated control or MCSF-






4.2.4 TNF-α and MDA-mϕ CM stimulation of FLEC up-regulated 
expression of MMP2, MMP3, collagen, fibronectin, veriscan, TGFBI and 
integrins α2, 5 
Data from sections 4.2.1 and 4.2.3 showed that the enhancement of tumour-
endothelial interactions by TNF-α and MDA-mϕ CM stimulation was specific 
to the lung endothelium. The increase in tumour adhesion could be mediated 
by the increased expression of surface molecules on stimulated lung ECs, 
which can function as tumour binding receptors that are important for the 
observed increase in trans-endothelial migration of breast cancer cells. As 
such, I sought to identify adhesion molecules or ECM proteins on the lung 
endothelium that could contribute to the increase in tumour adhesion as a 
result of TNF-α and MDA-mϕ CM stimulations. For this purpose, I used the 
RT² Profiler PCR Array (Qiagen, SAbioscience) as it can simultaneously 
analyses the expression of 84 adhesion molecules and ECM protein genes in 
each sample. Due to the scarcity of ALEC, only FLEC was used in this series 
of experiments. From this array, I shortlisted targets that showed at least a 1.5 
fold increase in mRNA expression following TNF-α and MDA-mϕ CM 
stimulations, but not for MCSF-mϕ CM stimulation compared to untreated 
control. 
 
Expression of E-selectin, ICAM-1 and VCAM-1  on endothelial cells are 
known to be up-regulated during inflammation to aid leukocytes recruitment 
384
. Consistent with that, the PCR data showed up-regulation of E-selectin, 
ICAM-1 and VCAM-1 mRNA in FLEC upon TNF-α stimulation (mRNA 
expression compared to untreated control –           E-selectin:    244.3 ± 144.5 
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fold, ICAM-1: 32.3 ± 16.8 fold, VCAM-1: 89.8 ± 52.3 fold). Both MCSF-mϕ 
CM and MDA-mϕ CM stimulation of FLEC also showed an up-regulation of 
E-selectin, ICAM-1 and VCAM-1 mRNA expression, but at a much lower 
magnitude (Fig 4.9A). 
 
The PCR data also showed more than 1.5 fold increase in MMP2 and MMP3 
mRNA level in TNF-α- and MDA-mϕ CM-stimulated FLEC compared to 
untreated FLEC control (Fig 4.9B). This increase was not seen in the MCSF-
mϕ CM-stimulated FLEC. Since MMP2, 3 and 8 are involved in facilitating 
the transmigration of the MDA-MB-231 across FLEC (section 3.2.4), this 
increase in MMP2 and MMP3 expressions in TNF-α and MDA-mϕ CM 
stimulated FLEC further support the role of these MMPs in the transmigration 
of MDA-MB-231 across lung endothelium. 
 
Other adhesion molecules and ECM proteins that increased more than 1.5 
folds after TNF-α and MDA-mϕ CM stimulations were collagen alpha 1 (XII) 
chain (COL12A1), collagen alpha 1 (XVI) chain (COL16A1), collagen alpha 
2 (IV) chain (COL4A2), fibronectin (FN1), Transforming growth factor, beta-
induced protein (TGFBI), versican (VCAN), integrin alpha 2 subunit (ITGA2) 
and integrin alpha 5 subunit (ITGA5). There were negligible changes to these 
target mRNA levels after MCSF-mϕ CM stimulation. These targets could be 
responsible in mediating tumour-endothelial adhesion. Hence, the up-
regulation of these targets following TNF-α and MDA-mϕ CM stimulations 




Figure 4.9: TNF-α and MDA-mϕ CM stimulation of FLEC up-regulated 
mRNA level of MMP2, MMP3, collagen, fibronectin, veriscan, TGFBI, 
integrin α2 and α5 subunits  
(A) TNF-α, MCSF-mϕ CM and MDA-mϕ CM stimulation of FLEC increased 
E-selectin, ICAM-1 and VCAM-1 mRNA levels compared to untreated 
control. (B) TNF-α and MDA-mϕ CM stimulation increased MMP2 and 
MMP3 mRNA levels by more than 1.5 fold compared to untreated control. 
There was negligible changes to MMP2 and MMP3 mRNA levels after 
MCSF-mϕ CM stimulation. (C) TNF-α and MDA-mϕ CM stimulation 
increased COL12A1, COL16A1, COL4A2, FN1, TGFBI, VCAN, ITGA2 and 
ITGA5 mRNA levels by more than 1.5 fold compared to untreated control. 
There was negligible changes to these targets mRNA level after MCSF-mϕ 
CM stimulation. RT-PCR data presented as fold expression values. Data 







4.2.5 Integrins α5β1, α6β1 and α6β4 on tumour cells are involved in the 
adhesion of MDA-MB-231 and MCF-7 to TNF-α- and MDA-mϕ CM-
stimulated FLEC 
From the PCR array data, I shortlisted a few potential adhesion molecules on 
FLEC that could play a role in mediating the enhanced tumour-endothelial 
interactions following TNF-α and MDA-mϕ CM stimulations. However, the 
exact adhesion molecules involved in tumour adhesion to lung endothelial 
cells are still unknown. I speculate that integrins, E-selectin, ICAM-1 and 
VCAM-1 which are involved in various cellular adhesion and migratory 
processes of leukocytes 385,386 might play a role in mediating the adhesion of 
MDA-MB-231 and MCF-7 to lung ECs. Hence, a series of static tumour binding 
assays following pre-treatment of MDA-MB-231, MCF-7 or FLEC with 
functional blocking mAbs against various integrins α and β subunits, E-selectin, 
ICAM-1 and VCAM-1 was carried out. Murine lgG1 (MuIgG1) was used as a 
non-binding, non-blocking negative control. To eliminate the possibility of steric 
inhibition as a result of antibody binding to the cell surface, cells were similarly 
treated with the anti- MHCI mAb (clone w6/32) as a binding, non-blocking 
control. Adhesion of tumour cells to MulgG1-treated and anti-MHC1-bound 
FLEC; or adhesion of MulgG1-treated and anti-MHC1-bound tumour cells to 
FLEC was not statistically different from the binding interaction observed with 
untreated control FLEC (no antibody treatment) as presented in Fig 4.10 - 4.14.  
 
Henceforth, I systematically carried out function blocking assays to identify 
the cognate receptors partners involved in MDA-MB-231 and MCF-7 binding 
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to untreated FLEC (section 4.2.5.1), TNF-α-stimulated FLEC (section 4.2.5.2) 
and MDA-mϕ CM-stimulated FLEC (section 4.2.5.3).  
 
 
4.2.5.1 Identification of adhesion molecules that mediate breast cancer 
cells adhesion to untreated FLEC 
First, integrins on FLEC were blocked with function blocking antibodies prior 
to static tumour binding assay. However, the blocking of the individual α and 
β integrin subunit on FLEC did not result in any significant reduction in 
adhesion of MDA-MB-231 and MCF-7 (Data not shown). Since integrins 
expressed on tumour cells have been shown to be involved in the metastasis of 
cancer 
67
, I next blocked the individual integrins α and β subunits on MDA-
MB-231 and MCF-7 prior to the static tumour binding assay. Expression of 
integrins on MDA-MB-231 and MCF-7 were examined and integrins α1, α2, 
α3, α5, α6, αv, β1, β3, β4 and β5 subunits were detected on the breast tumour 
cells (data not shown). Hence I first carried out a series of experiments to 
examine the effects of blocking each of these integrin subunits individually on 
breast tumour cell binding to FLEC. 
 
Blocking of individual integrin α5, α6 and β1 subunits on MDA-MB-231 
significantly reduced MDA-MB-231 adhesion to FLEC by 13.7 ± 4.77%, 9.35 
± 3.08% and 10.48 ± 3.57% respectively (Fig 4.10A). For adhesion of MCF-7 
to FLEC, blocking of individual integrin α5, α6 and β1 subunits on MCF-7 
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also significantly reduced adhesion (13.39 ± 3.13% for α5, 12.97 ± 1.38% for 
α6, and24.15 ± 8.41% for β1) (Fig 4.10B). The blocking of integrin α1, α2, α3, 
αv, β5 and β8 subunits on MDA-MB-231 and MCF-7 did not reduce the 
adhesion to FLEC. As integrins work as heterodimers, double blocking of 
integrin subunit pairs on the tumour cells was also done. Double blocking of 
integrin heterodimer α5β1 on MDA-MB-231 and MCF-7 significantly reduced 
the adhesion of MDA-MB-231 and MCF-7 to FLEC by 17.47 ± 4.32% and 
31.52 ± 3.80% respectively (Fig 4.10 C and D). In contrast, blocking of 
integrin heterodimer α6β1 and α6β4 did not reduce the adhesion of MDA-MB-




Figure 4.10: Integrins α5β1 on tumour cells are involved in the adhesion 
of MDA-MB-231 and MCF-7 to untreated FLEC 
Blocking of individual integrin α5, α6 and β1 subunits on (A) MDA-MB-231 
and (B) MCF-7 significantly reduced the adhesion to FLEC. (C) Double 
blocking of integrin heterodimer α5β1 on (C) MDA-MB-231 and (D) MCF-7 
significantly decreased their respective adhesion to FLEC. Data shown is the 
mean ± SEM from four to eight independent experiments. * indicates 






4.2.5.2 Identification of adhesion molecules that mediate breast cancer cell 
adhesion to TNF-α-stimulated FLEC 
TNF-α stimulation of lung endothelium for 24 hours resulted in increased 
adhesion of MDA-MB-231 and MCF-7 (section 4.2.1) and an increase in E-
selectin, ICAM-1 and VCAM-1 mRNA expression in FLEC in section 4.2.4.  
E-selectin mediates the rolling mechanism of leukocytes, bringing leukocytes 
in close proximity to the endothelium for firm adhesion mediated by ICAM-1 
and VCAM-1 expressed on the endothelium 
384
. I went on to block these 
adhesion molecules on FLEC prior to adhesion assay with MDA-MB-231 and 
MCF-7. As expected, MDA-MB-231 and MCF-7 adhesion with untreated 
FLEC were not affected by the antibody blocking against E-selectin, ICAM-1 
and VCAM-1 as these adhesion molecules were not expressed on untreated 
FLEC (data not shown). Although E-selectin, ICAM-1 and VCAM-1 
expression on FLEC were up-regulated upon TNF-α stimulation, the blocking 
of these adhesion molecules did not reduce MDA-MB-231 and MCF-7 
adhesion to TNF-α-stimulated FLEC (data not shown).  
 
Next, individual integrin α and β subunits and integrin heterodimers α5β1, 
α6β1 and α6β4 on MDA-MB-231 and MCF-7 were blocked prior to static 
tumour binding assay. Similar to the results seen in section 4.2.5.1, the 
blocking of integrin α1, α2, α3, αv, β5 and β8 subunits on MDA-MB-231 and 
MCF-7 did not reduce the adhesion to TNF-α-stimulated FLEC. Consistently, 
blocking of individual integrin α5 and α6 subunits on MDA-MB-231 
significantly reduced the adhesion to TNF-α-stimulated FLEC by 14.51 ± 2.34% 
and 13.10 ± 2.49% respectively (Fig. 4.11A). Though not statistically 
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significant, blocking of integrin β1 and β4 subunits also resulted in reduction 
by 8.28 ± 2.10% and 20.03 ± 8.31% respectively. Blocking of individual 
integrin α5 subunits (19.68 ± 8.47%) and α6 subunits (13.54 ± 6.85%) on 
MCF-7 also reduced the number of adhered cells however these did not 
achieve statistical significance. Blocking of the β1 subunit significantly 
reduced the adhesion of MCF-7 to TNFα-stimulated FLEC by 13.73 ± 4.09% 
(Fig. 4.11B). Double blocking of integrin heterodimers, α5β1 and α6β4, on 
MDA-MB-231 significantly reduced the adhesion of MDA-MB-231 by 21.47 
± 3.87% and 19.66 ± 5.17% respectively (Fig 4.11C). Blocking of integrin 
heterodimer, α6β1, on MDA-MB-231 did not reduce the adhesion of MDA-
MB-231 to TNFα-stimulated FLEC. Interestingly, double blocking of all three 
integrin heterodimers, α5β1, α6β1 and α6β4, on MCF-7 significantly reduced 
their respective adhesions by 30.15 ± 6.56%, 18.97 ± 6.63% and 17.09 ± 5.41% 




Figure 4.11: Integrins α5β1, α6β1 and α6β4 on tumour cells are involved 
in the adhesion of MDA-MB-231 and MCF-7 to TNF-α-stimulated FLEC  
(A) Blocking of individual integrin α5 and α6 subunits, but not β1 and β4 
subunits, on MDA-MB-231 significantly reduced the adhesion of MDA-MB-
231 to TNFα-stimulated FLEC. (B) Blocking of individual integrin α5, α6 and 
β1 subunits on MCF-7 also reduced the adhesion of MCF-7 to TNFα-
stimulated FLEC but only the β1 condition achieved statistical significance. (C) 
Double blocking of α5β1 and α6β4 on MDA-MB-231 significantly decrease 
the adhesion of MDA-MB-231 to TNFα-stimulated FLEC. (D) Double 
blocking of α5β1, α6β1 and α6β4 on MCF-7 significantly decrease the 
adhesion of MCF-7 to TNF-α-stimulated FLEC. Data shown is the mean ± 
SEM from three to four independent experiments. * indicates statistical 






4.2.5.3 Identification of adhesion molecules that mediate breast cancer cell 
adhesion to MDA-mϕ CM stimulated FLEC  
Data from section 4.2.5.2 indicated the importance of integrin heterodimers 
α5β1, α6β1 and α6β4 on tumour cells in mediating the adhesion of tumour 
cells to TNF-α-stimulated FLEC. Next, I checked whether these integrins are 
also responsible for tumour adhesion to MDA-mϕ CM-stimulated FLEC. My 
data show that single blocking of β1 and β4 subunits on MDA-MB-231 
resulted in 21.55 ± 9.44% and 18.29 ± 7.43% reduction in MDA-MB-231 
adhesion to MDA-mϕ CM-stimulated FLEC respectively (Fig. 4.12A). 
Blocking of integrin β1 and β4 subunits on MCF-7 respectively also resulted 
in a reduction in adhesion by 44.22 ± 0.37% and 28.68 ± 8.17% (Fig. 4.12B). 
However, blocking of integrin α5 and α6 subunits on MDA-MB-231 and 
MCF-7 did not reduce the adhesion of tumour cells to MDA-mϕ CM 
stimulated FLEC. Double blocking of integrin heterodimers α5β1, α6β1 and 
α6β4 on MDA-MB-231 significantly reduced the adhesions by 28.42 ± 5.41%, 
20.05 ± 3.15%, and 26.42 ± 3.77% respectively. For MCF-7, blocking α5β1 
resulted in a 54.85 ± 10.67% reduction, blocking of α6β1 reduced the 
adhesions by 41.16 ± 5.98%, and blocking α6β4 resulted in 31.56 ± 6.17% 
reduction (Fig 4.12A and B). The magnitude of reduction in adhesion of MCF-





Figure 4.12: Integrins α5β1, α6β1 and α6β4 on tumour cells mediate 
adhesion to MDA-mϕ CM-stimulated FLEC 
(A) While single blocking of individual integrin subunits did not result in any 
statistically significant reductions, double blocking of integrin heterodimers, 
α5β1, α6β1 and α6β4, on MDA-MB-231 significantly decreased the adhesion 
of MDA-MB-231 to MDA-mϕ CM-stimulated FLEC. (B) Single blocking of 
β1 subunit and of integrin heterodimers, α5β1, α6β1 and α6β4, on MCF-7 
significantly decreased the adhesion of MCF-7 to MDA-mϕ CM-stimulated 
FLEC. Data shown is the mean ± SEM from three to four independent 
experiments. * indicates statistical significant compared to each individual 






4.2.6 Breast tumour-lung endothelium adhesion is mediated by the 
binding of α5β1 integrin on breast tumour cells to fibronectin on the lung 
endothelium 
Data from section 4.2.5 indicated that integrin α5β1 expressed on tumour cells 
is responsible for the adhesion of tumour cells to the endothelium. In addition, 
α5β1, α6β1 and α6β4 integrins on tumour cells are also responsible for the 
observed enhanced adhesion to TNF-α- and MDA-mϕ CM-stimulated FLEC. 
The known binding partner of α5β1 is fibronectin while the binding partner of 
α6β1 and α6β4 is laminin 44. Fibronectin has long been linked with cancer 
progression, especially in metastasis 
258,387-389
. Fibronectin was one of the 
shortlisted targets that showed at least 1.5 fold increase in mRNA expression 
upon TNF-α and MDA-mϕ CM stimulations, but not following MCSF- mϕ 
CM stimulation, compared to untreated FLEC (section 4.2.4). This suggests 
that fibronectin could be a potential candidate molecule on FLEC that mediate 
the enhance tumour adhesion following TNF-α and MDA-mϕ CM stimulation. 
Therefore, I decided to examine whether fibronectin could be the binding 
partner of integrin α5β1 that mediates the adhesion of tumour cells to the lung 
endothelium. 
 
4.2.6.1 Integrins α5β1 on tumour binds to fibronectin 
First, I wanted to confirm that fibronectin can indeed bind integrin α5β1 on 
MDA-MB-231 and MCF-7. Using the static binding assay, breast tumour cells 
were allowed to interact with the fibronectin under static conditions for 2 
hours. To confirm the specific binding of integrin α5β1 on tumour cells to the 
fibronectin-coated surface, the cells were also pre-treated with functional 
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blocking mAbs against integrins α5β1 prior to the binding assay. Adhesion of 
MDA-MB-231 and MCF-7 to uncoated surface was negligible compared to their 
respective adhesion to fibronectin-coated surface (Data not shown). This suggests 
that the tumour cells were able to bind to fibronectin. Individual blocking of 
integrin α5 and β1 subunits on MDA-MB-231 significantly reduced adhesion 
of MDA-MB-231 to fibronectin by 25.82 ± 6.81% and 39.25 ± 8.34% 
respectively. Double blocking of integrin heterodimer α5β1 on MA-MB-231 
further reduced the adhesion to 51.77 ± 8.97% (Fig. 4.13A). Similarly, 
individual blocking of integrin α5 subunits (45.58 ± 5.95%) and β1 subunits 
(51.99 ± 5.95%) on MCF-7 also significantly reduced adhesion of MCF-7 to 
fibronectin. Double blocking of the α5β1 integrin heterodimer reduced the 
adhesion of MCF-7 to fibronectin by 63.26 ± 5.98% (Fig4.13B). However, 
adhesion of tumour cells to fibronectin was not completely abrogated when 
α5β1 integrin on tumour cells was blocked. This is not unexpected since 
fibronectin is known to bind to several other integrins, including α4β1 and 
αvβ1 44,258. Thus, the observed residual binding suggest that other integrins on 
the tumour cells can still mediate binding to fibronectin following blocking of 
α5β1 function.  
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Figure 4.13: Integrins α5β1 on tumour cells mediate adhesion to 
fibronectin  
Blocking of individual α5, β1 subunits and double blocking of α5β1 integrin on 
(A) MDA-MB-231 and (B) MCF-7 significantly reduced the adhesion of 
MDA-MB-231 and MCF-7 to fibronectin. Data shown is the mean ± SEM 
from four independent experiments. * indicates statistical significant 






4.2.6.2 TNF-α and MDA-mϕ CM stimulation significantly increase 
surface fibronectin expression on lung endothelium 
After confirming that the integrins α5β1 on MDA-MB-231 and MCF-7 
mediates adhesion of these cells to fibronectin, I wanted to find out whether 
fibronectin is indeed expressed on the endothelial surface to mediate the 
adhesion of tumour cells. Fibronectin is known to be a major component of the 
extra-cellular matrix 
390
. Following TNF-α and MDA-mϕ CM stimulations, 
fibronectin could be up-regulated on FLEC. The presence of fibronectin in 
FLEC was examined using immunofluorescence staining. Fibronectin was 
stained with anti-fibronectin antibody and followed by a FITC-conjugated 
secondary antibody while EC junctions were stained with anti-CD31 antibody 
directly conjugated to PE.  
 
First, I compared total cytoplasmic fibronectin expression on untreated FLEC 
and on TNF-α, MCSF-mϕ CM and MDA-mϕ CM stimulated FLEC. As shown 
in figure 4.14 A and B, stimulation of FLEC with TNF-α and MDA-mϕ CM 
increased fibronectin expression by 1.73 ± 0.04 fold and 1.87 ± 0.37 fold 
respectively. MCSF-mϕ CM stimulation has negligible effect on the 
fibronectin expression. This was consistent with the fibronectin mRNA levels 
expression shown in section 4.2.4 (fig. 4.9C). Fibronectin expression in the 
adult lung ECs (ALEC) and non-metastatic site, HUVEC were also verified. A 
similar trend following TNF-α, MCSF-mϕ CM and MDA-mϕ CM 
stimulations in ALEC (Fig 4.14C) was observed. On the contrary, TNF-α, 
MCSF-mϕ CM and MDA-mϕ CM stimulations has no effect on the total 
cytoplasmic fibronectin expression in HUVEC (Fig 4.14D). 
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When I examined the cells for surface fibronectin expression, indeed, traces of 
fibronectin were observed on the surface of the untreated FLEC (Fig.4.15 A, 
left panel) and ALEC (Fig.4.15 B, left panel). After TNF-α stimulation, the 
expression of surface fibronectin on FLEC (Fig. 4.15A) and ALEC (Fig. 
4.15B) were up-regulated. Likewise, MDA-mϕ CM stimulation of FLEC and 
ALEC also significantly increased the expression of surface fibronectin (Fig. 
4.15A and B). The increased fibronectin expression co-localised with the 
CD31 junctions of the TNF-α- and MDA-mϕ CM-stimulated lung 
endothelium. While MCSF-mϕ CM stimulation of ALEC also increased the 
surface fibronectin expression, the expression was lower compared to that 
seen with MDA-mϕ CM stimulation. Quantification of the fibronectin 
fluorescent intensity showed that TNF-α MCSF-mϕ CM and MDA-mϕ CM 
stimulations significantly increased the surface fibronectin expression on 
FLEC by 3.94 ± 0.69 fold, 1.29 ± 0.06 fold and 9.81 ± 1.67 fold respectively 
compared to untreated FLEC (Fig. 4.15C). The surface fibronectin expression 
on MDA-mϕ CM-stimulated FLEC was also significantly greater than the 
expression on MCSF-mϕ CM-stimulated FLEC. Similar profile of increased in 
fibronectin fluorescence expression in ALEC, by 6.96 ± 0.13 fold, 3.21 ± 0.88 
fold and 7.42 ± 2.08 fold respectively, was observed following TNFα, MCSF-
mϕ CM and MDA-mϕ CM stimulations (Fig. 4.15D). Surface fibronectin 
expression on HUVEC was not affect by TNFα, MCSF-mϕ CM and MDA-mϕ 
CM stimulations (Fig. 4.15E).   
 
Taken together, my data strongly suggest that the tumour secreted factors 
could influence the phenotype of the macrophages in the target organ 
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microenvironment to assist in the preparation of the pre-metastatic site. 
Furthermore, my data showed that these conditioned macrophages, in turn, 
will secrete factors that can act on the endothelium to render it more 
conducive for tumour cell interactions. I have shown that pro-inflammatory 
cytokine, TNF-α and soluble factors in MDA-mϕ CM were able to enhance 
the tumour cell–lung endothelial interactions. Such effect was not observed for 
tumour cells interactions with endothelial cells from non-metastatic site. This 
difference in response between ECs from metastatic and non-metastatic sites 
to MDA-mϕ CM stimulation is consistent with the notion that there exist 
functional heterogeneity between endothelial cells from different organ sites 
339,340
. Up-regulation of surface fibronectin expression on lung endothelial 
after TNFα and MDA-mϕ CM stimulations gave rise to the increased tumour 
adhesion to lung endothelium. The increased fibronectin expression 
demonstrated that it is one of the key factors in formation of a pre-metastatic 





Figure 4.14:  TNF-α and MDA-mϕ CM stimulation increase total 
fibronectin expression in lung endothelial cells 
(A) Images show the immunofluorescence staining of cytoplasmic fibronectin 
in FLEC in untreated condition, and following TNF-α, MCSF-mϕ CM and 
MDA-mϕ CM stimulation. Fibronectin expression increased following 
stimulation by TNF-α and MDA-mϕ CM. Images shown are representative of 
two independent experiments. (B) Quantification of the fibronectin 
fluorescence is presented as percentage area of expression relative to the 
untreated control.  Stimulation of FLEC with TNF-α and MDA-mϕ CM 
increased fibronectin expression. Data shown is the mean ± SD from two 
independent experiments. (C) Similar increase in fibronectin expression in 
ALEC following TNF-α, MCSF-mϕ CM and MDA-mϕ CM stimulations was 
observed (D) TNF-α, MCSF-mϕ CM and MDA-mϕ CM stimulations did not 
affect the fibronectin fluorescence expression in HUVEC. Data shown is from 
one experiment.  
Green: Fibronectin    Red: CD-31    Blue: Nucleus    Magnification: 40X 
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Figure 4.15: TNF-α and MDA-mϕ CM stimulation significantly increase 
surface fibronectin expression in lung endothelial cells 
Images represent the immunofluorescence staining of surface fibronectin in (A) 
FLEC and (B) ALEC in untreated condition, TNFα, MCSF-mϕ CM and 
MDA-mϕ CM stimulations. Fibronectin expression increased following 
UT TNF-α MCSF-mϕ CM MDA-mϕ CM 
UT TNF-α MCSF-mϕ CM MDA-mϕ CM 
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stimulation by TNFα and MDA-mϕ CM. Quantification of the fibronectin 
fluorescence on (C) FLEC and (D) ALEC was presented as percentage area of 
expression relative to the untreated control. TNFα, MCSF-mϕ CM and MDA-
mϕ CM stimulations significantly increased the fibronectin expression. There 
was also a significant difference in the expression of fibronectin following 
MCSF-mϕ CM and MDA-mϕ CM stimulations. Data shown are from four 
independent experiments for (A&C) and from two independent experiments 
for (B&D). (E) TNFα, MCSF-mϕ CM and MDA-mϕ CM stimulations did not 
affect the fibronectin fluorescence expression in HUVEC. Data shown is from 
one representative experiment. * indicates statistical significant compared to 






Previously, most cancer research focused on characterising the adhesive and 
migratory ability of the tumour cells rather than on the metastatic 
microenvironment. The target organ microenvironment, which includes the 
stromal cells, inflammatory cells, extracellular matrix proteins, endothelial 
cells and soluble secreted factors, are in constant interaction with the 
oncoming circulating tumour cells 
247,391
 and play an active role in the 
regulation of tumour seeding. Factors secreted by cells in the organ 
microenvironment can exert both autocrine and paracrine effects to modulate 
the behaviour of the cells in the microenvironment and assist cancer 
progression. However, this niche environment that is supportive of metastatic 
growth is not well characterised. Therefore in this study I examined whether 
the soluble factors known, or speculated, to be present in the organ 
microenvironment is able to stimulate the EC to transform them to be 
conducive for tumour cells adhesion and transmigration.  
My findings so far show that  
1. TNF-α-stimulated lung endothelium also showed enhanced tumour 
interactions.  
2. Tumour secreted factors do not act directly on the EC but could readily 
prime macrophages to turn them into M2-like phenotype. These M2-like 
macrophages, in turn, stimulate the EC to enhance tumour interactions. 
3. Integrins α5β1 on breast tumour cells binds to the fibronectin expressed on 
the endothelium surface.  
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Chronic inflammation has long been associated with cancer progression as it is 
able to accelerate the events in cancer development. Several pro-inflammatory 
products (e.g. TNF-α, IL-1α, IL-1β, IL-6, IL-8, and many others) have been 
shown to play a critical role in events such as malignant cells transformation 
and promotion, tumour cells survival and proliferation, induction of 
angiogenesis, tumour invasion and eventual metastasis 
146,392,393
. TNF-α, a 
major mediator of inflammation, is frequently detected in a wide variety of 
human cancers, including breast cancer and is associated with poor prognosis 
185,394
, pancreatic cancer 
395,396
 and ovarian cancer 
397-399
. My data showed that 
TNF-α stimulation of lung endothelium (FLEC and ALEC) was able to 
increase the adhesion of breast tumour cells (MDA-MB-231 and MCF-7) and 
increase the trans-endothelial migration of MCF-7. Other groups have also 
reported that TNF-α promotes tumour cell adhesion to endothelial cells due to 
the up-regulation of adhesion molecules on the endothelium or production of 
chemokines that specifically recruit tumour cells from circulation. For 
example, TNF-α induced the up-regulation of E-selectin on HUVEC which 
enhanced colon carcinoma cells adhesion in-vitro 
400
 and breast cancer cells 
adhesion and transmigration across lung microvascular endothelium in-vitro 





Lung is one of the common sites of metastasis and my data showed that lung 
endothelium is more receptive to tumour cells after TNF-α stimulation. On the 
contrary, while TNF-α stimulation of ECs from non-metastatic sites (HUVEC 
and SVEC) can bind leukocytes 
402-405
, TNFα-stimulated HUVEC and SVEC 
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did not show enhanced adhesion or trans-endothelial migration of MDA-MB-
231 and MCF-7. This suggests that ECs from different organs exhibit different 
responses to the inflammatory mediators and organs with appropriately 
responsive ECs could be conditioned to become potential sites of metastasis. 
This finding is supported by studies showing that inflammatory mediators 
from the primary tumour site can “pre-condition” specific microenvironment 
in distant organs to form pre-metastatic niche 
406,407
. Hiratsuka et al 
demonstrated that primary tumour cells secrete vascular endothelial growth 
factor-A (VEGF-A), transforming growth factor beta (TGF-β) and TNF-α, to 
induce the expression of pro-inflammatory chemokines, S100A8 and S100A9, 
in the pre-metastatic lung microenvironment to recruit circulating tumour cells 
231
. Allergic respiratory inflammation was also shown to recruit circulating 
tumour cells to the lung and placed breast cancer patients at higher risk of lung 
metastases development 
408
.  These evidences together refute the ‘anatomical 
hypothesis’ of metastasis which suggests that tumour cell enter the lung is 
purely due to mechanical or anatomical trapping in the narrow 
microvasculature 
9
. These studies and my data show that lung endothelium 
could be readily modulated to become the suitable ‘soil’ for tumour cell 
‘docking’ while ECs from other sites could not. 
 
The inflammatory mediators that can condition the distant organ sites to form 
pre-metastatic niche can be secreted by the primary tumours or by stromal 
cells present in the target organ. In recent years, studies have shown that 
secreted factors from the primary tumour help to generate a suitable 
microenvironment in distant organs with up-regulation of inflammatory–
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related pathways or the recruitment of inflammatory cells (i.e. bone marrow-
derived cells, BMDC, myeloid cells, myeloid-derived suppressor cells, MDSC) 
to form the pre-metastatic niche 
230-232,409
. Under the influence of the tumour 
secreted factors, these pre-metastatic sites are populated by myeloid cells or 
inflammatory cells which help to modulate the local microenvironment to 
recruit tumour cells. Han and colleagues showed that the primary melanoma 
induced inflammation in the lung resulting in the clustering of inflammatory 
cells in the lung prior to the arrival of the tumour cells 
410
. In my study, I 
showed that the direct stimulation of EC with the soluble secreted factors from 
MDA-MB-231 did not enhance the endothelial interactions with MDA-MB-
231 and MCF-7. However, the soluble factors from MDA-MB-231 were able 
to condition macrophages to the M2-like phenotype. Lung endothelium 
stimulated by MDA-mϕ CM was more receptive to the tumour cells (MDA-
MB-231 and MCF-7), resulting in enhanced adhesion and trans-endothelial 
migration. The stimulation of ECs with MCSF-mϕ CM did not elicit such 
enhancement in tumour-endothelial interactions. This suggests that resident 
macrophages in the lung, my target organ of investigation, could be activated 
and phenotypically modified upon encounter with primary tumour secreted 
factors in circulation.  
 
Different tumour cells have different preferred metastatic sites 
6
. Some in-vivo 
studies that showed that the seeding of tumour cells at specific distant organ 
pre-metastatic niches could be modulated by the type or composition of 
factors secreted by the primary tumour 
230,247,411
. Kaplan and colleagues have 
shown that by changing the soluble factors of tumour cells present in the 
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circulation or microenvironment, metastasis can be redirected to another site. 
The metastasis of lewis lung carcinoma (LLC) cells in mice is usually 
observed in the lung and liver. However, in mice that had been conditioned 
repeatedly (before LLC implantation and daily thereafter) with the 
intraperitoneal injection of melanoma cell conditioned media, metastasis of 
LLC was redirected to the kidneys, spleen, intestine and oviduct which are 
common metastatic sites of melanoma.  Furthermore, cluster of BMDCs was 
observed in those metastatic sites, suggesting their role in altering the local 
microenvironment prior to the arrival of the LLC cells 
230
. This indicates that 
the preferred sites selection can be influenced by the primary tumour cells and 
the surrounding stroma. Thus, resident cells in target organs could also be 
remotely exploited by the primary tumour to assist in the formation of a pre-
metastatic niche.   
 
Studies to date focus on the tumour-macrophages interactions in the primary 
tumour lesion. These macrophages recruited into the primary tumour 
microenvironment are termed tumour-associated-macrophages (TAMs). 
TAMs are shown to share M2 macrophage characteristics and are essential for 
the tumoural angiogenesis 
330,412,413
 and invasion by promoting cancer cell 
intravasation 
414-416
. In my study, I showed that the collaboration between the 
tumour cells in the primary lesion and macrophages at the target organ is also 
important in enhancing tumour-endothelial interactions to facilitate 
extravasation at the distant organ. Similar to TAMs at the primary tumour site, 





). At this junction it is unclear what is/are the MDA-MB-
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231-derived factor(s) that can modulate macrophage phenotype. MCSF 
secreted by primary tumour has been shown to polarize macrophages to M2 
phenotype and educate them to be trophic to tumour 
330,417,418
. MDA-MB-231 
cells used in my study also produce MCSF 
419,420
, thus MCSF could be one of 
the factors that directs the MDA-mϕ towards M2 polarisation. However, the 
use of MCSF alone to generate MCSF-mϕ in this study gave rise to 
macrophages that did not promote tumour-endothelial interactions. This 
suggests that there are other soluble factors in the MDA-MB-231 CM that 
is/are acting together with MCSF to induce MDA-mϕ that are functionally 
more tumour-promoting. 
 
My data showed that TNF-α and MDA-mϕ secreted factors were able to 
stimulate lung endothelium and enhanced tumour cell adhesion. Therefore, 
adhesion molecules mediating the tumour cells adhesion was examined. 
Stimulation with pro-inflammatory factors (including TNF-α and IL-1β) up-
regulate expression of adhesion molecules (E-selectin, ICAM-1 and VCAM-1), 
MMPs (MMP3), chemokines and cytokines (MCP-1, MCP-2, IL-8), redox 
enzymes (SOD-2), toll like receptors, and MCSF on endothelial cells 
421-423
. 
Consistent with this, FLEC that we used in this study also up-regulated E-
selectin, ICAM-1 and VCAM-1 upon TNF-α stimulation. However, the 
adhesion of MDA-MB-231 and MCF-7 to TNF-α stimulated FLEC was not 
affected by blocking of these adhesion molecules. This finding suggests that 
the enhanced adhesion of MDA-MB-231 and MCF-7 to TNF-α stimulated 
FLEC is not mediated by other adhesion molecules. Although my data did not 
show the involvement of E-selectin, ICAM-1 and VCAM-1, other studies have 
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shown their role in mediating tumour cells adhesion and metastasis 
61
. Jiang et 
al. showed that the up-regulated E-selectin on lipopolysaccharide (LPS)-
stimulated lung endothelium mediates the adhesion of 4TI cells in-vitro and an 
increase in lung metastasis in LPS-treated mice 
424
. E-selectin was also 
reported to be involved in the adhesion of HT-29 colon cancer cells to 
endothelium and in the subsequent trans-endothelial migration 
425
. ICAM-1 
was also shown to mediate the adhesion and transmigration of breast cancer 
cells to HUVEC via MUC1 expressed on the breast cancer cells 
63,426,427
. 
Furthermore, integrin α4β1 on melanoma cells were shown to bind to VCAM-




Many integrins have been shown to be involved in cancer progression. The 
up-regulation or down-regulation of certain integrins has been correlated to the 
metastatic potential of different types of tumour cells 
67,429,430
. When integrins 
on tumour cells were blocked, partial reduction in adhesion to FLEC was 
observed. My data showed that the blocking of integrin α6 subunit and 
integrins α6β1 and α6β4 on MDA-MB-231 and MCF-7 could effectively 
reduce adhesion of MDA-MB-231 and MCF-7 in some of my experimental 
conditions. Integrin α6 subunit, integrins α6β1 and α6β4 have been shown to 
be up-regulated in several cancers such as breast cancer 
431
, prostate cancers 
432
 and head and neck cancers 
433,434
. Furthermore, laminin, the binding partner 
of α6β1 and α6β4, has been associated with cancer progression particularly in 
promoting tumour proliferation, evasion of apoptosis, angiogenesis and 
metastasis 
435-438
. The integrin β1 subunit has often been associated with 
invasion. Yamada et al had shown that treatment with anti-β1 monoclonal 
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antibodies blocked migration and invasion of human fibrosarcoma line HT-
1080, SV40 virus transformed embryonic lung WI38 cell line VA13, bladder 
carcinoma 5637, and colon carcinoma HCT 116 across various extracellular 
matrix components (vitronectin, laminin, collagen and fibronectin) in-vitro 
90
. 
Indeed, blocking of integrin β1 subunit on MDA-MB-231 and MCF-7 also 
reduced tumour cell adhesion to FLEC in my assays. Integrin β1 subunit forms 
heterodimer with almost every α integrin subunit (α1-9,v) 32. Integrins α1β1, 
α2β1, α3β1, α5β1, α6β1 and αvβ1 are involved in regulating tumour 




Integrins α5β1, αvβ1 and αvβ3 which share a common binding partner, 
fibronectin, have been shown to play a role in tumour adhesion and spreading 
67,440,441,443,444
. Of these three integrins, the blocking of α5 subunit and integrin 
α5β1 on MDA-MB-231 and MCF-7 consistently reduced the adhesion of the 
tumour cells to untreated, TNFα-stimulated and MDA-mϕ CM-stimulated 
FLEC. However, the blocking of integrin α5β1 on breast tumour did not 
completely reduce the adhesion to fibronectin and lung endothelium. This 
suggests that other adhesion partners of fibronectin or other adhesive pathways 
could be involved. For instance, the blocking data revealed that blocking the 
integrins α6β1 and α6β4 on the breast tumour cells also significantly reduced 
their adhesion to lung endothelium. α6β1 and α6β4 are the receptors for 
laminin, thus suggesting that laminin could contribute to the observed 
enhanced tumour cell adhesion to lung endothelium. Interestingly, studies 
have shown that hCLCA2, a Ca2+-sensitive chloride channel, expressed on 
lung ECs, binds to β4 subunit on metastatic breast tumour cells 350,386. 
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Together, my data suggest that integrins α5β1, α6β1 and α6β4 play a role in 
mediating breast tumour adhesion to lung endothelium stimulated by 
inflammatory mediators or by factors secreted by primary tumour-conditioned 
macrophages in the pre-metastatic niche. However, I have yet to confirm the 
binding partner(s) of integrins α6β1 and α6β4 and elucidate their involvement 
in the adhesion tumour cells to MDA-mϕ CM-stimulated FLEC. 
 
In my study, MDA-MB-231 indirectly increased the fibronectin expression on 
lung endothelium by secreting factors that acted on macrophages, which, in 
turn activated the endothelium. TNFα stimulation of lung endothelium was 
also able to increase the fibronectin expression. This increase in lung 
fibronectin expression is consistent with an earlier report that suggested that 
fibronectin is an essential component of a pre-metastatic niche. Kaplan et al. 
showed that during the formation of a pre-metastatic niche in the lung, 
primary tumour-secreted factors stimulated fibroblasts to increase fibronectin 
expression 
230
. Fibronectin was observed around the terminal bronchioles and 
bronchiolar veins which are common metastatic region in the lung 
230,244
. 
However, the source of the fibronectin in the metastatic niche is often linked 
to either the host fibroblasts 
230
 or the tumour cells 
244
. My findings showed 
that the enhanced fibronectin expression can also be contributed by the lung 
endothelium. Furthermore, my study clearly demonstrated the presence of 
fibronectin on the luminal surface, thus further supporting its role as an 
important receptor for disseminated breast cancer cells to home to the lung. 
The importance of fibronectin in cancer was confirmed by other studies that 





. Adhesion of tumour cells to fibronectin have also been shown 
to aid the tumour cells survival 
447,448
, which suggest that this could help the 
attached circulating tumour cells at the pre-metastatic niche to survive at the 
new organ site and proliferate to form micrometastases. Fibronectin has also 




I have shown that MDA-MB-231 could indirectly enhance tumour-endothelial 
interactions by conditioning macrophages (remotely via soluble factors) to 
secrete factors that up-regulate fibronectin expression on endothelium surface. 
Similarly, TNF-α, a common product of activated macrophages, was also able 
to do so. This up-regulation of fibronectin on the endothelium was shown to 
mediate adhesion of tumour via tumour integrin α5β1. Most importantly, it is 
only lung endothelium, and not ECs from non-metastatic sites, that was 
responsive to such stimulations resulting in the up-regulation of fibronectin 
and enhanced tumour-endothelial interactions. Fibronectin has several binding 
partners, such as integrins α3β1, α4β1, α5β1, α8β1, αvβ1, αvβ3, αvβ6, αvβ8 
and α4β7 67. From my data, integrin α5β1 is responsible for the adhesion of 
MDA-MB-231 and MCF-7 to fibronectin on the lung endothelium which is 
up-regulated in the pre-metastatic niche.  
 
Taken together, data from my in-vitro model that examined the crosstalk 
between breast tumour cells, macrophages and endothelial cells strongly 
support the hypothesis that tumour cells are able to modulate distant organs to 
form a pre-metastatic niche to enhance tumour endothelial interactions and 
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subsequent colonization. This ability to induce a pre-metastatic niche in target 
organs is probably an important determinant in organ-specific metastasis 
observed in many cancers, including breast cancer.   
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CHAPTER 5:  
MDA-mϕ derived IL6 up-regulates endothelial 
fibronectin expression via activation of the STAT3 
signalling pathway 
5.1 Introduction 
Interaction between tumour cells and stromal cells, ECM or soluble factors 
would activate multiple cellular signalling pathways in the tumour cells. In 
addition, genetic mutations including gain-of-function mutation of signalling 
receptors or loss-of-function mutation of signalling suppressor protein 
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could also result in aberrant activation of signalling pathways during 
tumourigenesis. These signalling pathways control the multiple acquired 
characteristics of the tumour cells such as self-sufficiency in growth signals, 
insensitivity to anti-growth signals, evasion of apoptosis, unlimited 





In cancer research, the study of aberrant signalling pathways and its effects on 
cell behaviour/function is often focused on the tumour cells. The emerging 
role of tumour–stroma interactions in cancer progression indicates that 
signalling pathways activated in the stromal cells are evidently important as 
well. The activation of the signalling pathways in the different non-malignant 
cell types, including endothelium and macrophages within the tumour or in the 
pre-metastatic niche could also contribute to metastatic progression.  
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Chronic inflammation, as reviewed in earlier chapters, is known to contribute 
to tumourigenesis and cancer progression. The endothelium lining the 
vasculature when activated by the inflammatory cytokines, such as TNFα and 
IL-1β during inflammation 450, are known to undergo various functional 
changes including up-regulation of inducible adhesion molecules and 
increased vascular permeability. Simulation of endothelial cells with these 
cytokines will induce the activation of NF-κB and AP1 signalling which are 
important for the transcription of many pro-inflammatory proteins 
451
. Indeed, 
the up-regulation of adhesion molecules E-selectin, ICAM1 and VCAM1, 
which is essential for leukocyte recruitment to the inflammatory site, is 
dependent on NF-κB and AP1 signalling 452. Similarly, pro-inflammatory 
cytokine activation also results in increased vascular permeability thus 
affecting endothelium integrity and barrier function. Increased vascular 
permeability is often associated with formation of gaps between adjacent cells. 
Gap formation is dependent on actin and tubulin cytoskeleton reorganization 
which in turn is regulated by the NF-κB signalling pathway 450,451,453,454.  
 
Chronic inflammation is also associated with angiogenesis 
455
. Neo-
angiogenesis is an essential component for cancer progression. Without the 
supply of oxygen and nutrients, tumour cells would not be able to grow 
beyond 1mm
3
 in volume. The key cell involved in angiogenesis is the 
endothelial cell. Inflammatory cytokine TNFα, which can also acts as an 
angiogenic factor, binds to TNFR2 and elicit the downstream signalling via 
endothelial tyrosine kinase and partly activate VEGF2 and the PI3K/AKT 
signalling 
456
. Other angiogenic factors, such as VEGFA, FGF2, ANG-1 and 
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ANG-2, signal through their respective receptor tyrosine kinases on the 
endothelial cells to activate ERK-MAPK, PI3K/AKT, STAT and PLCγ /PKC 
signalling pathways. These pathways are required to promote endothelial cell 
growth, survival and migration, resulting in effective angiogenesis 
451,457-460
. 
The formation of neo-vasculatures, which are associated with disrupted 
endothelial integrity (vascular leakiness) increases the migration of the tumour 




The inflammatory cells present in the microenvironment also secrete 
inflammatory factors that orchestrate cancer progression and direct metastasis. 
The tumour milieu is a complex mixture of pro-inflammatory and 
immunosuppressive mediators including TNFα, IL-1β, IL6, TGFβ, IL10, 
chemokines and growth factors 
5,10,138,139,146
. The collective effect of these 
mediators on the stromal compartment is able elicit a range of conflicting 
cellular functions, including activating or suppressing a response, promote 
proliferation or induce apoptosis, depending on the stromal cell type involved 
323,464,465
. For example, TAMs-derived TNFα and VEGF could act on 
endothelial cells to induce activation and up-regulation of adhesion molecule 
expression, and promote angiogenesis respectively. 
 
In the previous chapter, my results showed that MDA-mϕ CM stimulation of 
lung endothelium enhanced the tumour interactions. This finding once again 
highlighted the contribution of non-malignant cells in the microenvironment in 
driving tumour progression. As such, in this chapter, I aimed to determine the 
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molecular mechanisms underlying the priming of the lung endothelial cells by 
the MDA-mϕ CM to enhance the tumour interactions. I sought to identify the 
signalling pathways activated in the MDA-mϕ CM stimulated lung 
endothelium and the soluble factors secreted by the MDA-mϕ that are 





I investigated whether MDA-mϕ CM could activate MAPK and STAT3 
signalling pathways in FLEC. Since MDA-mϕ CM enhanced tumour-
endothelial interactions while MCSF-mϕ CM did not, the focus was to identify 
signalling pathways that are activated by MDA-mϕ CM but not by MCSF-mϕ 
CM. Then involvement of the candidate signalling pathways in the up-
regulation of endothelial-derived fibronectin to bind tumour cells was 
confirmed using the various function assays described below. 
 
5.2.1 MDA-mϕ CM stimulation activates the JNK/cJUN and STAT3 
signalling pathways in FLEC 
Protein analysis of MAPKs (ERK1/2, p38 isoforms and JNK) and STAT3 
were done on FLEC stimulated with MCSF-mϕ CM and MDA-mϕ CM. Since 
studies have shown that TNF-α activates the MAPK signalling pathway in 
endothelial cells 
466,467
.  TNF-α stimulated FLEC was used as the positive 
control for MAPK activation. First, a time course study (15, 30, 60 minutes) 
was done to determine the duration of stimulation required for the detection of 
the signalling protein activity. It was decided that 15 minutes of stimulation 
was sufficient to induce phosphorylation of the MAPKs and STAT3 protein in 
the CM-stimulated and TNFα-stimulated FLEC (Data not shown). As such, 
subsequent signalling pathway analysis was done after 15 minutes of 




In untreated FLEC, phosphorylation of ERK and p38 was observed. TNF-α 
stimulation of FLEC slightly increased p38 phosphorylation but not ERK 
phosphorylation. Similarly, MCSF-mϕ CM and MDA-mϕ CM stimulation 
increased p38 phosphorylation but not ERK phosphorylation (Fig 5.1A). 
However, there was no difference in the levels of phosphorylated ERK and 
p38 in MCSF-mϕ CM- and MDA-mϕ CM-stimulated FLEC. In contrast, 
MDA-mϕ CM stimulation resulted in higher phosphorylation of JNK than that 
seen with MCSF-mϕ CM-stimulated FLEC and untreated FLEC. AP-1 
transcription complex component c-Jun is a known substrate of JNK 
266,468
. As 
expected, I observed enhanced phosphorylation of cJUN in MDA-mϕ CM-
stimulated FLEC but not in FLEC that were stimulated with MCSF-mϕ CM 
(Fig 5.1B). MDA-mϕ CM stimulation resulted in a lower JNK 
phosphorylation and yet higher c-JUN phosphorylation as compared to TNF-α 
stimulation.  
 
Higher phosphorylation of STAT3 was observed in MDA-mϕ CM-stimulated 
FLEC compared to MCSF-mϕ CM-stimulated FLEC. There was no 
phosphorylation of STAT3 in untreated FLEC (Fig 5.1C). Hence, western blot 
analysis showed that MDA-mϕ CM stimulation activated both the JNK/cJUN 
and STAT3 signalling pathways in FLEC. In comparison, much lower 
activities in these pathways was detected following MCSF-mϕ CM stimulation 
under similar conditions.   
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Figure 5.1: Greater phosphorylation of JNK, cJUN and STAT3 protein 
was seen in FLEC following MDA-mϕ CM stimulation 
(A) Western blot analysis on total cell lysate showed that MCSF-mϕ CM and 
MDA-mϕ CM stimulation of FLEC did not affect the level of phosphorylated 
ERK but slightly increased the phosphorylation of p38. (B) MDA-mϕ CM 
stimulation resulted in greater the phosphorylation of JNK and cJUN 
compared to MCSF-mϕ CM stimulation and untreated condition. Untreated 
and TNF-α-stimulated endothelial cells served as negative and positive 
controls respectively (C) MDA-mϕ CM stimulation resulted in greater the 
phosphorylation of STAT3 compared to MCSF-mϕ CM stimulation and 
untreated condition. Beta actin served as a loading control for the western blot 

















































5.2.2 JNK/cJUN and STAT3 signalling pathways are involved in 
regulating FLEC fibronectin surface expression 
As seen in the previous chapter, MDA-MB-231 cells were able to condition 
macrophages to indirectly stimulate the lung endothelium and enhanced 
tumour-interactions through surface fibronectin up-regulation. Since MDA-mϕ 
CM activated the JNK/cJUN and STAT3 signalling pathways in FLEC, I went 
on to elucidate whether these pathways could be responsible for the up-
regulation of endothelial fibronectin and the resultant enhanced tumour-
endothelial interactions. To confirm the involvement of JNK/cJUN and 
STAT3 signalling pathways, inhibition of these pathways was carried out via 
two methods. First, the phosphorylation of the JNK and STAT3 was inhibited 
by the treatment of FLEC with JNK inhibitor (SP600125) and STAT3 
inhibitor (WP1066) respectively. Second, the cJUN protein (downstream 
substrate of JNK) and STAT3 protein were transient knockdown via the 
respective cJUN and STAT3 siRNA transfection of FLEC. Functional 
analyses were carried out by examining the endothelial surface fibronectin 
expression and the static adhesion of MDA-MB-231 to MDA-mϕ CM-
stimulated FLEC following inhibitor treatments and the siRNA transfections.  
 
5.2.2.1 Inhibition of JNK/cJUN and STAT3 signalling pathways in MDA-
mϕ CM stimulated FLEC 
Inhibition of JNK phosphorylation was carried out by treatment of FLEC with 
SP600125, which is a reversible ATP-competitive JNK inhibitor. By 
preventing phosphorylation of JNK, phosphorylation of c-Jun will be inhibited 





Consistently, the stimulation of FLEC with MDA-mϕ CM resulted in the 
expression of phosphorylated JNK and cJUN. Treatment of FLEC with 
vehicle control, DMSO, did not affect the phosphorylation of JNK and cJUN 
upon MDA-mϕ CM stimulation. The treatment of FLEC with SP600125 
resulted in no phosphorylation of JNK and cJUN when stimulated with MDA-
mϕ CM (Fig. 5.2A). Quantification of the western blot bands (expression 
relative to UT control) showed that there was significant reduction in the 
expression of phosphorylated JNK (2.11 ± 0.33 vs 7.96 ± 1.09) and cJUN 
(3.39 ± 1.13 vs 8.43 ± 1.56) respectively in in MDA-mϕ CM-stimulated 
SP600125-treated FLEC compared to FLEC stimulated with MDA-mϕ CM 
only (Fig. 5.2 B and C).  
 
As for inhibition of STAT3 phosphorylation, FLEC was treated with a STAT3 
inhibitor, WP1066, which is a small molecule STAT3 inhibitor that prevents 
the phosphorylation of STAT3 and its nuclear translocation 
471,472
. Similar to 
MDA-mϕ CM-stimulated FLEC, MDA-mϕ CM stimulation of DMSO-treated 
FLEC increased the phosphorylation of STAT3 compared to the untreated 
FLEC. Whereas, WP1066-treated FLEC reduced the phosphorylation of 
STAT3 compared to MDA-mϕ CM-stimulated FLEC (Fig. 5.3A).  
Quantification of the western blot bands (expression relative to UT control) 
showed that there were significant reduction in the expression of 
phosphorylated STAT3 in MDA-mϕ CM-stimulated WP1066-treated FLEC 
(8.19 ± 0.52) compared to the MDA-mϕ CM-stimulated FLEC (15.93 ± 0.95) 
(Fig. 5.3B). WP1066 and SP600125 have been shown to inhibit the AKT 
pathway. However, expression of AKT in FLEC was not affected by the 
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stimulations with the macrophages CM (data not shown). Therefore, the off-
target effect of WP1066 and SP600125 will not affect the functional analysis.  
 
The second method of inhibiting the signalling pathways was by transient 
knockdown of the protein of interest in FLEC via siRNA transfection prior to 
MDA-mϕ CM stimulation. cJUN siRNA and STAT3 siRNA transfections of 
FLEC were done to transient knockdown cJUN and STAT3 respectively. For 
each target, two different siRNAs were used to ensure that the observed 
reduction in target expression was indeed due to the specific target mRNA 
transient knockdown.  
 
Western blot analysis showed that both mock and negative control siRNA 
transfections of FLEC did not affect the phosphorylation of cJUN and the total 
cJUN expression upon MDA-mϕ CM stimulations compared to the MDA-mϕ 
CM-stimulated FLEC. Both cJUN siRNAs transfections of FLEC resulted in a 
partial reduction in total cJUN protein expression compared to MDA-mϕ CM-
stimulated FLEC (Fig. 5.4C). With the decrease in total cJUN protein 
expression, there was also reduction in the expression of phosphorylated cJUN 
in cJUN siRNAs transfected-FLEC after MDA-mϕ CM stimulations, 
compared to the MDA-mϕ CM-stimulated FLEC (Fig. 5.4A). Quantification 
of the western blot bands (expression relative to UT control) showed that 
cJUN siRNA transfection of FLEC reduced the expression of total cJUN 
protein (siRNA 1: 0.31 ± 0.16, siRNA 2: 0.22 ± 0.02) compared to non-
transfected MDA-mϕ CM stimulated FLEC (1.02 ± 0.11) (Fig. 5.4B). 
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Expression of phosphorylated cJUN protein was also reduced in cJUN siRNA 
transfected FLEC (JUN siRNA 1: 0.63 ± 0.39, JUN siRNA 2: 0.55 ± 0.47) 
compared to non-transfected FLEC (3.05 ± 0.54) after MDA-mϕ CM 
stimulation (Fig. 5.4C). This data showed that cJUN siRNA transfection of 
FLEC resulted in a reduction in the cJUN activity upon MDA-mϕ CM 
stimulation by reducing the expression of total cJUN protein.  
 
The phosphorylation of STAT3 and total STAT3 expression upon MDA-mϕ 
CM stimulation was also not affected in FLEC subjected to mock and negative 
control siRNA transfections, compared to MDA-mϕ CM-stimulated FLEC.  
Both STAT3 siRNAs transfections of FLEC resulted in a partial reduction in 
total STAT3 protein expression which led to a decrease expression of 
phosphorylated STAT3 in STAT3 siRNAs transfected-FLEC after MDA-mϕ 
CM stimulations, compared to the MDA-mϕ CM-stimulated FLEC (Fig. 5.5A). 
Quantification of the western blot bands (Expression relative to UT control) 
showed that both STAT3 siRNAs transfection of FLEC reduced the 
expression of total STAT3 protein (STAT3 siRNA 1: 0.32 ± 0.01, STAT3 
siRNA 2: 0.32 ± 0.15) compared to MDA-mϕ CM-stimulated FLEC (0.97 ± 
0.10) (Fig. 5.5B). Compared to MDA-mϕ CM-stimulated FLEC, 
phosphorylated STAT3 protein expression in FLEC was also reduced after 
STAT3 siRNAs transfection (STAT3 siRNA 1: 1.34 ± 0.40, STAT3 siRNA 2: 
1.11 ± 0.37) compared to that seen in un-transfected-MDA-mϕ CM-stimulated 
FLEC (5.74 ± 0.29) (Fig. 5.5C). This data showed that STAT3 siRNAs 
transfections of FLEC resulted in a reduction in the STAT3 activity upon 
MDA-mϕ CM stimulation by reducing the total STAT3 protein.  
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Figure 5.2: SP600125 treatment of FLEC significantly reduced the 
activity of JNK/cJUN signalling pathway in MDA-mϕ CM-stimulated 
FLEC  
(A) Western blot analysis of total cell lysate showed that SP600125 treatment 
reduced the phosphorylation of JNK and cJUN upon MDA-m CM 
stimulation compared to MDA-m CM-stimulated FLEC. Beta actin served as 
a loading control for the western blot data. Images shown are representative of 
three independent experiments. Quantification of the western blots showed 
significant reduction of (B) phosphorylated JNK expression; and (C) 
phosphorylated c-JUN expression in MDA-m CM-stimulated SP600125-
treated FLEC compared to MDA-m CM-stimulated FLEC. Data are the mean 
± SEM from three independent experiments. * indicates statistical significant 
compared to MDA-m CM-stimulated data at p≤0.05.  
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Figure 5.3: WP1066 treatment of FLEC significantly reduced the activity 
of STAT3 signalling pathway in MDA-mϕ CM-stimulated FLEC  
 
(A) Western blot analysis of total cell lysate showed that phosphorylation of 
STAT3 was reduced in MDA-m CM-stimulated WP1066-treated FLEC 
compared MDA-m CM-stimulated FLEC. Beta actin served as a loading 
control for the western blot data. Images shown are representative of three 
independent experiments. (B) Quantification of the western blots showed 
significant reduction of phosphorylated STAT3 expression in MDA-m CM-
stimulated WP1066-treated FLEC compared to MDA-m CM-stimulated 
FLEC. Data are the mean ± SEM from three independent experiments. * 
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Figure 5.4: Transient knockdown of cJUN in FLEC resulted in reduced 
cJUN activity upon MDA-mϕ CM stimulation  
(A) Western blot analysis of total cell lysate showed both mock and negative 
control siRNA transfections of FLEC did not affect the expression of total 
cJUN and phosphorylation of cJUN upon MDA-mϕ CM stimulation. JUN 
siRNA1 and JUN siRNA2 transfections of FLEC resulted in a partial 
reduction in total cJUN and phosphorylated cJUN expression following MDA-
mϕ CM stimulation compared to MDA-mϕ CM-stimulated FLEC. Beta actin 
served as a loading control for the western blot data. Images shown are 
representative of two independent experiments. Quantification of the western 
blots showed JUN siRNA1 and JUN siRNA2 transfection of FLEC resulted in 
a reduction of (B) total cJUN expression; and (C) phosphorylated c-JUN 
expression upon MDA-mϕ CM stimulation compared to  MDA-mϕ CM 



























Figure 5.5: Transient knockdown of STAT3 in FLEC resulted in reduced 
STAT3 activity upon MDA-mϕ CM stimulation  
(A) Western blot analysis of total cell lysate showed both mock and negative 
control siRNA transfections of FLEC did not affect the expression of total 
STAT3 and phosphorylation of STAT3 upon MDA-mϕ CM stimulation 
compared to MDA-mϕ CM-stimulated FLEC. STAT3 siRNA1 and STAT3 
siRNA2 transfections of FLEC resulted in a partial reduction in total STAT3 
and phosphorylated STAT3 expression following MDA-mϕ CM stimulation 
compared to MDA-mϕ CM-stimulated FLEC. Beta actin served as a loading 
control for the western blot data. Images shown are representative of two 
independent experiments. Quantification of the western blots showed STAT3 
siRNA1 and STAT3 siRNA2 transfection of FLEC resulted in a reduction of 
(B) total STAT3 expression; and (C) phosphorylated STAT3 expression upon 
MDA-mϕ CM stimulation compared to  MDA-mϕ CM-stimulated FLEC. Data 
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5.2.2.2 Significant reduction in surface fibronectin expression on MDA-
mϕ CM-stimulated FLEC after inhibition of JNK/cJUN and STAT3 
signalling pathways 
The previous section showed that the activity of JNK/cJUN and STAT3 
pathways could be inhibited by the inhibition of phosphorylation with the 
respective inhibitors (Fig. 5.2 and 5.3) and by the reduction of cJUN and 
STAT3 protein expression via siRNA transfection (Fig. 5.4 and 5.5). Next, I 
went on to establish whether the activities of the JNK/cJUN and STAT3 
signalling pathways were required for the induction of the surface fibronectin 
expression on FLEC following MDA-mϕ CM stimulation.  
 
FLEC was pre-treated with the DMSO vehicle control/ SP600125/ WP1066 
and then subjected to MDA-mϕ CM stimulation before immunofluorescence 
staining for surface fibronectin was carried out. The DMSO-treated FLEC 
showed an up-regulation of surface fibronectin expression following MDA-
mϕ CM stimulation compared to untreated FLEC. There was no difference in 
the fibronectin expression between MDA-mϕ CM-stimulated FLEC and 
MDA-mϕ CM-stimulated DMSO-treated FLEC. When FLEC was treated with 
SP600125, the surface fibronectin expression was reduced compared to MDA-
mϕ CM-stimulated FLEC (Fig. 5.6A). Similarly, treatment of FLEC with 
WP1066 also reduced the surface fibronectin expression compared to MDA-
mϕ CM-stimulated FLEC (Fig. 5.6B). Quantification of the fibronectin 
fluorescence intensity (percentage area of fibronectin expression relative to 
untreated control) showed that treatment of FLEC with SP600125 (1.50 ± 0.36 
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vs 6.20 ± 0.15) or with WP1066 (1.36 ± 0.28 vs 8.59 ± 1.34) significantly 
reduced the surface fibronectin (Fig 5.6 C and D).  
 
Likewise, immunofluorescence staining for surface fibronectin was done on 
MDA-mϕ CM-stimulated FLEC following cJUN and STAT3 transient 
knockdown. The mock and negative control siRNA transfection of FLEC did 
not affect the up-regulation of surface fibronectin due to MDA-mϕ CM 
stimulation. When cJUN was knockdown in FLEC by JUN siRNA 1 and JUN 
siRNA 2 transfections, the expression of surface fibronectin following MDA-
mϕ CM stimulation was reduced compared to un-transfected MDA-mϕ CM-
stimulated FLEC (Fig. 5.7A). Similarly, knockdown of STAT3 in FLEC by 
STAT3 siRNA 1 and STAT3 siRNA 2 transfections, also reduced the 
expression of surface fibronectin after MDA-mϕ CM stimulation compared to 
un-transfected MDA-mϕ CM-stimulated FLEC (Fig. 5.7A). The fibronectin 
fluorescence intensity of each condition was also quantified. Mock and 
negative control transfection of FLEC did not affect the surface fibronectin 
expression. There was significant reduction in the surface fibronectin 
expression after MDA-mϕ CM stimulation (13.68 ± 2.73) compared to MDA-
mϕ CM-stimulated FLEC when cJUN was knockdown (siRNA 1: 3.05 ± 0.52, 
siRNA 2: 2.78 ± 0.72) or when STAT3 was knockdown (siRNA 1: 4.05 ± 0.78, 




Figure 5.6: Inhibition of JNK/cJUN and STAT3 phosphorylation in 
MDA-mϕ CM-stimulated FLEC significantly reduced the surface 
fibronectin expression 
Treatment of FLEC with (A) SP600125 and (B) WP1066 reduced the surface 
fibronectin expression after MDA-m CM stimulation compared to MDA-mϕ 
CM-stimulated FLEC. DMSO vehicle control did not affect the fibronectin 
expression. Images shown in A and B are representatives of two and five 
independent experiments respectively. Quantification of the fibronectin 
fluorescence is presented as percentage area of expression relative to the 
untreated control. (C) SP600125 and (D) WP1066 treatment of FLEC reduced 
the surface fibronectin expression compared to MDA-mϕ CM-stimulated 
FLEC. Data shown in C are the mean ± SD from two independent experiments. 
Data shown in D are the mean ± SEM from five independent experiments. * 
indicates statistical significant compared to MDA-m CM-stimulated data at 
p≤0.05. 
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Figure 5.7: Transient knockdown of JUN and STAT3 in MDA-mϕ CM-
stimulated FLEC significantly reduced surface fibronectin expression 
(A) Mock and negative control siRNA transfection of FLEC did not affect the 
expression of fibronectin on the FLEC surface following MDA-mϕ CM 
stimulation compared to MDA-mϕ CM-stimulated FLEC. JUN siRNA1, JUN 
A 
JUN siRNA1 JUN siRNA2 
FLEC Surface Fibronectin staining 
STAT3 siRNA1 STAT3 siRNA2 
MOCK Negative control MDA m CM 
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siRNA2, STAT3 siRNA1 and STAT3 siRNA2 individual transfections of 
FLEC reduced the surface fibronectin expression following MDA-mϕ CM 
stimulation compared to MDA-mϕ CM-stimulated FLEC. Images shown are 
representative from three independent experiments. (B) Quantification of the 
fibronectin fluorescence is presented as percentage area of expression relative 
to the untreated control. Knockdown of cJUN in FLEC with JUN siRNA 1 and 
JUN siRNA 2 and the knockdown of STAT3 in FLEC with STAT3 siRNA 1 
and STAT3 siRNA 2 prior to MDA-mϕ CM stimulation significantly reduced 
the surface fibronectin expression compared to MDA-mϕ CM-stimulated 
FLEC. Data shown are the mean ± SEM from three independent experiments. 





5.2.2.3 Inhibition of JNK/cJUN and STAT3 signalling pathways 
significantly reduced the adhesion of MDA-MB-231 to MDA-m CM-
stimulated FLEC  
Since fibronectin was shown to be responsible for the tumour adhesion in 
section 4.2.6, I speculated that with the reduction in fibronectin expressed on 
the endothelium surface, adhesion of tumour cells to the MDA-m CM-
stimulated endothelium will be reduced. Thus, the effect of SP600125 and 
WP1066 on MDA-MB-231 adhesion to MDA-m CM-stimulated FLEC was 
examined. 
 
DMSO vehicle control treatment of FLEC did not affect the adhesion of 
MDA-MB-231 upon MDA-m CM stimulation compared to MDA-m CM-
stimulated FLEC. As expected, the adhesion of MDA-MB-231 to MDA-m 
CM-stimulated SP600125-treated-FLEC and WP1066-treated-FLEC (was 
significantly reduced by 19.41 ± 3.08% and 20.00 ± 1.28% respectively 
compared to MDA-m CM-stimulated FLEC (Fig 5.8). However, the 
reduction in adhesion of MDA-MB-231 to MDA-m CM-stimulated FLEC 
was not completely abrogated after the treatment of FLEC with SP600125 and 
WP1066.  
 
The effect of the knockdown of cJUN and STAT3 protein expression in FLEC 
with the respective siRNA transfection on MDA-MB-231 adhesion to MDA-
m CM-stimulated FLEC was also examined. There was no significant 
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difference in the adhesion of MDA-MB-231 to MDA-m CM-stimulated 
mock and negative control siRNA transfected FLEC compared to the adhesion 
of MDA-MB-231 to MDA-m CM-stimulated FLEC. MDA-m CM 
stimulation of cJUN knockdown-FLEC (Percentage reduction: JUN siRNA 1: 
24.11 ± 4.21%, JUN siRNA 2: 30.60 ± 1.64%) and STAT3 knockdown-FLEC 
(Percentage reduction: STAT3 siRNA 1: 19.22 ± 2.11%, STAT3 siRNA 2: 
24.44 ± 1.66%) resulted in a significant reduction in MDA-MB-231 adhesion 
compared to MDA-m CM-stimulated FLEC (Fig 5.9). The reduction in 
MDA-MB-231 adhesion due to cJUN and STAT3 expression knockdown 
though significant, was also not totally abrogated. 
 
Data in section 5.2.2 showed that both cJUN and STAT3 signalling pathways 
are responsible in the up-regulation of endothelial surface fibronectin by 
MDA-m CM. The reduction in fibronectin was consistent with the significant 
reduction of MDA-MB-231 adhesion to FLEC and thus confirming the role of 
fibronectin in mediating tumour adhesion. Although surface fibronectin was 
significantly reduced by cJUN and STAT3 knockdown in FLEC, MDA-MB-
231 adhesion to MDA-m CM-stimulated FLEC was not entirely eliminated. 
This suggests that, other than fibronectin, there could be other adhesion 






Figure 5.8: Inhibition of JNK/cJUN and STAT3 phosphorylation in 
MDA-mϕ CM-stimulated FLEC significantly reduced adhesion of MDA-
MB-231 to MDA-mϕ CM-stimulated FLEC 
There was no significant difference in the adhesion of MDA-MB-231 to 
MDA-m CM-stimulated DMSO-treated-FLEC compared to MDA-m CM-
stimulated FLEC.  Adhesion of MDA-MB-231 to MDA-m CM-stimulated 
SP600125-treated and WP1066-treated-FLEC was significantly reduced 
compared to MDA-m CM-stimulated FLEC. Data shown are the mean ± 
SEM from eight independent experiments. * indicates statistical significant 




Figure 5.9: Transient knockdown of JUN and STAT3 in MDA-mϕ CM-
stimulated FLEC significantly reduced adhesion of MDA-MB-231 to 
MDA-mϕ CM-stimulated FLEC 
There was no significant difference in the adhesion of MDA-MB-231 to 
MDA-m CM-stimulated mock-transfected and negative control siRNA-
transfected FLEC compared to MDA-m CM-stimulated FLEC.  Adhesion of 
MDA-MB-231 to MDA-m CM-stimulated JUN-knockdown-FLEC (JUN 
siRNA 1 and 2) was significantly reduced compared to MDA-m CM-
stimulated FLEC. Similarly, MDA-MB-231 adhesion was also significantly 
reduced for MDA-m CM-stimulated STAT3-knockdown-FLEC (STAT3 
siRNA 1 and 2) compared to MDA-m CM-stimulated FLEC. Data shown are 
the mean ± SEM from eight independent experiments. * indicates statistical 




5.2.3 MDA-mϕ secretes higher concentration of IL-6 compared to MCSF-
mϕ 
JNK/cJUN and STAT3 signalling pathways in FLEC were shown to be 
responsible for the up-regulation of endothelial surface fibronectin and 
tumour-adhesion following MDA-mϕ CM stimulation. I wanted to identify the 
soluble factor(s) in the MDA-mϕ CM that activates those signalling pathways. 
I first carried out a series of intra-cytoplasmic flow cytometry analysis of 
MDA-mϕ to identify the soluble factors produced by the MDA-mϕ. A 
comparison between MCSF-mϕ and MDA-mϕ was also made. 
 
As mentioned earlier, pro-inflammation signalling pathways, including the 
MAPK signalling pathways have been associated with the progression of 
many cancers. Signalling pathways analysis showed that JNK/cJUN signalling 
pathway in FLEC was activated upon MDA-mϕ CM stimulation (Fig 5.1B). 
TNF-α and IL-1β are key cytokines present in tumour microenvironment that 
drives tumour development and invasion 
175,473-475
. IL-1 β activates pathways 
similar to TNF-α. Both the TNF-α and IL-1 β receptors lead to the activation 
of the JNK signalling pathway 
476,477
. Therefore, I first examined whether 
MDA-mϕ produce TNF-α and IL-1β. However, intra-cytoplasmic flow 
cytometry data revealed that both MCSF-mϕ and MDA-mϕ did not secrete 
TNF-α and negligible level of IL-1β (Fig. 5.10 A and B). As such, it is unclear 





Similarly, STAT3 signalling pathway has also been shown to be activated in 
many cancers 
478-480
. A large number of cytokines and growth factors can 
activate STAT3 signalling pathways, such as IFN family and gp130 family 
481
. 
One signature of M2 macrophages and TAM is the secretion of IL-10 
377,378
. 
The observation of both MCSF-mϕ and MDA-mϕ being M2 phenotype in 
chapter 4 prompted me to examine whether these macrophages produce IL-10. 
As expected, both MCSF-mϕ and MDA-mϕ produced IL-10 but the level of 
IL-10 expression for MCSF-mϕ and MDA-mϕ was similar. As such, IL-10 is 
unlikely to be the soluble factor in MDA-mϕ CM responsible for the enhanced 
tumour-endothelial interactions.  
 
Members of gp130 family, such as IL-6 and oncostatin M (OSM) have been 
highly associated with cancer progression. High serum IL-6 in cancer patients 
have been correlated with advanced stage of several cancers 
482-484
. OSM had 
been implicated in tumour progression by enhancing angiogenesis 
485-487
. 
Therefore, I went on to examine whether MCSF-mϕ and MDA-mϕ produce 
IL-6 and OSM. Intra-cytoplasmic flow cytometry analysis showed that both 
MCSF-mϕ and MDA-mϕ secreted similar level of OSM (Fig. 5.10D). 
However, MDA-mϕ produced a higher level of IL-6 than MCSF-mϕ (Fig. 
5.10E). Quantification of soluble IL-6 concentration in the respective CM 
using ELISA confirmed that MDA-mϕ secreted significantly higher amounts 
of IL-6 than MCSF-mϕ (Fig 5.10F). MCSF-mϕ CM contained very low level 
of IL-6 (2.57 ± 1.61 pg/ml) compared to MDA-mϕ CM which contained a 
significantly higher concentration of IL-6 (3418.02 ± 537.25 pg/ml). Therefore, 
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MDA-mϕ-secreted IL-6 could be the factor that gave rise to the enhanced 




Figure 5.10: MDA-mϕ secretes significantly higher amount of IL-6 
Intra-cytoplasmic flow cytometry analysis showed that MCSF-mϕ and MDA-
mϕ did not produce (A) TNF-α and (B) IL-1β. Both MCSF-mϕ and MDA-mϕ 
produced (C) IL-10 and (D) OSM while (E) MDA-mϕ produced higher level 
of IL-6 compared to MCSF-mϕ. Data shown is a representative of two to six 
independent experiments. Geo mean of expression is indicated in each graph 
in red. (F) IL-6 ELISA data showed that MDA-mϕ secreted significantly 
higher concentration of IL-6 compared to MCSF-mϕ. Data shown are the 
mean ± SEM from nine independent experiments. * indicates statistical 
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5.2.4 MDA-mϕ-derived IL-6 plays a role in the up-regulation of 
endothelial surface fibronectin and tumour adhesion 
After confirming that IL-6 is present in the MDA-mϕ CM, I went on to 
examine whether IL-6 is able to activate STAT3 signalling pathway in FLEC, 
up-regulate surface fibronectin expression and enhance tumour-endothelial 
adhesion. Therefore, FLEC was stimulated with recombinant human (rh) IL-6 
prior to western blot analysis for STAT3 signalling pathway, surface 
fibronectin immunofluorescence staining and MDA-MB-231 binding assay. 
 
As expected, rhIL-6 stimulation of FLEC increased the phosphorylation of 
STAT3 compared to untreated FLEC (Fig. 5.11A). Quantification of the 
western blot bands showed that the phosphorylation of STAT3 in rhIL-6-
stimulated FLEC was significantly increased by 10.54 ± 2.17 times compared 
to untreated FLEC (Fig. 5.11B). In addition, fibronectin expression was up-
regulated on rhIL-6-stimulated FLEC compared to untreated FLEC (Fig. 
5.11C). Quantification of the fibronectin fluorescence intensity indicated that 
there is a 5.07 ± 0.61 fold higher fibronectin expression on rhIL-6-stimulated 
FLEC compared to untreated FLEC (Fig. 5.11D). Consistent with the increase 
in surface fibronectin expression on rhIL-6-stimulated FLEC, adhesion of 
MDA-MB-231 to rhIL-6-stimulated FLEC was also significantly increased by 
87.16 ± 1.76% compared to untreated FLEC (Fig. 5.11E).  
 
Next, to confirm that IL-6 in MDA-mϕ CM is responsible for the effect 
observed upon MDA-mϕ CM stimulation, IL-6 in MDA-mϕ CM was 
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neutralised with a IL-6 neutralising antibody before being used to stimulate 
FLEC. Alternatively, the IL-6 receptor (IL-6R) on FLEC was blocked with a 
IL-6R blocking antibody prior to MDA-mϕ CM stimulation. Prior to carrying 
out the function assays to determine fibronectin expression and MDA-MB-231 
adhesion, IL-6 concentration in MDA-mϕ CM was measured after incubation 
with IL-6 neutralising antibody. Results from the ELISA showed that 
treatment with the IL-6 neutralising antibody (3μg/ml) significantly reduced 
the IL-6 concentration in MDA-mϕ CM from 4914.55 ± 412.19pg/ml to 
459.03 ± 9.51pg/ml (Fig. 5.12A). The effect of IL6 neutralisation or the 
blocking of IL6R on fibronectin expression was first examined. Simultaneous 
treatment of rhIL-6, or MDA-mϕ CM, and FLEC monolayer with MuIgG, did 
not affect the surface fibronectin expression compared to that detected on 
rhIL-6-stimulated and MDA-mϕ CM-stimulated FLEC. Upon neutralisation of 
rhIL-6 and of IL-6 in MDA-mϕ CM, surface fibronectin expression was 
greatly reduced (Fig. 5.12B). Similarly, the blocking of IL-6R on FLEC prior 
to stimulation by rhIL-6 or MDA-mϕ CM also reduced the surface fibronectin 
expression compared to rhIL-6- and MDA-mϕ CM-stimulated FLEC 
respectively (Fig. 5.12B). As fibronectin expression was shown to be 
dependent on the activation of STAT3 signalling pathway, STAT3 signalling 
in IL-6R-blocked, IL-6-neutralised MDA-mϕ CM-stimulated FLEC was 
examined. As expected, western blot analysis showed that combination of IL-6 
neutralisation in MDA-mϕ CM with IL-6R blocking on FLEC resulted in a 




Lastly, MDA-MB-231 adhesion was examined. Prior to the stimulation of 
FLEC with rh-IL-6 or MDA-mϕ CM, IL-6R on FLEC was blocked and IL-6 
in rh-IL-6 or MDA-mϕ CM was neutralised. Combination treatment of rhIL-6, 
or MDA-mϕ CM, and FLEC with MuIgG, did not affect MDA-MB-231 
adhesion compared to the adhesion to rhIL-6 and MDA-mϕ CM-stimulated 
FLEC. On the other hand, the combination of IL-6 neutralisation of rh-IL6 and 
IL-6R blocking of FLEC significantly reduced the adhesion of MDA-MB-231 
by 23.0% when compared to the adhesion to IL-6-stimulated FLEC (Fig. 
5.13A). Similarly, combination of IL-6 neutralisation of MDA-mϕ CM and 
IL-6R blocking of FLEC significantly reduced MDA-MB-231 adhesion by 
21.9% when compared to the adhesion to MDA-mϕ CM-stimulated FLEC 
(Fig. 5.13B).  The data confirmed that IL-6 is the stimulating factor in MDA-
mϕ CM responsible for the induction of fibronectin expression on the 
endothelial surface which in turn leads to enhanced tumour adhesion to FLEC.   
 
In conclusion, MDA-mϕ CM activates the JNK/cJUN and STAT3 signalling 
pathways in FLEC to up-regulate endothelial surface fibronectin expression. 
MDA-mϕ-derived IL-6 contributes to the activation of STAT3 signalling 
pathway in FLEC and fibronectin up-regulation. The increased fibronectin on 
the endothelial surface facilitates the adhesion of tumour cells, resulting in the 
enhanced tumour-endothelial interactions. These data support the importance 
of JNK/cJUN and STAT3 signalling in the formation of the pre-metastatic 
niche; and that one of the mediators contributing to the activation of the 
STAT3 signalling pathway is IL-6.  
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Figure 5.11: Stimulation of FLEC with human recombinant IL-6 up-
regulated surface fibronectin expression and MDA-MB-231 adhesion 
(A) Western blot analysis on total cell lysate showed that rhIL-6 stimulation 
increased the phosphorylation of STAT3 compared to untreated condition. 
Beta actin served as a loading control for the western blot data. Images shown 
are representative of twelve independent experiments. (B) Quantification of 
the western blot bands showed that rhIL-6 stimulation significantly increased 
the phosphorylation of STAT3 compared to untreated condition. Data shown 
are the mean ± SEM from thirteen independent experiments. (C) 
Immunofluorescence staining images showed that the rhIL-6 stimulation 
increased surface fibronectin expression compared to untreated control. 
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Images shown are representative of four independent experiments. (D) 
Quantification of fibronectin fluorescence intensity showed that rhIL6 
stimulation of FLEC significantly increased surface fibronectin expression 
compared to untreated FLEC. Data shown in D are the mean ± SEM from four 
independent experiments. (E) Significantly more MDA-MB-231 adhered to 
rhIL-6-stimulated FLEC compared to untreated FLEC. Data shown are the 
mean ± SEM from three independent experiments. * indicates statistical 
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Figure 5.12: IL-6 present in MDA-mϕ CM played a role in up-regulation 
of surface fibronectin on MDA-mϕ CM-stimulated FLEC  
(A) IL-6 concentration in MDA-mϕ CM was reduced significantly after 
treatment with IL-6 neutralising antibody. Data shown are the mean ± SEM 
from four experiments. * indicates statistical significance compared to MDA-
m CM at p≤0.05. (B) Immunofluorescence staining images showed that the 
neutralisation of IL-6 in rhIL-6 and MDA-mϕ CM with neutralising IL-6 
antibody (3µg/ml) effectively decreased surface fibronectin expression. IL-6 
receptor blocking with IL-6R blocking antibody (3µg/ml) on FLEC also 
reduced surface fibronectin expression compared to rhIL-6- and MDA-mϕ 
CM-stimulated FLEC. Images shown are representative of two independent 
experiments. (C) Western blot analysis on total cell lysate showed that 
phosphorylation of STAT3 was reduced when both IL-6 in MDA-mϕ CM was 
neutralised and IL-6R on FLEC was blocked. Beta actin served as a loading 
control for the western blot data. Images shown are representative of three 


















Figure 5.13: IL-6 present in MDA-mϕ CM contributes to the enhanced 
MDA-MB-231 adhesion to MDA-mϕ CM-stimulated FLEC 
(A) Static adhesion of MDA-MB-23 to IL-6-stimulated FLEC was 
significantly reduced when IL-6 was neutralised with neutralising antibody 
(6µg/ml) together with IL-6R on FLEC was blocked with blocking antibody 
(6µg/ml). (B) Similarly static adhesion of MDA-MB-231 was significantly 
reduced by when IL-6 in MDA-mϕ CM was neutralised in combination with 
the blocking of IL-6R on FLEC. Data shown are the mean ± SEM from three 
experiments. * indicates statistical significant compared to IL-6- stimulated or 







During metastatic progression, the primary tumour cells actively modify the 
local and remote organ’s stromal compartments to promote their own 
propagation. The modulated distant organ microenvironment that is favourable 
to the disseminated tumour cells is known as the pre-metastatic niche. This in-
vitro study showed that tumour cells (MDA-MB-231) were able to condition 
macrophages to stimulate lung endothelium leading to enhanced tumour 
adhesion and transmigration. Importantly, my data also showed that the 
modulated lung endothelium up-regulated fibronectin expression and that was 
responsible for the observed increase in tumour adhesion. Consistent with that, 
various in-vivo studies have shown that secreted factors of primary tumour 
such as VEGF, PIGF, TNF-α and TGF-β, along with the recruitment or 
clustering of BMDCs, VEGFR1
+
 haematopoietic progenitor cells, Mac 1
+
 
myeloid cells and CD11b
+
 myeloid cells initiate the pre-metastatic niche in the 
distant organs 
230-232,410,411
. The induction of STAT3 activation in myeloid 
cells by primary tumour-derived factors is also crucial for this process 
265
.   
 
5.3.1 MDA-mϕ CM activates JNK/cJUN and STAT3 signalling pathways 
in lung endothelium 
One of the areas in cancer research is the role of signalling pathways in 
promoting cancer progression. However, these studies were usually focused 
on understanding the signals that were activated in the tumour cells rather than 
the cells of the stromal compartment. In my pre-metastatic niche study model, 
the specific modulation of endothelial cells by MDA-mϕ CM activated the 
pro-inflammatory JNK/cJUN and STAT3 signalling pathways and enhanced 
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tumour adhesion and extravasation. In comparison, stimulation of FLEC by 
MCSF-mϕ CM resulted in lower/ negligible JNK/cJUN and STAT3 activities.  
 
JNK/cJUN activation is important in inflammation as well as regulation of cell 
proliferation 
269,488,489
. In endothelial cells, JNK signalling was shown to 
contribute to increasing angiogenic potential 
490
. Although no work has 
specifically shown the importance of JNK/cJUN signalling pathway in 
endothelial cells found within a pre-metastatic niche formation, there have 
been in-vivo evidences indicating the importance of JNK in the successful 
establishment of metastatic secondary sites. Nasrazadani and Van Den Berg 
showed that JNK2 activity in tumour cells and stromal cells in the secondary 
site is important for secondary colonization of breast cancer in bone and lung 
in a mouse model 
491
. Yamada SD et al. showed that the expression of 
mitogen-activated protein kinase (MAPK) kinase 7/c-Jun NH2-terminal kinase 
(JNK)-activating kinase (MKK7) which phosphorylates JNK contributed to 
metastasis in a mouse model of ovarian carcinoma 
492
. However, there is also 
contradicting evidence where the phosphorylation of JNK prevented the 




STAT3 also play an important role in inflammation. STAT3 can function as a 
regulator for both pro-inflammatory and anti-inflammatory responses 
depending on the active cytokine involved 
295,494
. STAT3 activation in the 
distant organ stromal cells such as myeloid cells, fibroblast and endothelial 





. The study showed that activation of STAT3 in myeloid cells 
clustering in the lung led to the secretion of factors that, in turn, activated 
other cells in the environment such as fibroblast to aid in the initiation and 
maintenance of the pre-metastatic niche 
265
. Kujawski et al. showed that 
activation of STAT3 in myeloid-derived suppressor cells and macrophages 
isolated from tumours were necessary for the activation of STAT3 in 
endothelium to promote angiogenesis 
215
. Consistent with these reports, my 
data showed that STAT3 signalling in lung endothelium can be activated by 
the TAMs. However, I have yet to examine whether STAT3 activity is up-
regulated in the MDA-mϕ and is necessary for IL-6 production.  
 
5.3.2 JNK/cJUN and STAT3 pathways regulate fibronectin expression on 
MDA-mϕ CM stimulated lung endothelium 
The expression of fibronectin is regulated by the binding of transcription 
factors to the CRE element located upstream of the transcription start site in 
the human fibronectin gene 
495,496
. Transcription control of fibronectin can be 
regulated by the binding of AP-1 complex to the CRE element on the 
fibronectin gene in cardiac fibroblast 
497
 and endothelial cells 
498
. In my study, 
MDA-mϕ stimulation of FLEC resulted in the phosphorylation cJUN protein. 
This suggested that the phosphorylated cJUN which is part of the AP-1 
heterodimer can activate the transcription of fibronectin. Another member of 
the AP-1 complex, ATF-2, can form a complex with cJUN to bind to the 
ATF/CRE motif to enhance gene transcription 
499
. ATF-2/cJUN AP-1 complex 
has been shown to bind to the ATF/CRE motif to up-regulate the expression of 
E-selectin 
499





expression could also be regulated by the ATF-2/cJUN AP-1 complex. ATF-2 
is a known downstream substrate of JNK signalling 
500
. My data showed 
concurrent JNK activation in the FLEC. Although the activity of ATF-2 was 
not examined in my study, it is possible that ATF-2 could also be 
phosphorylated in FLEC and form a heterodimer with cJUN to regulate 
fibronectin transcription. 
 
The up-regulation of fibronectin expression on FLEC surface was also shown 
to be regulated by STAT3 signalling in my study. This observation is 
consistent with numerous studies carried out in different cell types, which 
showed that fibronectin is a direct STAT3 target gene. Reduction of STAT3 
activity using dominant negative STAT3 in mouse embryonic stem cells 
resulted in the down-regulation of fibronectin mRNA expression 
501
. Another 
study showed that constitutively activated STAT3 in prostate epithelial cells 
resulted in increased fibronectin expression 
502
. In breast tumour cells, 
fibronectin was also shown to be a downstream effect of the STAT3 signalling 
cascade promoting tumour progression 
503-505
. However, the STAT protein 
activated may also be dependent on the cell type involved. Wang el al showed 
that fibronectin synthesis in glomerular mesangial cells was regulated by 
STAT1 instead of STAT3 
506
. In the context of pre-metastatic niche, STAT3 
activation in fibroblast due to the secreted factors by the myeloid cells/ 
haematopoietic stem cells clustered in the distant organ was required for 
fibronectin secretion 
230,265
. Similarly, my data showed that activation of 
STAT3 in lung ECs stimulated by MDA-mϕ secreted factors contributed to 




Other than JNK/cJUN and STAT3 signalling pathways, fibronectin expression 
can also be regulated by various other signalling pathways including the 
MAPK signalling pathways, ERK and p38 
507,508





 and the Wnt signalling pathway 
513
 depending on the cell type and 
the stimulating agent involved. In addition to transcriptional regulation, 
fibronectin expression is also regulated by post-transcriptional RNA level 




5.3.3 MDA-mϕ-derived IL-6 is the stimulating factor that up-regulates 
fibronectin expression in lung endothelium 
Although TAMs exhibit anti-inflammatory M2 macrophage phenotype, they 
also secrete various pro-inflammatory cytokines, including TNF-α and IL-1β 
517
. TNF-α and IL-1β are key cytokines that drives tumour development and 
metastasis 
175,473-475
 and activate JNK signalling pathways 
266,269
.  Co-culture 
of monocytes/ macrophages with tumour cells (e.g. breast tumour cells, MCF-
7 and SK-BR-3, pancreatic adenocarcinoma cells, HPC-4, and ovarian cancer 
cells, IGROV1) induced the secretion of TNF-α by the macrophages. The 
presence of TNF-α increased the invasiveness of the tumour cells and induced 
tumour expression of MMP2 and MMP9 
172,289
.  TAMs in tumour have also 
been shown to be anti-tumour. In colorectal tumours, TAMs secrete IL-1β to 
activate T cells and elicit an anti-tumour response 
518
. However, intra-
cytoplasmic flow cytometry analysis of MDA-mϕ generated in my study 
showed that TNF-α and IL-1β were absent. Mytar and colleagues showed that 
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re-stimulation of tumour-conditioned macrophages with tumour cells 
deactivate the anti-tumour response by decreasing the macrophage production 
of TNF-α, IL-1β and IL-12 and increased the production of IL-10. The 
inhibition of tumour-conditioned macrophages anti-tumour effect was due to 
the tumour cell-derived hyaluronan 
519
. In my study, I have yet examine what 
are the factors secreted by MDA-MB-231 that conditioned the macrophages. 
As such, it is unclear what tumour-derived factors could switch the role of the 
macrophages towards pro-tumour to enhance tumour-endothelial interactions.  
 
Inflammatory cytokines such as IL-6 family of cytokines (i.e. IL-6 and 
oncostatin M, OSM) and IL-10 are activators of the STAT3 signalling 
pathway 
295,520
. MDA-mϕ generated in my study produced all three cytokines, 
IL-6, OSM and IL-10, while normal MCSF-mϕ only produced OSM and IL-
10. OSM was initially shown to inhibit tumour growth in-vitro 
521,522
, but 
subsequent studies showed that its presence can contribute to tumour 
detachment and angiogenesis 
523,524
. Co-culture of neutrophils and tumour 
cells stimulate neutrophils to secrete of OSM which can contribute to 
angiogenesis and tumour invasion in-vitro 
485,525
. OSM has been shown to 
contribute to M2 polarization of TAMs 
526
. Similarly, IL-10 present in the 





IL-10 secreted by TAMs is known to create an anti-inflammatory 
microenvironment 
464,528,529
. Exposure to IL-10 could modulate macrophages 
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to secrete chemokines (e.g. CXCL13, CCL16 and CCL18) to specifically 
attract Tregs and Th2 cells in the upkeep of an immune-suppressive 
environment 
168,530
.  Other than the inflammatory roles, OSM and IL-10 are 
able to influence the expression of extra cellular matrix. OSM strongly induces 
fibronectin expression in MCF-7 via the STAT3 signalling cascade 
503
. 
Conversely, IL-10 was shown to up-regulate collagen and decorin but down-




Since there was a significant difference in the amount of IL-6 secreted by 
MCSF-mϕ and MDA-mϕ, it was hypothesized that MDA-mϕ-derived IL-6 is 
responsible for the differential effect on FLEC to modulate tumour 
interactions. IL-6 plays an important role in the pathogenesis of cancer, 
ranging from tumour initiation, subsequent growth and to eventual metastasis 
139,207
. High serum concentration of IL-6 is related to poor prognosis in many 
cancers, including breast cancer and lung cancer 
220,221
. IL-6 is one of the 
cytokines secreted by TAM to promote tumour survival, proliferation and 
angiogenesis 
214,215,532
. Roca et al. showed that IL-6 is also needed for the 
survival of CD11b
+
 monocytes and induced the M2 polarization by inhibiting 
caspase-8 cleavage and increase autophagy 
533
. Therefore, the TAM-derived 
IL-6 in the tumour microenvironment could promote the survival of newly 
recruited monocytes and differentiate them towards M2 phenotype. 
 
In my study, the stimulation of FLEC by IL-6 enhanced the adhesion of MDA-
MB-231 via the up-regulation of surface fibronectin. This suggests that the 
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presence of IL-6 in distant organ sites could also attract circulating tumour 
cells into the secondary organ via the induction of fibronectin expression in 
the vasculature. This finding is consistent with several studies that showed 
enhanced fibronectin expression at the induced pre-metastatic niches in their 




TAMs are known to contribute to immunosuppression in the tumour 
microenvironment by secretion of immunosuppressive cytokines such as IL-10 
and TGF-β 517. TGF-β and other growth factors released by TAMs such as 
epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and 
VEGF are important for promoting angiogenesis in tumour 
171,377,534
. Of note, 
TGF-β and EGF are also activators of the JNK/cJUN signalling pathway 535,536. 
In addition, both growth factors are also able to induce fibronectin expression 
in fibroblasts via PKC signalling 
508,510
. However, it is unclear whether the 
MDA-mϕ generated in my study secreted TGF-β and EGF.  
 
 
Results from this chapter and other studies highlighted the importance of 
STAT3 signalling in the development of pre-metastatic niche. IL-6/STAT3 
signalling is known to be crucial in the different stages of cancer progression, 
particularly in metastasis. My results also suggest that in response to the 
secreted factors by TAMs, particularly IL-6; endothelial cells in stroma can be 
induced to produce and deposit fibronectin on the apical surface. Furthermore, 
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I showed that both JNK/cJUN and STAT3 signalling pathways are important 
for regulating fibronectin production in endothelial cells. This new insight in 
the specific signalling pathways and soluble factors involved in pre-metastatic 
niche formation is crucial for the development of targeted treatment strategies 
to prevent metastasis.  




CHAPTER 6: GENERAL DISCUSSION 
All cancers have different preferred organ sites for metastatic establishment 
6
. 
This pattern of metastasis is not random thus suggesting that one distant organ 
is more prone to secondary growth than another. During the exit of the 
circulating tumour cells from either lymphatics or blood vessels, adherence to 
the endothelial surface is necessary prior to trans-endothelial migration. 
Importantly, tumour cells are not the only participant in this complex process. 
It is believed that the endothelium in different organs expresses different 
surface adhesion molecules and secretes different growth factors to facilitate 
organ-specific metastasis 
3,537,538
. In addition, other cells in the organ 
microenvironment, including myeloid cells, macrophages, and fibroblasts have 
been implicated in tumourigenesis and metastasis 
135,539,540
. Hence, the 
outcome of the metastasis progression is dependent on both the intrinsic 
properties of the tumour cells and the receptiveness of the host organ. This 
distant organ microenvironment that is rendered favourable to the colonisation 
by the disseminated tumour cells is termed as the pre-metastatic niche.  
 
Despite the growing knowledge on the role of the pre-metastatic niche in 
tumour metastasis, little is known about the long-range systemic effect of the 
tumour secreted factors on the distant organ microenvironment and the precise 
mechanism behind pre-metastatic niche formation. Current evidence 
supporting the pre-metastatic niche paradigm and the proposed mechanisms 
involved in its formation are determined predominantly in in-vivo mouse 
models 
230,231
. In this study, I have developed an in-vitro model to investigate 
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the cross-talk between tumour cells, macrophages and endothelial cells in 
organ-specific metastasis; specifically to model the formation of the lung pre-
metastatic niche in breast cancer.  
 
 
6.1 Activated endothelium is the gateway to successful colonisation of the 
distant target organ 
Endothelial cells play an important role in metastasis as tumour-endothelial 
interaction has been identified as one of the factors that contribute to organ-
specific metastasis 
541
. Circulating tumour cells have to arrest at the vascular 
endothelial cells of the target organ before extravasation and colonization. The 
endothelial cells in the vasculature of different organs express different surface 
adhesion receptors and secrete different growth factors thereby contributing in 




Numerous studies have identified specific surface molecules constitutively 
expressed in the target organs, either on the endothelium or in the parenchyma, 
that have acted as homing receptors for incoming tumour cells. For example, 
the expression of lung-specific endothelial cell adhesion molecule (Lu-
ECAM-1) on lung endothelium is responsible for the lung colonization of 
melanoma cells in-vivo 
542
. Integrin αvβ3 on melanoma cells was also shown 





In another study, Integrin α6β4 on breast cancer cells was shown to bind to 




Some of these homing receptors are inducible under the influence of soluble 
factors in the organ microenvironment. For instance, selectins are not normally 
expressed on resting endothelium but can be induced by inflammatory 
cytokines such as TNFα and IL-1β 18. The up-regulated E-selectin on liver 
endothelial cells, in response to TNFα, mediated the adhesion of lung 
carcinoma cells and colorectal carcinoma cells leading to liver metastasis 
57
. 
The induction of E-selectin in the liver of E-selectin-expressing transgenic 
mice redirected metastasis of melanoma cells to the liver from the usual 
metastatic organ (lung) in normal mice 
543
. These results suggest that the up-
regulation of homing receptors in distant organs could be part of the pre-
metastatic niche formation that directs future metastasis. 
 
Here, I have shown that the up-regulation of fibronectin on lung endothelial 
cells can enhanced the binding of breast tumour cells. This suggests that 
expression of fibronectin on the endothelium may act as a homing receptor for 
disseminated breast cancer cells in-vivo. In addition, binding of tumour cells to 
ECM has been shown to promote tumour cells survival and increase their 
migratory ability 
435,447,448
. This suggests that the interaction between newly 
arrived tumour cells and fibronectin expressed on the endothelium could also 
confer survival signals to the tumour cells to increase their chance of 
colonisation in their new environment. The up-regulation of fibronectin has 
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been shown to be necessary for the establishment of a pre-metastatic niche. 
Kaplan et al. showed that the deposition of fibronectin by fibroblast in the lung 
was necessary for the recruitment of haematopoietic progenitor cells during 
the formation of pre-metastatic niche 
230
. Although this aspect was not address 
in this study, the expression of fibronectin on the endothelium may also be 
important for the recruitment of haematopoietic progenitor cells prior to the 
arrival of the tumour cells. 
 
In this study, I have not examined the mechanism that regulates the cellular 
localisation of fibronectin deposition on the lung endothelial monolayer. In 
order to act efficiently as a tumour homing/binding receptor, fibronectin 
expression has to be concentrated at the apical surface. Fibronectin is known 
to be secreted basal-laterally by endothelial cells as part of the basement 
membrane 
544
. However, some studies have also noted that fibronectin can be 
deposited on the endothelial luminal surface 
545,546
. The direction of secretion 
was observed to be affected by culture confluence. Sub-confluent and newly 
confluent endothelial cells secrete fibronectin both apically and basally while 
post-confluent endothelial cells only secrete basally 
547
. In my in-vitro model, 
fibronectin expression was concentrated at the bicellular and tricellular 
junctions of the lung endothelium. The docking of breast tumour cells at these 
positions are ideal for tumour extravasation as cellular junctions are the ‘weak 
points’ and therefore the tumour cell would encounter the least resistance 
during the trans-endothelial migration process. While it is unclear at this 
juncture what mechanism regulates such a precise pattern of fibronectin 
deposition, it is probable that a change in endothelial permeability could 
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contribute to the observed apical fibronectin expression. TAMs in cancer 
secrete VEGF that can act on endothelial cells to promote angiogenesis 
377
 and 
increase endothelium permeability 
548
. Therefore, I speculate that upon 
stimulation by MDA-mϕ-secreted factors, the endothelial permeability might 
increase leading to apical fibronectin secretion and fibronectin deposition on 
the endothelium surface. Currently it has not been established whether 
treatment of the lung endothelial monolayers with MDA-mϕ-secreted factors 
has resulted a change in the permeability of the lung monolayers in my in-
vitro model. 
 
Fibronectin has several binding partners, such as integrins α3β1, α4β1, α5β1, 
α8β1, αvβ1, αvβ3, αvβ6, αvβ8 and α4β7 67. In my model, integrin α5β1 is 
responsible for the adhesion of MDA-MB-231 and MCF-7 to fibronectin. 
Taken together, the integrin α5β1 on the breast tumour cells binds to the 
fibronectin on the lung endothelium which is upregulated in the pre-metastatic 
niche. The importance of integrin α5β1 is also noted in the treatment of cancer 
as inhibitors of integrin α5β1 function are currently in clinical trials for 
inhibition of angiogenesis 
549,550
. However one clinical trial on a monoclonal 
antibody against integrin α5β1, PF-04605412, did not show anti-tumour 




There are several binding sites on the fibronectin protein structure for other 
ECM, heparin, fibrin and cells.  The type III module especially the Arg-Gly-
Asp (RGD) region in the type III10 domain is important for binding to the 
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integrin α5β1 on the target cell 544,552. Since my data showed that endothelial-
derived fibronectin is displayed on the apical surface to bind tumour cells via 
the integrin α5β1, it is conceivable that the binding of fibronectin to the 
endothelial surface is probably mediated by other domains. Heparan sulphate 
proteoglycan is able to bind to the second type III domain 
553
 and is known to 
be expressed on endothelial cells 
554,555
. As such, it is probably that the 
fibronectin could be bound to the endothelial luminal surface via the heparin 
sulphate proteoglycans.  
 
 
6.2 Tumour-conditioned macrophages promote pre-metastatic niche 
formation  
The interactions between tumour cells and the endothelial cells can be 
modulated by cytokines and chemokines in the organ microenvironment. 
These soluble factors can be secreted either by the primary tumour, the 
stromal cells or by both. These soluble factors primed the organ to form a 
favourable ‘docking bay’ for the circulating tumour cells. Involvement of 
stromal cells or recruited inflammatory cells in response to the primary 
tumour-derived factors to create a pre-metastatic niche is not a new concept. 
Tumour-derived factors such as VEGF, PIGF, TNF-α, TGF-β and LOX have 
been shown to modulate the microenvironment in distant organ and recruit 
myeloid cells in future-metastatic sites 
230,231,244
. Prior to the recruitment of the 
myeloid cells, the tumour-derived factors modify the distant organ 





 or activating STAT3 signalling in stromal cells such as 
endothelial cells and fibroblasts 
265
 or remodelling the ECM by up-regulating 
fibronectin expression to induce the myeloid cells clustering 
230,244,265
. To 
facilitate recruitment, tumour-derived LOX and VEGF were shown to 
stimulate myeloid cells and endothelial cells in distant sites to produce MMP2 
and MMP9 which increase the invasion of the myeloid cells 
244,556
. Once at the 
secondary site, the clusters of myeloid cells interact with stromal cells such as 
fibroblasts and endothelial cells to produce fibronectin and MMP-9 to create a 




Current studies on pre-metastatic niche highlighted that its formation in distant 
organs requires the recruitment of myeloid cells in response to tumour-derived 
factors into the organ. However, my study suggested that the resident 
macrophages in the lung can also be primed directly by the tumour-derived 
factors to mediate the formation of a pre-metastatic niche. MDA-MB-231-
derived factors were observed to modulate the phenotype of monocyte-derived 
macrophages to become M2-like. These MDA-conditioned macrophages in 
turn secrete factors that directly activate endothelial cells to facilitate tumour 
cell binding. In contrast, MCSF-derived macrophages did not exhibit the same 
stimulatory effects. This suggests that under normal physiological conditions, 
resident macrophages would not contribute to pre-metastatic niche formation. 
However, upon exposure to primary tumour-derived secreted factors in 
circulation, these macrophages could be remotely primed to become the pro-




IL-6 is one of the cytokines secreted into the tumour milieu by tumour 
associated stromal cells (macrophages and fibroblast) to promote tumour 
survival, proliferation, angiogenesis and drug resistance 
214,532,557,558
. In 
clinical studies, high serum IL-6 concentrations in breast cancer patients 
correlate with poor prognosis 
559-562
. However, the role of IL-6 in pre-
metastatic niche has not been shown. Data from this study suggests that 
tumour-conditioned macrophage-derived IL-6 may be important for 
endothelial cell activation and for the up-regulation of fibronectin expression. 
There are many different TAMs-derived different cytokines and chemokines 
(i.e. IL-8, IL-10, EGF and PDGF) that have been shown to be important for 
tumour progression 
517
; however their roles in pre-metastatic niche have yet to 
be elucidated.  
 
The discovery and understanding of the mechanisms underlying the pre-
metastatic niche formation is crucial to the treatment of cancer. The known 
tumour-derived factors, exosomes or microvesicles involved could be used as 
biomarkers to predict the metastatic progression or monitor treatment response. 
It may also be beneficial to target the pre-metastatic niche early, perhaps as an 
adjunct to the initial treatment of the primary lesion. This proposed early 
intervention targeting the pre-metastatic niche could possibly reduce 
metastatic dormancy present in some cancers such as breast cancer 
247
. Several 
mouse models have shown that targeting tumour-secreted factors such as LOX 






, VEGF, TNF-α and TGFβ 231 
could prevent the formation of the pre-metastatic niche and thus reducing 
metastasis. However, these factors drive different processes in the pre-
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metastatic niche. As such, treatment regimen simultaneously targeting 
multiple factors might be required to prevent pre-metastatic niche formation in 
patients. As such, more studies to elucidate the exact mechanisms involved in 
pre-metastatic niche development and maintenance will be required to 
generate the knowledge and understanding necessary for the design and 





Data from my study showed that endothelial cells at metastatic sites, including 
the lung, are more responsive to both direct tumour interactions, such as the 
release of MMPs to facilitate tumour cell transmigration; and to be modulated 
by TNF-α and tumour-derived factors, including IL-6 secreted by tumour-
conditioned macrophages. My data suggested that the development of the pre-
metastatic lung requires the activation of JNK/cJUN and STAT3 signalling in 
these IL-6-activated endothelial cells. This is the first report that focused on 
examining the activation of the endothelium and its inferred role in pre-
metastatic niche formation. The receptiveness of lung endothelium, compared 
to endothelium from non-metastatic sites, to such manipulations implies that 
metastasis to a particular organ is indeed not a random occurrence. 
Furthermore, this process is a pre-determined event as disseminated tumour 
cells, once in circulation, are recruited ‘directly’ to the pre-metastatic niche 
established in the target organ. 
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In elucidating the process of pre-metastatic niche formation, my data suggest a 
two-step mechanism is involved. The malignant cells in the primary lesion is 
able to modulate the phenotype of macrophages in the distant organs; which in 
turn act to increase the adhesiveness of the endothelium in the target organ for 
the binding of incoming tumour cells in circulation. The proposed mechanism 
is shown in figure 6.1.  
Figure 6.1: Mechanism for pre-metastatic niche formation to facilitate 
tumour cells recruitment into secondary sites  
(A) Step 1: Secreted factors from the primary tumour enter circulation and are 
carried in blood to distant organs such as lung. In response to these secreted 
factors, macrophages on site became tumour-conditioned macrophages. Step 2: 
These tumour-conditioned macrophages secrete soluble factors such as IL-6, 
which stimulate the lung endothelium. Upon stimulation, JNK/cJUN and 
STAT3 signalling are activated in the endothelium. This resulted in the up-
regulation of surface fibronectin expression which gives rise to the pre-
metastatic niche in the lung. (B) On the arrival of the circulating tumour cells 
from the primary tumour, the tumour cells bind to the fibronectin on the lung 
endothelium in the pre-metastatic niche and transmigrate into the lung 
interstitium.  
(A) Formation of Pre-metastatic Niche 
(B) Arrival of circulating tumour cells 
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Notably, the presence of fibronectin is essential in the pre-metastatic niche as 
it acts as a homing receptor for the tumour cells. Targeting fibronectin or 
fibronectin receptors at this phase could potentially prevent metastasis and 
possibly reduced cancer mortality. Despite the success of the treatment for 
primary breast tumour with surgery, radiotherapy and hormonal therapy, the 
mortality associated with breast cancer still remain high due to the 
complications of metastasis 
318
. My result suggests that this pre-metastatic 
niche created by the primary tumour is an attractive target for strategies to 
prevent metastasis. By blocking the homing receptors in the pre-metastatic 
niche, tumour cells in circulation will not be able to adhere and engraft at the 
prepared metastatic organ. Thus, metastatic events could be reduced or 
prevented. Suppression of the pre-metastatic or early metastatic events is 




6.4 Future work 
Findings from this study suggested the importance of the interactions between 
breast tumour cells and macrophages in mediating the formation of a pre-
metastatic niche in the lung. My data showed that the fibronectin on the 
endothelium was up-regulated upon stimulation by MDA-mϕ-derived IL-6. 
My study revealed that fibronectin also acts as a homing receptor for the 
breast tumour cells. Some studies have shown that fibronectin serve as a 
mediator for the recruitment of bone marrow cells in the pre-metastatic niche 
230,244
. This confirms the necessity of fibronectin during the establishment of 
pre-metastatic niche in the lung. To have a better understanding of the role of 
tumour cells in the formation of pre-metastatic niche, I have identified some 
areas that will give better insights on this pre-metastatic event but were not 
examined in this study. In addition, some caveats of this study will also be 
addressed in the future work. 
 
Other than fibronectin, I have also found the involvement of laminin ligands, 
integrins α6β1 and α6β4, in the adhesion of breast tumour cells to the MDA-
mϕ secreted factors stimulated lung endothelium. Members of laminin family 
are heterotrimers of α, β, γ chain and are known to be part of the basement 
membrane structure 
563
. Laminin nomenclature is based on its α, β and γ 
chains composition. For example, laminin 332 is made up of α3, β3 and γ2 
chains 
564
. Integrins α6β1 and α6β4 bind to laminin 332, laminin 511 and 
laminin 521. Integrin α6β1 also binds to laminin 111 565. Like fibronectin, 
laminins also adhere to other extra cellular matrix molecules, including other 





. It would be interesting to know whether laminin are also present 
on the endothelium surface to mediate the tumour adhesion. The laminin most 
associated with cancer is laminin 332, with its individual α3, β3 and γ2 chains 
found to be highly expressed and associated with metastasis in several cancers 
such as hepatocellular carcinoma 
567,568
 and pancreatic ductal adenocarcinoma 
569
. As such, it is important to identify the particular laminins present on the 
MDA-mϕ-secreted factors stimulated endothelium that contribute to the pre-
metastatic niche formation. Using immunofluorescence staining of the 
individual laminin chains, I could determine the possible laminin family 
members present on the endothelium. With function blocking laminin 
antibodies to different laminin chains, the laminin responsible for the tumour 
adhesion could be elucidated.  
 
My data showed that although both MCSF-mϕ and MDA-mϕ are of the same 
M2 phenotype, only the MDA-mϕ-secreted factors stimulation of the lung 
endothelium resulted in enhanced tumour interactions. Compared to MCSF-
mϕ, MDA-mϕ secreted significantly higher amount of IL-6 which resulted in 
the enhanced fibronectin expression. This suggests that MDA-MB-231-
secreted factors could modulate the phenotype of the macrophages. Hiratsuka 
et al. have identified primary tumour derived VEGF-A, TNF-α and TGFβ as 
the main factors that induced chemoattractants S100A8 and S100A9 in the 
lung resulting in the formation of a pre-metastatic niche 
231
. A cytokine/growth 
factor array could be used to examine whether those soluble factors are indeed 
present in the MDA-MB-231-derived conditioned medium and also to identify 
the possible novel candidates. One caveat of this study is that only MDA-MB-
225 
 
231 was used to produce the tumour-conditioned macrophages. Therefore, it is 
unclear whether other breast tumour cells are able to induce macrophage 
differentiation to produce TAMs. As such a variety of breast cell lines, varying 
from different invasiveness and classification, can be examined for their 
ability to produce TAMs and correlation to the invasiveness of the breast 
tumour cells. A comparison of their cytokine profiles would reveal the 
important factors that drive TAMs differentiation.  
 
My data suggests the importance of activation of JNK/cJUN signalling by 
MDA-mϕ to induce endothelial fibronectin expression for pre-metastatic niche 
formation. Several in-vivo mouse models have shown the importance of 
STAT3 involvement in pre-metastatic niche formation. However, JNK/cJUN 
signalling association with pre-metastatic niche has not been studied. 
Therefore, it is important to confirm that role JNK/cJUN signalling for the 
pre-metastatic niche formation in an in-vivo mouse model. The mice can be 
treated with a specific JNK inhibitor prior to tumour engraftment and after 
tumour engraftment until the lungs (site of secondary tumour growth) are 
harvested for analysis. The lungs will be examined for phosphorylated 
JNK/cJUN and fibronectin expression which would be used as a marker for 
pre-metastatic niche formation. Lastly, both STAT3 and JNK/cJUN signalling 
were observed to be activated in the MDA-mϕ-secreted factor-stimulated lung 
endothelium in my study. Therefore, a combination treatment of STAT3 and 
JNK inhibitors can also be done to determine whether blocking of both 
pathways could prevent metastasis in the mouse. This would provide us with 
preliminary evidence on whether JNK/cJUN and STAT3 inhibitors would be 
226 
 
useful to preventing metastasis in breast cancer patients. Mouse model has 
been shown in many studies as the study model for pre-metastatic niche. 
Although it might not be an accurate representative for the disease progression 
in human, it is impossible to study pre-metastatic niche formation in human. 
Prior to the occurrence of metastasis, biopsy sample of healthy organs in 
patient could not be obtained. As such, other than mouse model, in-vitro study 
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